A N N U A L R E P O R T 2 0 1 8
PERFORMANCE
Driving growth and profitability to maximize value for
our shareholders.
PRODUCTS
Innovative therapies developed and commercialized to meet the
needs of our patients across the continuum of orthopedic and
regenerative therapies.
PEOPLE
High-end talent driving innovation and a culture of achievement.
Dear Fellow Shareholders,
Since taking over as President and Chief Executive Officer in
March of last year, my driving vision has been the transformation of
Anika Therapeutics into a global commercial company delivering
a continuum of innovative orthopedic and regenerative medicine
therapies to fuel our next phase of growth and drive enduring
shareholder value. In 2018, we prioritized and advanced this
goal. We made the important decision to develop and deploy
our hybrid commercial business model in the United States
for orthopedic surgical product candidates. We onboarded
experienced new talent on the management team and across other
key functions to ensure we have the right winning team in place
to drive growth and enhance efficiencies. We also progressed
our broad and deep pipeline that we see as the leading edge
of a cascade of new product launches to propel us forward.
The last year also brought certain headwinds both with regards
to external circumstances, such as pricing pressure in the U.S.
market and disappointing clinical trial results, as well as internal
elements, such as our voluntary recall of certain HYAFF-based
products. We persevered through these setbacks, and we
believe that we have stabilized the company’s operations and
overall foundation. We have made strong progress on our 5-year
strategic plan to guide our continued transformation, and we are
confident in the long-term growth potential for our company.
We believe we have a strong platform, both from a financial and
technology standpoint, from which to launch our future. We
believe that our 2018 performance highlights our ability to capably
manage the elements of our business over which we can exert
control and that 2019 will be a year of execution and accelerated
performance as we drive forward into the next phase of growth.
We are focused on growing our business responsibly, ethically
and in a sustainable manner, while maintaining our strong culture
of innovation, operational excellence and financial discipline.
Finally, we remain committed to delivering long-term value to our
shareholders through the development and commercialization
of innovative orthopedic and regenerative therapies and smart
investment of our resources. Change will not occur immediately,
but we believe we can rapidly advance our strategic objectives.
On behalf of the management team and our Board of Directors, I
thank you for your continued trust and confidence in our company, and
I look forward to the future as we work tirelessly to drive innovation
and transform Anika Therapeutics into a global commercial company.
Sincerely,
Joseph Darling
President and Chief Executive Officer
Joseph Darling,
President & CEO
2019 is a
transformational
year for Anika,
as we build our
hybrid commercial
business model
in the U.S. and
strengthen our
international
commercial
infrastructure to
drive the next phase
of our growth.
ANNUAL REPORT 2 018
2
FY 2018
HIGHLIGHTS
A NEW DAY FOR ANIKA
TRANSFORMING INTO A GLOBAL COMMERCIAL COMPANY
Today is a new day for Anika Therapeutics. In 2018, we took important steps to
transition the company for its next phase of growth, as we evolve into a global
commercial company. From expanding our leadership team and Board of Directors to
advancing our deep product pipeline and progressing toward the deployment of our
hybrid commercial model in the U.S., we further solidified our strong foundation built
over the past decade.
In 2019, we plan to approach the
market proactively and directly to
gain greater visibility and control
of our future. We are investing
in commercial expansion efforts
through our U.S. hybrid commercial
model and the optimization of our
distribution model outside of the
United States.
This is a very exciting time for Anika
as we build and strengthen our
global commercial infrastructure
and capabilities to drive the next
phase of our growth and evolution.
Fundamentally, we believe our
company and future growth are
powered by a strategy focused
around our people, our products,
and our performance. Throughout
this annual report, we will highlight
our 2018 achievements and near-
and long-term growth drivers within
the context of these foundational
strategic pillars.
We are committed
to transforming
Anika into a
global commercial
company with an
innovative portfolio
of orthopedic
and regenerative
medicine solutions
spanning a broad
continuum of care
27%
Vitality Index for New
Products Launched
Since 2014
11%
Orthobiologics
5-Year CAGR
#1
Market Share in the
U.S. Viscosupplement
Market
34%
CINGAL Revenue Growth
$35M
Cash from Operations
$30M
Accelerated Share
Repurchase Program
$
$159M$159M
Cash and Investments;
No Debt
4
ANNUAL REPORT 2 018
PEOPLE
HIGH-END TALENT DRIVING INNOVATION
AND A CULTURE OF ACHIEVEMENT
Over the course of 2018, we prioritized a shift in our culture and sought to energize the
human element of our organization to focus on the many growth drivers we see for the
company. This focus extended from our Board of Directors, where we added two new
directors to broaden our overall knowledge base, to every function within the company
with the goal of increasing our sophistication, efficiency, and overall level of expertise.
With our U.S. headquarters located in the Boston area, a life science innovation
hotbed, and our European headquarters located in Padova, Italy, a historic
university town rich with culture and progressive thought, we intend to leverage
our physical locations to recruit and retain the strongest talent available. Our Chief
Human Resources Officer and the leader of our talent management function,
Thomas Finnerty, has been tasked with aggressively recruiting talented individuals
across the organization to maximize our performance, while empowering our
employees to continuously seek innovative solutions in all areas of our business.
Since mid-2018, we have added executive leadership to our operations, commercial
and research and development functions. These bright and ambitious industry veterans
are already making positive contributions toward achieving our strategic objectives.
Our Vice President of Operations, Alex Goraltchouk, has enhanced and galvanized
our operational teams with his energy and commitment to continuous improvement
and sustainable business practices. We have seen the beginnings of the expected
financial benefits through expanded operating margins, and we anticipate even greater
improvements as the team further integrates his innovative thinking into our operations.
We increased our focus on international expansion with the appointment of James Chase
as our Vice President of International Sales and our first European-based commercial lead.
We are increasing our attention on the markets outside of the United States and building
a team of experts to support international growth through direct interaction with all key
stakeholders. We plan to create an organization optimally positioned to maximize the global
potential of our current and future product portfolio and product development activities.
In the first quarter of 2019, we appointed Robert Richard, Ph.D. to the newly created
position of Vice President of Research and Development (R&D). Dr. Richard’s extensive
leadership and product development experience will help us accelerate and advance
our orthopedic and regenerative medicine pipeline to deliver a cascade of innovative
treatments to patients over the next several years. He will also enable us to leverage the
broad utility of our technology platform, with a renewed focus on regenerative medicine.
We are empowering our R&D team to step outside our traditional development paradigms,
including through interaction with physicians and other external stakeholders to understand
current unmet needs in the market, where we feel we can drive innovation in our portfolio.
In addition, we are currently structuring the internal programs and hiring the expert
resources necessary to successfully deploy our U.S.-based hybrid commercial organization.
We believe in ourselves, in our culture, and in our product offerings, both present and
future, and our employees hard work and passion are at the heart of our organization.
We are committed
to transforming
Anika into a
global commercial
company with an
innovative portfolio
of orthopedic
and regenerative
medicine solutions
spanning a broad
continuum of care
“Efficiency,innovation,andafocus
onexecutionisatthecoreof
ourorganization.Thiswillenable
ustodrivesustainabilityand
maximizevalueforpatientsandour
shareholders.Withourfocusonthe
keyoperationalfundaments,we
believethatefficiencyimprovements
willalsoyieldenhancedquality
andasaferworkplace,aswellas
improvedontimedeliveryand
overallcompliance.”
—AlexeiGoraltchouk,
VicePresidentofOperations
“Aswetransformintoaglobal
commercialorganization,itis
criticalforustobeengagedinthe
marketsinwhichweparticipate.
Wearebuildingourinternational
commercialinfrastructureto
strengthenourbrand,accelerate
internationalpenetrationanddrive
adoption,andimportantlybring
usclosertothepatientsweserve
throughenhancedrelationshipswith
keycliniciansandourdistributors.”
—JamesChase,
VicePresidentofInternationalSales
ANNUAL REPORT 2 018
5
PEOPLEHIGH-END TALENT DRIVING INNOVATION AND A CULTURE OF ACHIEVEMENT DRIVING INNOVATION IN
ORTHOPEDIC THERAPIES
PRODUCTS
MONOVISC
Single Injection
Osteoarthritis Treatment
CINGAL
Next Generation
Osteoarthritis Therapy;
Combination Hyaluronic
Acid and Steroid
INNOVATIVE TREATMENTS DEVELOPED AND
COMMERCIALIZED TO MEET THE NEEDS OF OUR PATIENTS
ACROSS THE CONTINUUM OF ORTHOPEDIC THERAPIES
While our strategic focus has historically been centered on our strong viscosupplement
portfolio anchored by MONOVISC and CINGAL, we believe that our future lies in
regenerative medicine and other potential areas leveraging the broad utility of our
HYAFF technology platform. There are over 4 million sports-related injuries per year, and
the cartilage repair market represents an approximate $2 billion opportunity in the U.S.
Based on feedback from physicians and other stakeholders, it is clear there is an urgent
and growing global need for solutions that delay surgery and heal patients naturally
while maintaining and supporting overall cost control initiatives. We believe we are well-
positioned to meet this global need through innovation utilizing our HYAFF technology
platform, as well as potential synergistic acquisitions. Our goal is to transform into a market
leader in orthopedic and regenerative medicine with a product portfolio spanning a broad
continuum of care.
We expect our surgically-delivered bone repair and rotator cuff repair therapies to be
the first two pipeline products launched under our hybrid commercial model. The first,
our bone repair treatment, is scheduled to make its debut in the second half of 2019.
We continue to believe in the U.S. commercial potential of HYALOFAST, and we are
advancing initiatives to accelerate enrollment in the ongoing Phase III trial required for U.S.
approval. We have refreshed our approach to more directly align our commercial and R&D
functions to engage with external stakeholders to proactively analyze and seek to address
unmet clinical needs. Additionally, we are continually exploring synergistic acquisition
opportunities and targeted partnerships to augment our organic growth.
EXPANDING REGENERATIVE
MEDICINE PORTFOLIO
HYBRID COMMERCIAL BUSINESS MODEL
Improving
Operational
Efficiency
As we develop and launch products with a different call point than our current portfolio
in palliative pain management, we intend to utilize a hybrid commercial business model
in the United States. This approach will pair a small in-house team of elite and highly-
skilled business development specialists with a strategic partner or regional distribution
partnerships. We intend to
structure any new partnership
contracts to provide more
favorable economics and greater
control over market access, sales
and marketing, minimum annual
growth objectives, and pricing
than our previous commercial
partnerships have had historically.
We intend to continue with
our existing distribution model
outside of the United States and
expect the development of our
international commercial team
to drive similar benefits as well
as a greater ability to hold our
commercial partners accountable
for their performance. We are
pleased with the progress we are
collectively making across our
organization as we evolve into a
global commercial company and
gain greater visibility and control
of our future.
“ As an Orthopedic Surgeon and Sports
Medicine Physician, I am constantly
scanning the horizon to identify new
therapies and technologies with the
potential to be the best possible
treatment option for my patients. I have
been following the Anika story for a
number of years now and successfully
utilized certain of their offerings, and I
am very excited about their next
generation of products and the potential
benefits that they may one day provide
to my patients to help them recover from
injury and restore their active lifestyles.”
Plancher Orthopaedics & Sports Medicine
– Kevin D. Plancher, MD
HYALOFAST
A Hyaluronic Acid Based
Matrix Supports Regeneration
of Hyaline-like Cartilage
BONE REPAIR TREATMENT
Commercial Launch Planned
for 2H 2019
6
ANNUAL REPORT 2 018
PERFORMANCE
DRIVING PROFITABLE GROWTH TO MAXIMIZE VALUE FOR OUR
SHAREHOLDERS
Our ongoing evolution into a global commercial company, which is supported by our
people and products, is focused on maximizing value for our shareholders. In 2018,
we effectively managed and stabilized the company’s operations following significant
organizational change and business challenges. Our focus on operational excellence
enabled us to continue to deliver strong profitability and cash flow for the year. We
believe that this work has positioned us to accelerate our growth in the years ahead.
CORPORATE SOCIAL
RESPONSIBILITY
Anika is committed to creating a
sustainable and diverse workplace,
while ensuring we operate with the
highest standards of quality, ethics and
corporate governance. We are pleased
to highlight our environmental, social
and corporate governance progress and
achievements in 2018.
In 2019, we will take advantage of the multiple levers we have to drive growth
throughout our business. We remain committed to achieving our long-term goal of
delivering sustained double-digit revenue growth.
Environmental
Developing Hybrid
Commercial Model
Improving
Operational
Efficiency
$
Disciplined &
Balanced Capital
Allocation
Advancing Orthopedic
and Regenerative
Medicine Pipeline
International Expansion
of Orthobiologics
Franchise
We look forward to completing the development of our hybrid commercial organization
in 2019 and launching multiple new and innovative orthopedic and regenerative therapies
over the next several years to fuel our growth. We have carefully considered the paths in
front of us as we near completion of our 5-year strategic plan, and we are confident we
have the right people, products and strategies to drive sustained growth and value for our
shareholders.
• Material Recycling - Redundant
component waste elimination
• Emissions and other environmental data
tracking initiative from company processes
• Ozone depleting substance program
• Heat recovery projects
• Lighting upgrade - LED lights on automatic
timers/dimmers
Social
• UMASS Amherst iCons program annual
contribution
• Charitable contributions - Meals for Kids;
Cradles to Crayons
• Employee health and wellness initiatives
Corporate Governance
• Commitment to diversity
• Expansion of Board of Directors
– Cheryl R. Blanchard, Ph.D. - President
and Chief Executive Officer, Keratin
Biosciences, Inc.
– Susan N. Vogt - Formerly President
and Chief Executive Officer, Aushon
Biosystems, Inc.
– Joseph Darling - President and Chief
Executive Officer, Anika Therapeutics
• Risk management programs
ANNUAL REPORT 2 018
7
EXECUTIVE OFFICERS
BOARD OF DIRECTORS
SHAREHOLDER MEETING
Joseph Darling
President and Chief Executive Officer
Joseph L. Bower, D.B.A.
Chairman - Independent
Sylvia Cheung
Chief Financial Officer
Cheryl R. Blanchard, Ph.D.
Keratin Biosciences, Inc.
Edward Ahn, Ph.D.
Chief Technology and Strategy Officer
Joseph G. Darling
President and Chief Executive Officer
Thomas Finnerty
Chief Human Resources Officer
Raymond J. Land
Formerly of Clarient, Inc.
Glenn R. Larsen, Ph.D.
Aquinnah Pharmaceuticals, Inc.
Jeffery S. Thompson
HealthEdge Investment Partners, LLC
Susan N. Vogt
Formerly of Aushon Biosystems, Inc.
June 18, 2019
11:30 a.m. EDT
Anika Therapeutics
Corporate Headquarters
HEADQUARTERS
32 Wiggins Avenue
Bedford, MA 01730 USA
EMPLOYEES
133 (as of December 31, 2018)
STOCK LISTING
NASDAQ: ANIK
INVESTOR RELATIONS
Sylvia Cheung
Chief Financial Officer
Phone: 781.457.9000
investorrelations@anikatherapeutics.com
AUDITORS
CORPORATE COUNSEL
TRANSFER AGENT
Deloitte & Touche LLP
200 Berkeley Street
Boston, MA 02116
Phone: 617.437.2000
www.deloitte.com
K&L Gates LLP
1 Lincoln Street
Boston, MA 02111
Phone: 617.261.3100
www.klgates.com
American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, NY 11219
Phone: 800.937.5449
www.astfinancial.com
help@astfinancial.com
FORWARD LOOKING STATEMENT
This document contains “forward-looking statements,” which are not statements of historical fact, and are forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to,
those relating to the Company’s long-term strategies and growth plans, the Company’s 5-year strategic plan, the Company’s expectations with respect to its 2019 finan-
cial performance, the Company’s U.S. and international commercial efforts, the Company’s launch of its bone repair product via its hybrid commercial model, and the
Company’s pursuit of strategic acquisitions and partnerships. These statements are based upon the current beliefs and expectations of the Company’s management and
are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance,
or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully
commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and
international pre-market approval applications, 510(k) applications, ornew drug applications, or to timely file and receive FDA or other regulatory approvals or clearances
of its products; (iii) that such approvals will not be obtained in a timely manneror without the need for additional clinical trials, other testing or regulatory submissions,
as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new
products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company’s clinical studies, man¬ufacturing operations, and production planning; (vi)
the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future deter-
minations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its
products, in the U.S. and abroad; (ix) quarterly sales volume variation experienced by the Company, which can make future results difficult to predict and period-to period
comparisons potentially less meaningful; (x) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (xi) the Company’s ability
to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they
are available on the SEC’s website at www.sec.gov.
8
ANNUAL REPORT 2 018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2018
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 000-21326
Anika Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation or Organization)
04-3145961
(IRS Employer Identification No.)
32 Wiggins Avenue, Bedford, Massachusetts 01730
(Address of Principal Executive Offices) (Zip Code)
(781) 457-9000
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Common Stock, par value $0.01 per share
Name of Each Exchange on Which Registered
NASDAQ Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). Yes No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
Non-accelerated filer
Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The aggregate market value of voting common stock held by non-affiliates of the registrant as of June 30, 2018, the last day of the
registrant’s most recently completed second fiscal quarter, was $460,209,312 computed by reference to the closing price of common stock
on such date. The registrant does not have any non-voting stock outstanding.
At February 10, 2019, there were 14,211,672 shares of the registrant’s common stock outstanding.
Documents Incorporated By Reference
Portions of the registrant’s proxy statement for its 2019 annual meeting of stockholders are incorporated by reference in Part III of this
Annual Report on Form 10-K.
ANIKA THERAPEUTICS, INC.
TABLE OF CONTENTS
Page
Cautionary Note Regarding Forward-Looking Statements .......................................................................... 3
Part I
Item 1.
Business ....................................................................................................................................................... 4
Item 1A. Risk Factors ................................................................................................................................................. 13
Properties ..................................................................................................................................................... 26
Item 2.
Item 3.
Legal Proceedings ........................................................................................................................................ 27
Part II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities ...................................................................................................................................................... 27
Item 6.
Selected Financial Data ................................................................................................................................ 28
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations ....................... 29
Item 7A. Quantitative and Qualitative Disclosures About Market Risk ..................................................................... 45
Item 8.
Financial Statements and Supplementary Data ............................................................................................ 46
Item 9A. Controls and Procedures .............................................................................................................................. 76
Part III
Item 10. Directors, Executive Officers and Corporate Governance ........................................................................... 78
Item 11. Executive Compensation ............................................................................................................................. 78
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters .... 78
Item 13. Certain Relationships and Related Transactions, and Director Independence ............................................. 78
Item 14. Principal Accounting Fees and Services ...................................................................................................... 78
Part IV
Item 15. Exhibits and Financial Statement Schedules ................................................................................................ 78
Signatures .......................................................................................................................................................................... 81
References in this Annual Report on Form 10-K to “we,” “us,” “our,” “our company,” and other similar references refer to
Anika Therapeutics, Inc. and its subsidiaries unless the context otherwise indicates.
ANIKA, ANIKA THERAPEUTICS, ANIKAVISC, CINGAL, HYAFF, HYDRELLE, HYVISC, MONOVISC, and
ORTHOVISC are our registered trademarks, and HYALOSS and ELEVESS, are our trademarks. For convenience, these
trademarks appear in this Annual Report on Form 10-K without ® and ™ symbols, but that practice does not mean that we
will not assert, to the fullest extent under applicable law, our rights to the trademarks. This Annual Report on Form 10-K also
contains trademarks and trade names that are the property of other companies.
2
FORM 10-K
ANIKA THERAPEUTICS, INC.
For Fiscal Year Ended December 31, 2018
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 concerning our business, consolidated
financial condition, and results of operations. The Securities and Exchange Commission ("SEC") encourages companies to
disclose forward-looking statements so that investors can better understand a company’s future prospects and make informed
investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our
control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of
these forward-looking statements. Forward-looking statements can be identified by such words as "will," "likely," "may,"
"believe," "expect," "anticipate," "intend," "seek," "designed," "develop," "would," "future," "can," "could," and other
expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. All
statements other than statements of historical facts included in this Annual Report regarding our strategies, prospects,
financial condition, operations, costs, plans, and objectives are forward-looking statements. Examples of forward-looking
statements include, among others, statements regarding expected future operating results, expectations regarding the timing
and receipt of regulatory results, anticipated levels of capital expenditures, and expectations of the effect on our financial
condition of claims, litigation, and governmental and regulatory proceedings.
Please refer to "Risk Factors" for important factors that we believe could cause actual results to differ materially
from those in our forward-looking statements. Any forward-looking statement made by us in this Annual Report on Form
10-K is based only on information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments, or otherwise.
3
ITEM 1. BUSINESS
Overview
PART I
We are a global, integrated orthopedic and regenerative medicines company committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the
continuum of care, from palliative pain management to regenerative tissue repair. We have over two decades of global
expertise developing, manufacturing, and commercializing more than twenty products based on its proprietary Hyaluronic
Acid (“HA”) technology. Our orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which
alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration.
Our therapeutic offerings consist of products in the following areas: Orthobiologics, Dermal, Surgical, and Other,
which includes our ophthalmic and veterinary products. All of our products are based on HA, a naturally occurring,
biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an
important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the
maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.
Our proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to
therapeutic use. Our patented technology chemically modifies HA to allow for longer residence time in the body. We also
offer products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an
autocross-linked polymer of HA. Our technologies are protected by an extensive portfolio of owned and licensed patents.
Since our inception in 1992, we have utilized a commercial partnership model for the distribution of our products to
end-users. Our strong, worldwide network of distributors has historically provided, and continues to provide, a solid
foundation for our revenue growth and territorial expansion. For near-term and long-term opportunities in the U.S. market,
we have evaluated a potential hybrid commercial approach that would see us balance a small direct model with an optimal
form of strategic partnership, an approach we intend to utilize for the commercialization of our injectable, HA-based surgical
bone repair product. For longer-term future products in the U.S. market, we intend to evaluate our commercial model and
possible alternatives or augmentations in each instance on a case-by-case basis, based on market dynamics and other factors.
These models could include direct sales, distribution partnerships, or a hybrid of those forms. We believe that the combination
of the direct and distribution commercial models will maximize the revenue potential from our current and future product
portfolio.
On May 2, 2018, we publicly disclosed a voluntary recall of certain production lots of our HYAFF-based products,
HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. We communicated with all affected distributors in advance of
that announcement, and we took all required or otherwise appropriate actions with respect to applicable regulatory bodies.
We initiated the voluntary recall following internal quality testing, which indicated that the products were at risk of not
maintaining certain measures throughout their entire shelf life. While there was no indication of any safety or efficacy issue
related to the products, we are committed to the highest standards of quality and removed the products from the field as a
precautionary measure. During the first quarter of 2018, we recorded a revenue reserve of $1.1 million, $0.9 million of which
related to revenue recorded in prior periods, and adjustments during the balance of the year were immaterial. We also recorded
an inventory charge for fiscal year 2018 of $0.8 million for the related non-saleable inventory, and we incurred $0.3 million
of expenses associated with the administration and remediation of the voluntary recall. During the fourth quarter of 2018, we
resolved this matter and resumed shipment of these products, and as of December 31, 2018, all of the affected products had
been returned to us without the need for any material change to the related reserves. As a result of this voluntary recall,
revenue generated from the affected products during fiscal year 2018 declined between $1 million and $2 million as compared
to fiscal year 2017.
The following sections provide more specific information about our products and related activities:
4
Orthobiologics
Our Orthobiologics products primarily consist of viscosupplement and regenerative orthopedic products. These
products are used in a wide range of treatments, from providing pain relief from osteoarthritis to regenerating damaged tissue
such as cartilage. Osteoarthritis is a debilitating disease that causes pain, swelling, and restricted movement in joints. It occurs
when the cartilage in a joint gradually deteriorates due to the effects of mechanical stress, which can be caused by a variety
of factors, including the normal aging process. In an osteoarthritic joint, particular regions of the joint’s articulating surfaces
are exposed to irregular forces, which results in the remodeling of tissue surfaces that disrupt the normal equilibrium or
mechanical function. As osteoarthritis advances, the joint gradually loses its ability to regenerate cartilage tissue, and the
cartilage layer attached to the bone eventually deteriorates to the point that the bone becomes exposed. Advanced
osteoarthritis often requires surgery and the possible implantation of artificial joints. The current treatment options for
osteoarthritis, prior to joint replacement surgery, include viscosupplements, analgesics, non-steroidal anti-inflammatory
drugs, and steroid injections.
Our viscosupplement franchise includes ORTHOVISC, MONOVISC, ORTHOVISC mini, and CINGAL. Our first
viscosupplement product, ORTHOVISC, is a three-injection osteoarthritis treatment regimen available in the United States,
Canada, and other international markets throughout the world. ORTHOVISC has been marketed by us internationally since
1996, and it was approved for sale in the United States in 2004. MONOVISC is our second generation, single-injection
osteoarthritis treatment, and it is also available in the United States, Canada, and other international markets throughout the
world. MONOVISC has been marketed by us internationally since 2008 and was approved by the FDA for sale in the United
States in February 2014, with the related U.S. commercial introduction of the product in April 2014. In the United States, our
viscosupplement franchise, consisting of our ORTHOVISC and MONOVISC products, continues to maintain the overall
market leadership position. ORTHOVISC mini has been available in Europe since 2008, and it is designed for the treatment
of osteoarthritis in small joints. CINGAL, our third generation single-injection osteoarthritis product, combining the HA
formulation utilized in MONOVISC with an active steroid component, is available in Canada, the European Union, and other
international markets throughout the world. Commercial launch of this next generation viscosupplement was achieved in
Canada during May 2016 and in the European Union during June 2016. For additional information about CINGAL in the
United States, see the section captioned “Business—Research and Development of Potential Products.”
In the United States, ORTHOVISC is indicated for the treatment of pain caused by osteoarthritis of the knee in
patients who have failed to respond adequately to conservative, non-pharmacologic therapy and to simple analgesics, such as
acetaminophen. ORTHOVISC is a sterile, clear, viscous solution of hyaluronan dissolved in physiological saline and
dispensed in a single-use syringe. A complex sugar of the glycosaminoglycan family, hyaluronan is a high-molecular-weight
polysaccharide composed of repeating disaccharide units of sodium glucuronate and N-acetyl glucosamine. ORTHOVISC is
injected into joints in a series of three intra-articular injections one week apart. ORTHOVISC became available for sale in
the United States on March 1, 2004, and it is marketed by DePuy Synthes Mitek Sports Medicine, a division of DePuy
Orthopaedics, Inc. (“Mitek”) under the terms of an initial ten-year licensing, distribution, supply, and marketing agreement
which was entered into in December 2003 (the “Mitek ORTHOVISC Agreement”). The Mitek ORTHOVISC Agreement has
been extended for two additional five-year terms, and it will now expire on December 20, 2023, unless it is further extended
by Mitek. Outside of the U.S., we have a number of distribution relationships servicing international markets including
Canada, Europe, the Middle East, Latin America, and Asia. We continue to seek to establish distribution relationships in
other key markets. See the sections captioned “Management’s Discussion and Analysis of Financial Condition and Results
of Operations—Management Overview” and “Risk Factors.”
In the United States, MONOVISC is also indicated for the treatment of pain caused by osteoarthritis of the knee in
patients who have failed to respond adequately to conservative, non-pharmacologic therapy and to simple analgesics, such as
acetaminophen. MONOVISC is a sterile, clear, viscous solution of partially cross-linked sodium hyaluronate in a phosphate
buffered saline solution. A treatment of MONOVISC is comprised of one injection of the product delivered directly into the
affected joint. MONOVISC became available for sale in the United States in April 2014, and it is marketed by Mitek under
the terms of a fifteen-year licensing, distribution, supply, and marketing agreement, which was entered into on December 21,
2011 (the “Mitek MONOVISC Agreement”). Outside of the United States, we have a number of distribution relationships
servicing international markets including Canada, Europe, the Middle East, Latin America, Asia, Australia, and certain other
international countries. We continue to seek to establish distribution relationships in other key markets. See the sections
captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Management
Overview” and “Risk Factors.”
5
In addition to the four viscosupplement products discussed above, we also offer several additional products used in
connection with orthopedic regenerative medicine. These products are based on the HYAFF technology and are currently
available in Europe, South America, Asia, and certain other international markets. They include HYALOFAST, a
biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for
microfracture surgery; HYALONECT, a resorbable knitted fabric mesh for use in orthopedic and trauma reconstructive
procedures to maintain the relative position of engrafted bone tissue or bone fragments from comminuted fractures; and
HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration. We also offer
HYALOGLIDE, an ACP gel used in tenolysis treatment, with the potential for use in flexor tendon adhesion prevention and
for use in the shoulder for prevention of adhesive capsulitis with additional clinical data. This product is commercialized
through a network of distributors, primarily in Europe and the Middle East. We also received CE Mark approval in December
2016 for a product which utilizes our proprietary HA technology to treat pain associated with lateral epicondylitis, better
known as tennis elbow. Outside of the United States, this product is marketed under the trade name ORTHOVISC-T.
Additionally, in the second quarter of 2016, we submitted an Investigational Device Exemption (“IDE”) to the FDA to
conduct a Phase III clinical trial for this treatment, and the IDE was approved by the FDA in June 2016. In addition to these
products, we also received 510(k) clearance for an injectable, HA-based surgical bone repair product in December 2017,
which we intend to launch in the U.S. during 2019 utilizing the previously-described hybrid commercial approach. In total,
Orthobiologics products accounted for 89%, 87%, and 87% of our product revenue in 2018, 2017, and 2016, respectively.
Dermal
Our dermal products consist of advanced wound care products, based on the HYAFF technology, and an aesthetic
dermal filler, based on our proprietary chemically modified, cross-linked HA technology. Products utilizing our HYAFF
technology are used for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of
wound treatment solutions including debridement agents, advanced therapies to aid healing, and scaffolds used as skin
substitutes. Leading products include HYALOMATRIX and HYALOFILL, for the treatment of complex wounds such as
burns and ulcers. The dermal products are commercialized through a network of distributors, primarily in the United States,
Europe, Latin America, and the Middle East. Products cleared for sale in the United States include HYALOMATRIX,
HYALOFILL, HYALOGRAN, HYALOSAFE, and HYALOMATRIX 3D. In 2014, we entered into an agreement with
Medline Industries, Inc. with a current expiration date of December 31, 2022 to commercialize HYALOMATRIX in the
United States.
Our aesthetic dermatology product is a dermal filler based on our proprietary, chemically modified, cross-linked
HA, and it is commercially available in select countries in the Middle East. Internationally, this product is marketed under
the ELEVESS name. In the United States, the trade name is HYDRELLE, although the product is not currently marketed in
the United States.
Surgical
Our surgical business consists of products used to prevent post-surgical adhesions after abdominal-pelvic, spinal,
and ear, nose, and throat (“ENT”) surgeries. HYALOBARRIER is a clinically proven, post-operative adhesion barrier for
use in the abdominopelvic area. The product is currently commercialized in Europe, the Middle East, and certain African and
Asian countries through a distribution network, but it is not approved for sale in the United States.
Surgical adhesions occur when fibrous bands of tissues form between adjacent tissue layers during the wound
healing process. Although surgeons attempt to minimize the formation of adhesions, they nevertheless occur quite frequently
after surgery. Adhesions in the abdominal and pelvic cavity can cause particularly serious problems such as intestinal
blockage following abdominal surgery and infertility following pelvic surgery. Fibrosis following spinal surgery can
complicate re-operation and may cause pain.
6
We also offer several products used in connection with the treatment of ENT disorders. The lead products are
MEROGEL, a woven fleece nasal packing, and MEROGEL INJECTABLE, a thick, viscous hydrogel composed of cross-
linked hyaluronic acid—a biocompatible agent that creates a moist wound-healing environment. We have partnered with
Medtronic XoMed, Inc. (“Medtronic”) for worldwide distribution of these ENT products.
Other
Our other products include our ophthalmic and veterinary products, which are legacy products and not a part of our
core business. Our ophthalmic business includes injectable, high molecular weight HA products used as viscoelastic agents
in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. These products coat, lubricate,
and protect sensitive tissue such as the endothelium, and they function to maintain the shape of the eye, thereby facilitating
ophthalmic surgical procedures. Our veterinary product, HYVISC, is a high molecular weight injectable HA product for the
treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. HYVISC has
viscoelastic properties that lubricate and protect the tissues in horse joints. HYVISC is distributed by Boehringer Ingelheim
Vetmedica, Inc. (“Boehringer”) in the United States and in selected countries in the Middle East.
See Note 3 “Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic
Information” to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for a
discussion regarding our segments and geographic sales.
See also the section captioned “Risk Factors—Risks Related to Our Commercialization Activities—We experience
quarterly sales volume variation, which makes our future results difficult to predict and makes period-to-period comparisons
potentially not meaningful” for a discussion regarding the effect that quarterly sales volume variation could have on our
business and financial performance.
See also the section captioned “Risk Factors —Risks Related to Our Business and Competitive Position—A
significant portion of our revenues are derived from a small number of customers, the loss of which could materially adversely
affect our business, financial condition and results of operations” for a discussion regarding our dependence on large-volume
customers and the effects that the loss of any such customer could have on our business and financial performance.
See also the section captioned “Risk Factors—Risks Related to Our Business and Industry—Our manufacturing
processes involve inherent risks, and disruption could materially adversely affect our business, financial condition and results
of operations” for a discussion of the sources and availability of raw materials related to the manufacture of our products.
Research and Development of Potential Products
Our research and development efforts primarily consist of the development of new medical applications for our HA-
based technology, the management of clinical trials for certain product candidates, the preparation and processing of
applications for regulatory approvals or clearances at all relevant stages of product development, and process development
and scale-up manufacturing activities for our existing and new products. Our development focus is orthopedic and
regenerative medicines and includes products for tissue protection, repair, and regeneration. For the years ended
December 31, 2018, 2017 and 2016, these expenses were $18.2 million, $18.8 million, and $10.7 million, respectively. We
anticipate that we will continue to commit significant resources to, and increase our aggregate spending on, research and
development activities, including in relation to preclinical activities and clinical trials, in the future.
7
Our third generation, single-injection osteoarthritis product under development in the United States, CINGAL,
which is composed of our proprietary cross-linked HA material combined with an approved steroid and is designed to provide
both short- and long-term pain relief to patients, is our lead pipeline product and a critical component of our growth strategy.
We completed an initial CINGAL Phase III clinical trial, including the associated statistical analysis for 368 enrolled patients,
during the fourth quarter of 2014 with data indicating that the product met all primary and secondary endpoints relative to
placebo set forth for the trial. During the first half of 2015, we completed a CINGAL retreatment study with 242 patients who
had participated in the Phase III clinical trial and reported safety data related to the retreatment study. This initial Phase III
clinical trial and the associated retreatment study supported the Health Canada and CE Mark approval of the product, and the
commercial launch of the product in both Canada and the European Union occurred in the second quarter of 2016. In the
United States, after discussions with the U.S. Food and Drug Administration (“FDA”) related to the regulatory pathway for
CINGAL, we conducted a formal meeting with the FDA’s Office of Combination Products (“OCP”) to present and discuss
our data in September 2015, and we submitted a formal request for designation with OCP a month later. In its response to
our formal request for designation, OCP assigned the product to the FDA’s Center for Drug Evaluation and Research
(“CDER”) as the lead agency center for premarket review and regulation. We then held discussions with CDER to understand
the requirements for submitting a New Drug Application (“NDA”) for CINGAL. We held a meeting with CDER in September
2016 to align on an approval framework and on submission requirements for this NDA for CINGAL, including the execution
of an additional Phase III clinical trial to supplement our existing CINGAL pivotal study data. We submitted an
Investigational New Drug Application (“IND”) in late 2016, and discussions with CDER indicated that they did not have
objections to our clinical protocol design. As a result, we commenced work on this second Phase III clinical trial (“CINGAL
16-02 Study”) in the first quarter of 2017, and the first patient was treated in the second quarter of 2017. Enrollment of the
576 patients in this second Phase III clinical trial was completed during October 2017, and we completed the six-month
patient follow-up in April 2018. We received and analyzed the data from the CINGAL 16-02 Study during the second quarter
of 2018, and, while substantial pain reduction associated with CINGAL was evident at each measurement point, we
determined based on statistical analysis that it did not meet the primary study endpoint of demonstrating a statistically
significant difference in pain reduction between CINGAL and the approved steroid component of CINGAL at the six-month
time point. In the third quarter of 2017, we initiated an additional three-month extended follow-up study in conjunction with
the CINGAL 16-02 Study to investigate the efficacy of CINGAL over this longer period. The first patients were enrolled in
this follow-up study in the fourth quarter of 2017 and we completed the nine-month patient follow-up in the third quarter of
2018. Given the totality of the results from our studies related to CINGAL, we have evaluated multiple strategies to optimize
the potential U.S. regulatory pathway for the product. We recently met with FDA to discuss this potential approval pathway
for CINGAL in the United States moving forward. In the meeting, FDA indicated that an additional Phase III clinical trial
would be necessary to support U.S. marketing approval for CINGAL, and we are continuing to align with FDA on the
parameters and requirements for this additional clinical trial, which we expect to commence once alignment is achieved.
We have several research and development programs underway for new products, including for HYALOFAST (in
the United States), an innovative product for cartilage tissue repair, and other early stage regenerative medicine development
programs. HYALOFAST, which received CE Mark approval in September 2009, is commercially available in Europe and
certain international countries. During the first quarter of 2015, we submitted an Investigational Device Exemption (“IDE”)
for HYALOFAST to the FDA, which was approved in July 2015. We commenced patient enrollment in a clinical trial in
December 2015, and we are advancing site initiations and patient enrollment activities. In the second quarter of 2016, a
supplement to the HYALOFAST IDE was approved to expand the inclusion criteria for the clinical study, which was aimed
at decreasing the time needed to complete the clinical trial. The previously-described voluntary recall of certain production
lots of our HYAFF-based products did not impact the HYALOFAST clinical trial, as the product used in the clinical trial is
not sourced from the affected production lots. Given the changing medical landscape with respect to the randomization arm
for this trial, the microfracture procedure, we are actively pursuing alternative strategies to accelerate patient enrollment.
In the third quarter of 2017, we submitted an application to the FDA for 510(k) clearance of an injectable, HA-based
surgical bone repair product that is reabsorbed by the body and replaced by the growth of new bone during the healing process.
The 510(k) clearance was received from the FDA in December 2017, and we expect to make this bone repair product
commercially available in the United States during 2019 utilizing the previously-described hybrid commercial approach. In
addition to other early stage research and development initiatives we are currently undertaking, we are working to expand
our regenerative medicine pipeline with a new product candidate in the form of an implant for rotator cuff repair utilizing our
proprietary solid HA, which could be used to repair partial and full-thickness rotator cuff tears. We finalized development of
an initial product prototype during the fourth quarter of 2018, and we are performing important preclinical testing of and
developing the surgical instrumentation for the potential product.
We are also currently proceeding with other research and development programs, one of which utilizes our
proprietary HA technology to treat pain associated with common repetitive overuse injuries, such as lateral epicondylitis, also
known as tennis elbow. We submitted a CE Mark application for this treatment during the first quarter of 2016 and received
a CE Mark for the treatment of pain associated with tennis elbow in December 2016. We began work towards a post-market
8
clinical study in relation to the CE Mark for this product in the fourth quarter of 2018. Outside of the United States, this
product is marketed under the trade name ORTHOVISC-T. Additionally, in the second quarter of 2016, we submitted an IDE
to the FDA to conduct a Phase III clinical trial for this treatment, which was approved by the FDA in June 2016. We also
have several other research and development programs underway focused on expanding the indications of our current
products, including MONOVISC. Notwithstanding those internal programs, the previously-disclosed program conducted and
funded by Mitek seeking to expand MONOVISC’s indication to include treatment of pain associated with osteoarthritis of
the hip was cancelled in the fourth quarter of 2018 after the performance of an independent interim analysis required by the
related clinical protocol. During 2019, we will also be performing post-market clinical work in relation to the CE Mark for
MONOVISC.
In June 2015, we entered into an agreement with the Institute for Applied Life Sciences at the University of
Massachusetts Amherst to collaborate on research to develop a therapy for rheumatoid arthritis. The purpose of this research
was to develop a novel modality for the treatment of rheumatoid arthritis. The agreement with the University of Massachusetts
Amherst was extended in January 2018, and it was terminated in October 2018 after discussions between the parties. In
January 2018, we entered into an agreement with the University of Liverpool to develop an injectable mesenchymal stem cell
therapy for the treatment of age-related osteoarthritis with the goal of bringing a therapeutics candidate through clinical trials
to market to meet an unmet therapeutic need. We are currently in the preclinical phase of this program and aim to finalize
proof of concept during the second quarter of 2020.
Our research and development efforts may not be successful in (1) developing our existing product candidates,
(2) expanding the therapeutic applications of our existing products, or (3) resulting in new applications for our HA
technology. There is also a risk that we may choose not to pursue development of potential product candidates. We may not
be able to obtain regulatory approval for any new applications we develop. Furthermore, even if all regulatory approvals are
obtained, there can be no assurances that we will achieve meaningful sales of such products or applications.
See also the section captioned “Risk Factors—Risks Related to Our Product Development and Regulatory
Compliance —Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental approvals for our
products may have a material adverse effect on our business, financial condition and results of operations.” for a discussion
regarding the impact of government regulations on our product development activities.
Patent and Proprietary Rights
Our products and trademarks, including our corporate name, product names, and logos, are proprietary. We rely on
a combination of patent protection, trade secrets and trademark laws, license agreements, and confidentiality and other
contractual provisions to protect our proprietary information.
We have a policy of seeking patent protection for patentable aspects of our proprietary technology. In the United
States, we own 19 patents, 1 of which is co-owned with other parties, license 10 patents, and have 4 patent applications
currently pending. These U.S. patents have expiration dates through 2030. Internationally, we own 181 patents, 7 of which
are co-owned with other parties, license 71 patents, and have 29 patent applications currently pending. Outside of the United
States, we own, co-own, license, or have filed for patents in 39 jurisdictions. Our international patents have expiration dates
through 2032. In 2018, we were granted 29 new patents in Austria, Czech Republic, Denmark, France, Germany, Great
Britain, Ireland, Italy, the Netherlands, Poland, Spain, Sweden, and Switzerland. Many of these patents, including all licensed
patents, belong to the Anika S.r.l. patent estate, which is extensive and partly intertwined with its former parent company
Fidia Farmaceutici S.p.A. (“Fidia”) through a patent licensing agreement that provides Anika S.r.l. with access to certain of
Fidia’s patents to the extent required to support Anika S.r.l.’s products. In 2018, 3 of the patents belonging to the Anika S.r.l.
patent estate expired in the United States, and 13 expired internationally. We intend to seek patent protection for products
and processes developed in the course of our activities when we believe such protection is in our best interests and when the
cost of seeking such protection is not inordinate relative to the potential benefits.
Other entities have filed patent applications for, or have been issued patents concerning, various aspects of HA-
related products or processes. In addition, the products or processes we develop may infringe the patent rights of others in
the future. Any such infringement may have a material adverse effect on our business, financial condition, and results of
operations.
9
We rely upon trade secrets and proprietary know-how for certain non-patented aspects of our technology. To protect
such information, we require certain customers and vendors, and all employees, consultants, and licensees to enter into
confidentiality agreements limiting the disclosure and use of such information. These agreements, however, may not provide
adequate protection.
See also the section captioned “Risk Factors—Risks Related to Our Intellectual Property—We may be unable to
adequately protect our intellectual property rights, which could have a material impact on our business and future financial
results” for a discussion of the risks we face with respect to protecting intellectual property we develop.
We have granted Mitek an exclusive and non-transferable, royalty-bearing license to develop, commercialize, and
sell ORTHOVISC and MONOVISC in the United States pursuant to the Mitek ORTHOVISC Agreement and the Mitek
MONOVISC Agreement. These agreements include a license to manufacture and have manufactured such products in the
event that we are unable to supply Mitek with ORTHOVISC or MONOVISC in accordance with the terms of the relevant
agreement. We have also granted Mitek the exclusive, royalty free right to use the trademarks ORTHOVISC and MONOVISC
in connection with the marketing, distribution, and sale of the licensed products within the United States.
Government Regulation
The clinical development, manufacturing, and marketing of our products are subject to governmental regulation in
the United States, the European Union, and other territories worldwide. Various statutes, regulations and interpretations
thereof, directives, and guidelines, including the Food, Drug, and Cosmetic Act in the United States, govern the development,
design, non-clinical and clinical research, testing, manufacture, safety, efficacy, labeling, packaging, storage, record keeping,
premarket clearance or approval, adverse event reporting, advertising, and promotion of our products. Product development
and approval within these various regulatory frameworks takes a number of years and involves the expenditure of substantial
resources. Pharmaceutical and medical device manufacturers are also inspected regularly by the FDA and other applicable
regulatory bodies.
Medical products regulated by the FDA are generally classified as drugs, biologics, or medical devices, and the
current classification standards for our current or future may be altered over time. Drugs and biologic products undergo
rigorous preclinical testing prior to beginning clinical trials. Clinical trials for new drugs or biologic products include Phase
I trials in healthy volunteers to understand safety, dosage tolerance, and pharmacokinetics, Phase II trials in a limited patient
population to identify initial efficacy and side effects, and Phase III pivotal trials to statistically evaluate the safety and
efficacy of the product. Medical devices intended for human use are classified into three categories (Class I, II or III) on the
basis of the controls deemed reasonably necessary by the FDA to assure their safety and effectiveness. Class II devices are
cleared for marketing under the premarket notification 510(k) regulatory pathway, which may include clinical testing.
Class III devices require pre-market approval based on valid scientific evidence of safety and effectiveness, including
evidence elicited through appropriate clinical testing. The failure to adequately demonstrate the quality, safety, and efficacy
of a product under development can delay or prevent regulatory approval of the product. In order to gain marketing approval,
we must submit to the relevant regulatory authority for review information on the quality aspects of the product as well as
the non-clinical and clinical data. The FDA undertakes this review in the United States.
In the European Union, medical devices must be CE Marked in order to be marketed. CE marking a device involves
working with a Notified Body, and in some cases a Competent Authority, to demonstrate that the device meets all applicable
requirements of the Medical Devices Directive and that our Quality Management System is compliant. Drug approval in the
European Union follows one of several possible processes: (i) a centralized procedure involving members of the European
Medicines Agency’s Committee for Medicinal Products for Human Use; (ii) a “mutual recognition procedure” in which an
individual country's regulatory agency approves the product followed by “mutual recognition” of this approval by regulatory
agencies of other countries; or (iii) a decentralized procedure in which the approval is sought through the regulatory agencies
of multiple countries at the same time.
10
Approval timelines can range from several months to several years, or applications can be denied entirely. Product
or product component classifications as drugs, biologics, or medical devices may change over time due to new regulations or
augmented interpretation of data or current regulations. The approval process can be affected by a number of factors. For
example, additional studies or clinical trials may be requested during the review, which may delay marketing approval and
involve unbudgeted costs. As a condition of approval, the regulatory agency may require post-marketing surveillance to
monitor for adverse effects, and may require other additional studies, as it deems appropriate. After approval for an initial
indication, further clinical studies are generally necessary to gain approval for any additional indications. The terms of any
approval, including labeling content, may be more restrictive than expected and could affect the marketability of a product.
As a condition of approval, the relevant regulatory agency requires that the product continues to meet applicable
regulatory requirements related to quality, safety, and efficacy, and it requires strict procedures to monitor and report any
adverse effects. Where adverse effects occur or may occur, the regulatory agency may require additional studies or changes
to the labeling. Compelling new “adverse” data may result in a product approval being withdrawn at any stage following
review by an agency and discussion with the product manufacturer.
The branch of the FDA responsible for product marketing oversight routinely reviews company marketing practices
and also may impose pre-clearance requirements on materials intended for use in marketing of approved drug products. We
are also subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback and
false claims laws. Similar review and regulation of advertising and marketing practices exists in the other geographic areas
where we operate.
The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply
with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, including, without
limitation, issuing an FDA Form 483 notice of inspectional observations or a warning letter, imposing civil money penalties,
suspending or delaying issuance of approvals, requiring product recall, imposing a total or partial shutdown of production,
withdrawal of approvals or clearances already granted, pursuing product seizures, consent decrees or other injunctive relief,
or criminal prosecution through the Department of Justice. The FDA can also require us to repair, replace, or refund the cost
of products that we manufactured or distributed. Outside the United States, regulatory agencies may exert a range of similar
powers.
We are also subject to various laws and regulations concerning data privacy. Changing privacy laws in the United
States, Europe, Brazil and elsewhere, including the adoption by the European Union of the General Data Protection
Regulation (“GDPR”) effective in May 2018, create new individual privacy rights and impose increased obligations on
companies handling personal data. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the
consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and
confidentiality of the personal data, data breach notification, and the use of third party processors in connection with the
processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the E.U. to the
U.S. and empowers enforcement agencies to impose large penalties for noncompliance, including the potential for fines of
up to €20 million or 4% of the annual global revenues of the infringer, whichever is greater.
See also the sections captioned “Risk Factors—Risks Related to Our Product Development and Regulatory
Compliance—Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental approvals for our
products may have a material adverse effect on our business, financial condition and results of operations,” “Risk Factors—
Risks Related to Our Product Development and Regulatory Compliance—Once obtained, we cannot guarantee that FDA or
international product approvals will not be withdrawn or that relevant agencies will not require other corrective action, and
any withdrawal or corrective action could materially affect our business and financial results,” “Risk Factors—Risks Related
to Our Product Development and Regulatory Compliance—Our operations and products are subject to extensive regulation,
compliance with which is costly and time consuming, and our failure to comply may result in substantial penalties, including
recalls of our products,” “Risk Factors—Risks Related to Our Product Development and Regulatory Compliance—Any
changes in FDA or international regulations related to product approval, including those that apply retroactively, could
adversely affect our competitive position and materially affect our business and financial results,” and “Risk Factors—Risks
Related to Our Product Development and Regulatory Compliance—We are subject to various healthcare laws and
regulations, and any failure to comply with applicable laws could subject us to significant liability and harm our business”
for a discussion regarding the potential impact of government regulations on our business and financial results.
11
Competition
We compete with many companies including large pharmaceutical firms and specialized medical products
companies across all of our product lines. Many of these companies have substantially greater financial resources, larger
research and development staffs, more extensive marketing and manufacturing organizations, and more experience in the
regulatory processes than we have. We also compete with academic institutions, government agencies, and other research
organizations, which may be involved in the research and development and commercialization of products. Many of our
competitors also compete against us in securing relationships with collaborators for their research and development and
commercialization programs.
We compete with other market participants primarily on the efficacy of our products, our products’ reputation for
safety, our focus on HA-based products, and the breadth of our HA-based product portfolio. Other factors that impact
competition in our industry are the timing and scope of regulatory approvals, the availability of raw material and finished
product supply, marketing and sales capability, reimbursement coverage, product pricing, and patent protection. Some of the
principal factors that may affect our ability to compete in the HA development and commercialization markets include:
The quality and breadth of our continued development of our technology portfolio;
Our ability to complete successful clinical studies and obtain FDA marketing and foreign regulatory approvals
prior to our competitors;
The execution by our key partners of their commercial strategies for our products and our ability to manage our
relationships with those key partners;
The successful execution of our commercial strategies, including our hybrid commercial approach;
Our ability to recruit and retain skilled employees; and
The availability of capital resources to fund strategic activities related to the significant expansion of our
business or product portfolio, including through acquisitions of third parties or certain assets.
We are aware of several companies that are developing and/or marketing products utilizing HA for a variety of
human applications. In some cases, competitors have already obtained product approvals, submitted applications for approval,
or commenced human clinical studies, either in the United States or in certain foreign countries. All of our products face
substantial competition. There exist major worldwide competing products, made from HA and other materials, for use in
orthopedics, surgical adhesion prevention, advanced wound care, ENT, cosmetic dermatology, ophthalmic surgery, and the
treatment of equine osteoarthritis. There is a risk that we will be unable to compete effectively against our current or future
competitors. Additionally, legislation and regulation aimed at curbing rising healthcare costs has resulted in a consolidation
trend in the healthcare industry to create larger companies, including hospitals, with greater market power. In turn, this has
led to greater and more intense competition in the provision of products and services to market participants. Important market
makers, like group purchasing organizations and integrated delivery networks, have increased their negotiating leverage, and
if these market makers demand significant price concessions or if we are excluded as a supplier by these market makers, our
product revenue could be adversely impacted.
See also the sections captioned “Risk Factors—Risks Related to Our Business and Competitive Position—
Substantial competition could materially affect our financial performance,” “Risk Factors—Risks Related to Our Business
and Competitive Position—We are dependent upon marketing and distribution partners and the failure to maintain strategic
alliances on acceptable terms will have a material adverse effect on our business, financial condition, and results of
operations,” “Risk Factors—Risks Related to Our Commercialization Activities—Our business may be adversely affected if
consolidation in the healthcare industry leads to demand for price concessions or if we are excluded from being a supplier
by a group purchasing organization or similar entity,” “Risk Factors—Risks Related to Our Business and Industry—We
actively explore acquisitions as a part of our future growth strategy, which exposes us to a variety of risks that could adversely
affect our business operations,” and “Risk Factors—Risks Related to Our Business and Industry—Attractive acquisition
opportunities may not be available to us” for additional discussion of the impact competition could have on our business and
financial results.
12
Employees
As of December 31, 2018, we had 133 employees, 24 of whom were located outside the United States. We consider
our relations with our employees to be good. None of our U.S. employees are represented by labor unions, but certain
employees based in Italy are represented by unions, adding complexity and additional risks to the wage and employment
decision processes.
Environmental Laws
We believe that we are in compliance with all foreign, federal, state, and local environmental regulations with respect
to our manufacturing facilities and that the cost of ongoing compliance with such regulations does not have a material effect
on our operations.
Product Liability
The testing, marketing, and sale of human health care products entails an inherent risk of allegations of product
liability, and we cannot assure that substantial product liability claims will not be asserted against us. Although we have not
received any material product liability claims to date and have coverage under our insurance policy of $5.0 million per
occurrence and $5.0 million in the aggregate, we cannot assure that if material claims arise in the future, our insurance will
be adequate to cover all situations. Moreover, we cannot assure that such insurance, or additional insurance, if required, will
be available in the future or, if available, will be available on commercially reasonable terms. Any product liability claim, if
successful, could have a material adverse effect on our business, financial condition, and results of operation.
Available Information
Our Annual Reports on Form 10-K, including our consolidated financial statements, Quarterly Reports on Form 10-
Q, Current Reports on Form 8-K, and other information, including amendments and exhibits to such reports, filed or furnished
pursuant to the Securities Exchange Act of 1934, as amended, are available free of charge in the “SEC Filings” section of our
website located at http://www.anikatherapeutics.com, as soon as reasonably practicable after the reports are filed with or
furnished to the SEC. The information on our website is not part of this Annual Report on Form 10-K. Reports filed with the
SEC may be viewed at www.sec.gov.
ITEM 1A. RISK FACTORS
Our operating results and financial condition have varied in the past and could vary significantly in the future
depending on a number of factors. You should consider carefully the risks and uncertainties described below, in addition to
the other information contained in this Annual Report on Form 10-K, before deciding whether to purchase our common stock.
If any of the following risks actually occurs, our business, financial condition, results of operations, and future prospects
could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could
lose part or all of your investment.
13
Risks Related to Our Business and Competitive Position
Our financial performance depends on the continued sales growth and increasing demand for our products and we may
not be able to successfully manage the expansion of our operations.
Our future success depends on substantial growth in product sales. There can be no assurance that such growth can
be achieved or, if achieved, sustained. There can be no assurance that, even if substantial growth in product sales and the
demand for our products is achieved, we will be able to:
Maintain and develop the necessary manufacturing capabilities;
Develop and successfully implement appropriate new commercial models to generate increased sales or obtain
the assistance of additional marketing partners;
Attract, retain, and integrate required key personnel; and
Implement the financial, accounting, and management systems needed to manage our overall business and
growing demand for our products.
Our failure to successfully manage future growth could have a material adverse effect on our business, financial
condition, and results of operations.
Substantial competition could materially affect our financial performance.
We compete with many companies, including large pharmaceutical companies, specialized medical products
companies, and healthcare companies. Many of these companies have substantially greater financial resources, larger research
and development staffs, more extensive intellectual technology portfolios, more extensive marketing and manufacturing
organizations, and more experience in the regulatory process than us. We also compete with academic institutions,
government agencies, and other research organizations that may be involved in research, development, and commercialization
of products similar to our own. Because a number of companies are developing or have developed HA products for similar
applications and have received FDA approval, the successful commercialization of a particular product will depend in part
upon our ability to complete clinical studies and obtain FDA marketing and foreign regulatory approvals prior to our
competitors, or, if regulatory approval is not obtained prior to our competitors, to identify markets for our products that may
be sufficient to permit meaningful sales of our products. For example, we are aware of several companies that are developing
and/or marketing products utilizing HA for a variety of human applications. In some cases, competitors have already obtained
product approvals, submitted applications for approval, or have commenced human clinical studies, either in the United States
or in certain foreign countries. For example, certain HA products made by our competitors for the treatment of osteoarthritis
in the knee received FDA approval before ours and have been marketed in the United States since 1997, as well as select
markets in Canada, Europe, and other countries. In addition, the market for our current or future products could be adversely
impacted if disruptive technologies or modalities are developed by third parties. There can be no assurance that we will be
able to compete against current or future competitors or that competition will not have a material adverse effect on our
business, financial condition, and results of operations.
A significant portion of our revenues are derived from a small number of customers, the loss of which could materially
adversely affect our business, financial condition and results of operations.
We have historically derived the majority of our revenues from a small number of customers who resell our products
to end-users, and most of these customers are significantly larger companies than us. For the year ended December 31, 2018,
five customers accounted for 86% of product revenue, with Mitek alone accounting for 73% of product revenue. We expect
to continue to be dependent on a small number of large customers, especially Mitek, for the majority of our revenues in the
near-term future. The failure of these customers to purchase our products in the amounts they historically have or in amounts
that we expect would seriously harm our business.
In addition, if present and future customers terminate their purchasing arrangements with us, significantly reduce or
delay their orders, or seek to renegotiate their agreements on terms less favorable to us, our business, financial condition, and
results of operations will be adversely affected. If we accept terms less favorable than the terms of the current agreements,
such renegotiations may have a material adverse effect on our business, financial condition, and/or results of operations.
Furthermore, in any future negotiations we may be subject to the perceived or actual leverage that these customers may have
given their relative size and importance to us. Any termination, change, reduction, or delay in orders could seriously harm
14
our business, financial condition, and results of operations. Accordingly, unless and until we diversify and expand our
customer base, or develop alternative commercial strategies, our future success will significantly depend upon the timing and
size of future purchases by our largest customers, and the financial and operational success of these customers. The loss of
any one of our major customers or the delay of significant orders from such customers, even if only temporary, could reduce
or delay our recognition of revenues, harm our reputation in the industry, and reduce our ability to accurately predict cash
flow, and, as a consequence, it could seriously harm our business, financial condition, and results of operations.
Our license agreements with Mitek provide substantial control of the U.S. marketing and development of MONOVISC
and ORTHOVISC to Mitek, and Mitek’s actions could have a material impact on our business, financial condition and
results of operations.
The Mitek MONOVISC Agreement and Mitek ORTHOVISC Agreement provide Mitek with, among other things,
the exclusive right to market and sell MONOVISC and ORTHOVISC in the United States, unilateral decision-making
authority over the sale, price, and promotion of MONOVISC and ORTHOVISC, substantial control over the future
development of MONOVISC and ORTHOVISC related to the treatment of pain associated with osteoarthritis, a license to
manufacture and have manufactured such products in the event that we are unable to supply Mitek with ORTHOVISC or
MONOVISC in accordance with the terms of the relevant agreement, and certain rights of first refusal with respect to future
products we develop for the treatment of pain associated with osteoarthritis. In exchange, Mitek pays us a transfer price
calculated with reference to historical end-user prices in the market and a fixed royalty on their net product sales. As Mitek
accounts for a large percentage of our yearly revenue and has unilateral decision-making authority over in-market activities,
including end-user pricing and discounts, reimbursement strategy, and overall promotion strategy, actions taken by Mitek
could impact our ability to predict and generate revenue and have a material impact on our business, financial condition, and
results of operations.
We are dependent upon marketing and distribution partners and the failure to maintain strategic alliances on acceptable
terms will have a material adverse effect on our business, financial condition, and results of operations.
Though we intend to implement a hybrid commercial approach in the United States in the near-term and evaluate
future opportunities for the optimal commercial approach, our success will remain dependent, in part, upon the efforts of our
marketing and distribution partners and the terms and conditions of our relationships with such partners. One partner, Mitek
accounted for 73% of our product revenue in fiscal year 2018. We cannot assure you that our partners, including Mitek, will
not seek to renegotiate their current agreements on terms less favorable to us or terminate such agreements. A failure to renew
these partnerships on terms satisfactory to us, or at all, could result in a material adverse effect on our operating results.
We continue to seek to establish long-term distribution relationships in regions and countries not covered by existing
agreements, and we may need to obtain the assistance of additional marketing partners to bring new and existing products to
market and to replace certain marketing partners. There can be no assurance that we will be able to identify or engage
appropriate distribution or collaboration partners or effectively transition to any such new partnerships. The failure to establish
strategic partnerships for the marketing and distribution of our products on acceptable terms and within our planned
timeframes could have a material adverse effect on our business, financial condition, and results of operations.
As our international sales and operations grow, we could become increasingly subject to additional economic, political,
and other risks that could harm our business.
Since we manufacture our products for sale worldwide, our business is subject to risks associated with doing business
internationally. During the years ended December 31, 2018, 2017, and 2016, 19%, 20%, and 19%, respectively, of our product
sales were to international distributors. We continue to be subject to a variety of risks, which could cause fluctuations in the
results of our international and domestic operations. These risks include:
The impact of recessions and other economic conditions in economies, including Europe in particular, outside
the United States;
Instability of foreign economic, political, and labor conditions;
15
Unfavorable labor regulations applicable to our European operations, such as severance and the unenforceability
of non-competition agreements in the European Union;
The impact of strikes, work stoppages, work slowdowns, grievances, complaints, claims of unfair labor
practices, or other collective bargaining disputes;
Difficulties in complying with restrictions imposed by regulatory or market requirements, tariffs, or other trade
barriers or by U.S. export laws;
Imposition of government controls limiting the volume of international sales;
Longer accounts receivable payment cycles;
Potentially adverse tax consequences, including, if required or applicable, difficulties transferring funds
generated in non-U.S. jurisdictions to the United States in a tax efficient manner;
Difficulties in protecting intellectual property, especially in international jurisdictions;
Difficulties in managing international operations; and
Burdens of complying with a wide variety of foreign laws.
Our success depends, in part, on our ability to anticipate and address these and any new risks. We cannot guarantee
that these or other factors will not adversely affect our business or operating results.
Risks Related to Our Commercialization Activities
We cannot be certain that we will be successful or timely in implementing changes to our current commercial model in
the United States, including the hybrid commercial approach we intend to utilize for the commercialization of our
injectable, HA-based surgical bone repair product and certain potential future products, and our failure to do so could
negatively impact our business and financial results.
For near-term opportunities in the U.S. market, including for our injectable, HA-based surgical bone repair product,
we intend to utilize hybrid commercial approach that would see us balance a small direct model with an optimal form of
strategic partnership. For longer-term future products in the U.S. market, we intend to evaluate the appropriate commercial
model for each on a case-by-case basis, based on market dynamics and other factors. These models could include direct sales,
distribution partnerships, or a hybrid of those forms. We cannot be certain that we will be successful in implementing these
models, including the hybrid commercial approach, as we may not be able to attract or retain the sophisticated personnel
required for such approach, to identify or negotiate favorable or acceptable terms with a desirable strategic partner, to timely
execute on our strategies, or to generate meaningful sales of our products as a result of other market dynamics. Our failure to
successfully or timely augment our current commercial model could have an adverse material effect on our business, financial
condition, and results of operations.
We are facing a delay in the pathway to commercialize our CINGAL product in the United States, and we may face other
unforeseen difficulties and delays in achieving regulatory approval for CINGAL, which could affect our business and
financial results.
In the second quarter of 2018, we received and analyzed the results of our second Phase III clinical trial for CINGAL
and found that, while substantial pain reduction associated with CINGAL was evident at each measurement point, the data
did not meet the primary study endpoint of demonstrating a statistically significant difference in pain reduction between
CINGAL and the approved steroid component of CINGAL at the six-month time point. After completing the analysis of the
data related to the totality of our studies for CINGAL, we recently met with FDA to discuss a potential approval pathway for
CINGAL in the United States moving forward. In the meeting, FDA indicated that an additional Phase III clinical trial would
be necessary to support U.S. marketing approval for CINGAL, and we are continuing to align with FDA on the parameters
and requirements for this additional clinical trial, which we expect to commence once alignment is achieved. Because these
results or other unforeseen future developments could have a substantial negative impact on the timeline for and the cost
associated with a potential CINGAL regulatory approval, if any, our overall business condition, financial results, and
competitive position could be affected.
16
We must achieve market acceptance of our products in order to be successful in the future.
Our success will depend in part upon the acceptance of our existing and future products by the medical community,
hospitals, physicians, other health care providers, third-party payers, and end-users. Such acceptance may depend upon the
extent to which the medical community and end-users perceive our products as safer, more effective, or more cost-competitive
than other similar products. Ultimately, for our new products to gain general market acceptance, it may also be necessary for
us to develop marketing partners or viable commercial strategies for the distribution of our products. There can be no
assurance that our new products will achieve significant market acceptance on a timely basis, or at all. Failure of some or all
of our future products to achieve significant market acceptance could have a material adverse effect on our business, financial
condition, and results of operations.
Sales of our products are largely dependent upon third party reimbursement and our performance may be harmed by
health care cost containment initiatives or decisions of individual third party payers.
In the United States and other foreign markets, health care providers, such as hospitals and physicians, that purchase
health care products, such as our products, generally rely on third party payers, including Medicare, Medicaid, and other
health insurance and managed care plans, to reimburse all or part of the cost of the health care product. We have generally
depended upon the distributors of our products to secure reimbursement and reimbursement approvals. Reimbursement by
third party payers, both in the United States and internationally, may depend on a number of factors, including the individual
payer’s determination that the use of our products is clinically useful and cost-effective, medically necessary, and not
experimental or investigational. Since reimbursement approval is required from each payer individually, seeking such
approvals can be a time consuming and costly process which, in the future, could require us or our marketing partners to
provide supporting scientific, clinical, and cost-effectiveness data for the use of our products to each payer separately.
Significant uncertainty exists as to the reimbursement status of newly approved health care products, and any failure or delay
in obtaining reimbursement approvals can negatively impact sales of our new products. In addition, we cannot be certain that
payers who currently provide reimbursement for our products will continue to provide such reimbursement in the future, and
such payer decisions could negatively impact the sales of our current or future products.
In addition, third party payers are increasingly attempting to contain the costs of health care products and services
by limiting both coverage and the level of reimbursement for new therapeutic products and by refusing, in some cases, to
provide coverage for uses of approved products for disease indications for which the FDA, or the applicable foreign regulatory
agency, has granted marketing approval. Also, the U.S. Congress, certain state legislatures, and certain foreign governments
and regulatory agencies have considered reforms, including, among other items, the potential repeal of the Affordable Care
Act in the United States, which may affect current reimbursement practices and create additional uncertainty about the pricing
of our products, including the potential implementation of controls on health care spending through limitations on the growth
of Medicare and Medicaid spending. There can be no assurance that third party reimbursement coverage will be available or
adequate for any products or services developed by us. Outside the United States, the success of our products is also dependent
in part upon the availability of reimbursement and health care payment systems. Domestic and international reimbursement
laws and regulations may change from time to time. Lack of adequate coverage and reimbursement provided by governments
and other third party payers for our products and services, including continuing coverage for MONOVISC and ORTHOVISC
in the United States, and any change of classification by the Centers for Medicare and Medicaid Services for ORTHOVISC
and MONOVISC, could have a material adverse effect on our business, financial condition, and results of operations.
17
Our business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions
or if we are excluded from being a supplier by a group purchasing organization or similar entity.
Because healthcare costs have risen significantly over the past decade, numerous initiatives and reforms have been
launched by legislators, regulators, and third-party payers to curb these costs. As a result, there has been a consolidation trend
in the healthcare industry to create larger companies, including hospitals, with greater market power. As the healthcare
industry consolidates, competition to provide products and services to industry participants has become and may continue to
become more intense. This may result in greater pricing pressures and the exclusion of certain suppliers from important
markets as group purchasing organizations, independent delivery networks, and large single accounts continue to use their
market power to consolidate purchasing decisions. If a group purchasing organization excludes us from being one of their
suppliers, our net sales could be adversely impacted. We expect that market demand, government regulation, third-party
reimbursement policies, and societal pressures will continue to change the worldwide healthcare industry, which may exert
further downward pressure on the prices of our products.
We experience quarterly sales volume variation, which makes our future results difficult to predict and makes period-to-
period comparisons potentially not meaningful.
We experience quarterly fluctuations in our products sales as a result of multiple factors, many of which are outside
of our control. These quarterly fluctuations create uncertainty as to the volume of sales that we may achieve in a given period.
As a result, comparing our operating results on a period-to-period basis might not be meaningful. You should not rely on our
past results as an indication of our future performance. Our operating results could be disproportionately affected by a
reduction in revenue because a proportionately smaller amount of our expenses varies with our revenue. As a result, our
quarterly operating results are difficult to predict, even in the near term.
Risks Related to Our Product Development and Regulatory Compliance
Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental approvals for our products may
have a material adverse effect on our business, financial condition and results of operations.
Several of our current products, and any future products we may develop, will require clinical trials to determine
their safety and efficacy for United States and international marketing approval by regulatory bodies, including the FDA.
Product development and approval within the FDA framework takes a number of years and involves the expenditure of
substantial resources. There can be no assurance that the FDA will accept submissions related to our new products or the
expansion of the indications of our current products, and, even if submissions are accepted, there can be no guarantee that the
FDA will grant approval for our new products, including CINGAL, HYALOFAST, or other line extensions of our current
products, or for the expansion of indications of our current products on a timely basis, if at all. In addition to regulations
enforced by the FDA, we are subject to other existing and future federal, state, local, and foreign regulations applicable to
product approval, which may vary significantly across jurisdictions. Additional approval of existing products may be required
when changes to such products may affect the safety and effectiveness, including for new indications for use, labeling
changes, process or manufacturing changes, the use of a different facility to manufacture, process or package the device, and
changes in performance or design specifications. Failure to obtain regulatory approvals of our products, including any changes
to existing products, could have an adverse material impact on our business, financial condition, and results of operations.
Even if ultimately granted, FDA and international regulatory approvals may be subject to significant, unanticipated
delays throughout the regulatory approval process. Internally, we make assumptions regarding product approval timelines,
both in the United States and internationally, in our business planning, and any delay in approval could materially affect our
competitive position in the relevant product market and our projections related to future business results.
We cannot be certain that product approvals, both in the United States and internationally, will not include significant
limitations on the product indications, and other claims sought for use, under which the products may be marketed. The
relevant approval or clearance may also include other significant conditions of approval such as post-market testing, tracking,
or surveillance requirements. Any of these factors could significantly impact our competitive position in relation to such
products and could have a negative impact on the sales of such products.
18
Once obtained, we cannot guarantee that FDA or international product approvals will not be withdrawn or that relevant
agencies will not require other corrective action, and any withdrawal or corrective action could materially affect our
business and financial results.
Once obtained, marketing approval can be withdrawn by the FDA or comparable foreign regulatory agencies for a
number of reasons, including the failure to comply with ongoing regulatory requirements or the occurrence of unforeseen
problems following initial approval. Regulatory authorities could also limit or prevent the manufacture or distribution of our
products. Any regulatory limitations on the use of our products or any withdrawal or suspension of approval or rescission of
approval by the FDA or a comparable foreign regulatory agency could have a material adverse effect on our business,
financial condition, and results of operations.
Our operations and products are subject to extensive regulation, compliance with which is costly and time consuming,
and our failure to comply may result in substantial penalties, including recalls of our products.
The FDA and foreign regulatory bodies impose extensive regulations applicable to our operations and products,
including regulations governing product standards, packing requirements, labeling requirements, quality system and
manufacturing requirements, import restrictions, tariff regulations, duties, and tax requirements. We cannot assure you that
we will be able to achieve and maintain compliance required for FDA, CE marking, or other foreign regulatory approvals for
any or all of our operations and products or that we will be able to produce our products in a timely and profitable manner
while complying with applicable requirements.
Failure to comply with applicable regulatory requirements could result in substantial penalties, including warning
letters, fines, injunctions, civil penalties, seizure of products, total or partial suspension of production, refusal to grant pre-
market clearance or pre-market approval for devices or drugs, withdrawal of approvals, and criminal prosecution.
Additionally, regulatory authorities have the power to require the recall of our products. It also might be necessary for us, in
applicable circumstances, to initiate a voluntary recall per regulatory requirements of one or several of our products. The
imposition of any of the foregoing penalties, whether voluntarily or involuntary, could have a material negative impact on
our business, financial condition, and results of operations.
Any changes in FDA or international regulations related to product approval or approval renewal, including those
currently under consideration by FDA or those that apply retroactively, could adversely affect our competitive position
and materially affect our business and financial results.
FDA and foreign regulations depend heavily on administrative interpretation, and we cannot assure you that future
interpretations made by the FDA or other regulatory bodies, with possible retroactive effect, will not adversely affect us.
Additionally, any changes, whether in interpretation or substance, in existing regulations or policies, or any future adoption
of new regulations or policies by relevant regulatory bodies, could prevent or delay approval of our products. In the event our
future, or current, products, including HA generally, are classified, or re-classified, as human drugs, combination products,
or biologics by the FDA or an applicable international regulatory body, the applicable review process related to such products
is typically substantially longer and substantially more expensive than the review process to which they are currently subject
as medical devices. In 2018, FDA publicly indicated its intent to consider HA products for certain indications for regulation
as a drug and has indicated that industry should submit new products or indication expansions to the OCP to designate the
appropriate FDA office for review. There exists uncertainty with respect to the final interpretation, implementation, and
consequences of this development, and this or any other potential regulatory changes in approach or interpretation similar in
substance to those mentioned in this paragraph and affecting our products could materially impact our competitive position,
business, and financial results.
Additionally, the implementation of the new European Medical Device Regulation (“EU MDR”), set to take full
effect in 2020, is expected to change several aspects of the existing regulatory framework in Europe. Specifically, the EU
MDR will require changes in the clinical evidence required for medical devices, post-market clinical follow-up evidence,
annual reporting of safety information for Class III products, and bi-annual reporting for Class II products, Unique Device
Identification (“UDI”) for all products, submission of core data elements to a European UDI database prior to placement of
a device on the market, reclassification of medical devices, and multiple other labeling changes. Approvals for certain of our
currently-marketed products could be curtailed or withdrawn as a result of the implementation of the EU MDR, and acquiring
approvals for new products could be more challenging and costly. For example, the CE Mark indication for MONOVISC of
the treatment of pain associated with osteoarthritis in all synovial joints was limited to the knee joint by our notified body as
a result of the EU MDR, pending our generation of adequate data to support the broader indication previously granted. We
do not expect this limitation to have a material impact on MONOVISC’s revenue generation, but compliance with this and
any other requirements could be time consuming and costly, and our failure to comply may subject us to significant liabilities,
which could have a material adverse effect on our business, financial condition, and results of operation.
19
We may rely on third parties to support certain aspects of our clinical trials. If these third parties do not successfully carry
out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval or commercialize
our products, and our business could be substantially harmed.
We have hired experienced clinical development and regulatory staff, and we have also retained the services of
knowledgeable external service providers, including consultants and clinical research organizations, to develop and supervise
our clinical trials and regulatory processes. Despite our internal investment in staffing, we will remain dependent upon these
third-party contract research organizations to carry out portions of our clinical and preclinical research studies for the
foreseeable future. As a result, we have had and will have less control over the conduct of the clinical trials, the timing and
completion of the trials, the required reporting of adverse events, and the management of data developed through the trials
than would be the case if we were relying entirely on our own staff. Outside parties may have staffing difficulties, may
undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct
our trials. Failure by these third parties to comply with regulatory requirements or to meet timing expectations may require
us to repeat clinical or preclinical trials, which would delay the regulatory approval process, or require substantial unexpected
expenditures.
We are subject to various healthcare laws and regulations, and any failure to comply with applicable laws could subject
us to significant liability and harm our business.
Our business involves substantial interaction and collaboration with healthcare professionals, including physician
consultants, clinical investigators, and actual and potential customers. These relationships are subject to federal and state
healthcare laws, as well as equivalent foreign regulations. These statutes and regulations include, without limitation, false
claims laws, anti-kickback regulations, the Foreign Corrupt Practices Act, and the Physician Payments Sunshine Act. Any
failure to comply with these laws could subject us to significant liabilities, which could have a material adverse effect on our
business, financial condition, and results of operation.
We are subject to environmental regulations and any failure to comply with applicable laws could subject us to significant
liabilities and harm our business.
We are subject to a variety of local, state, federal, and foreign government regulations relating to the storage,
discharge, handling, emission, generation, manufacture, and disposal of toxic or other hazardous substances used in the
manufacture of our products. Any failure by us to control the use, disposal, removal, or storage of hazardous chemicals or
toxic substances could subject us to significant liabilities, which could have a material adverse effect on our business, financial
condition, and results of operations.
Risks Related to Our Business and Industry
We actively explore acquisitions as a part of our future growth strategy, which exposes us to a variety of risks that could
adversely affect our business operations.
Our business and future growth strategy includes as an important component the acquisition of businesses,
technologies, services, or products that we believe are a strategic fit with or otherwise provide value to our business. We may
fund these acquisitions by utilizing our cash, incurring debt, issuing additional shares of our common stock, or by other
means. Completed acquisitions may expose us to a number of risks and expenses, including unanticipated liabilities,
amortization expenses related to intangible assets with definite lives, or risks associated with entering new markets with
which we have limited experience or where commercial alliances with experienced partners or existing sales channels are not
available. Whether or not completed, acquisitions may result in diversion of management resources otherwise available for
ongoing development of our business and significant expenditures.
20
We may not be able to realize the expected benefits of any completed acquisitions, including growth synergies and
cost savings from the integration of acquired businesses or assets with our existing operations and technologies, as rapidly as
expected, or at all. In addition, the integration and reorganization processes for our acquisitions may be complex, costly, and
time consuming and include unanticipated issues, expenses, and liabilities. We may have difficulty in developing,
manufacturing, and marketing the products of a newly acquired company in a manner that enhances the performance of our
combined businesses or product lines and allows us to realize value from expected synergies. Moreover, we may lose key
clients or employees of acquired businesses as a result of the change in ownership to us. Following an acquisition, we may
not achieve the revenue or net income levels that justify the acquisition. Acquisitions may also result in one-time charges,
such as write-offs or restructuring charges, impairment of goodwill or acquired In-Process Research and Development, which
could adversely affect our operating results. The failure to achieve the expected benefits of any acquisition may harm our
business, financial condition, and results of operations.
Attractive acquisition opportunities may not be available to us.
We routinely consider the acquisition of other businesses. However, we may not locate suitable acquisition targets
or have the opportunity to make acquisitions of such targets on favorable terms, which could negatively impact the growth
of our business. In order to pursue such opportunities, we may require significant additional financing, which may not be
available to us on favorable terms, if at all. Our current or potential competitors, many of which have significantly greater
resources than we do, may compete with us to acquire compatible businesses, which would increase the acquisition prices
and could cause us to expend significant time and funds on acquisitions we are unable to complete.
The acquisitions we have made or may make in the future may make us the subject of lawsuits from either an acquired
company’s stockholders, an acquired company’s previous stockholders, or our current stockholders.
We may be the subject of lawsuits from either an acquired company’s stockholders, an acquired company’s previous
stockholders, or our current stockholders. These lawsuits could result from the actions of the acquisition target prior to the
date of the acquisition, from the acquisition transaction itself, or from actions after the acquisition. Defending potential
lawsuits could cost us significant expense and distract management’s attention from the operation of the business.
Additionally, these lawsuits could result in the cancellation of, or the inability to renew, certain insurance coverage that would
be necessary to protect our assets.
Customer and employee uncertainty about the effects of any acquisitions could harm us.
Customers of any companies we acquire may, in response to the consummation of the acquisitions, delay or defer
purchasing decisions, which could adversely affect the success of our acquired businesses. Similarly, employees of acquired
companies may experience uncertainty about their future roles, which may adversely affect our ability to attract and retain
key management, sales, marketing, and technical personnel following an acquisition.
We may seek additional financing in the future, which could be difficult to obtain and which could dilute your ownership
interest or the value of your shares.
Our future capital requirements and the adequacy of available funds will depend, however, on numerous factors,
including:
Market acceptance of our existing and future products;
The success and sales of our products under various distributor agreements and other appropriate commercial
strategies, including the ability of our partners to achieve third party reimbursement for our products;
The successful commercialization of products in development through appropriate commercial models and
marketing channels;
Progress in our product development efforts;
The magnitude and scope of such product development efforts;
21
Any potential acquisitions of products, technologies, or businesses;
Progress with preclinical studies, clinical trials, and product approvals and clearances by the FDA and other
agencies;
The cost and timing of our efforts to manage our manufacturing capabilities and related costs;
The cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights and
the cost of defending any other legal proceeding;
Competing technological and market developments;
The development of strategic alliances for the marketing of certain of our products;
The terms of such strategic alliances, including provisions (and our ability to satisfy such provisions) that
provide upfront and/or milestone payments to us; and
The cost of maintaining adequate inventory levels to meet current and future product demand.
To the extent funds generated from our operations, together with our existing capital resources, are insufficient to
meet future requirements, we will be required to obtain additional funds through equity or debt financings, through strategic
alliances with corporate partners and others, or through other sources. The terms of any future equity financings may be
dilutive to our investors and the terms of any debt financings may contain restrictive covenants, which limit our ability to
pursue certain courses of action. Our ability to obtain financing is dependent on the status of our future business prospects as
well as conditions prevailing in the relevant capital markets at the time we seek financing. No assurance can be given that
any additional financing will be made available to us or will be available on acceptable terms should such a need arise.
Our manufacturing processes involve inherent risks, and disruption could materially adversely affect our business,
financial condition, and results of operations.
The operation of biomedical manufacturing plants involves many risks, including the risks of breakdown, failure, or
substandard performance of equipment, the occurrence of natural and other disasters, and the need to comply with the
requirements of directives of government agencies, including the FDA. In addition, we rely on a small number of suppliers
for certain key raw materials and a small number of suppliers for a number of other materials required for the manufacturing
and delivery of our HA products. Although we believe that alternative sources for many of these and other components and
raw materials that we use in our manufacturing processes are available, we cannot be certain that the supply of key raw
materials, specifically HA, will continue be available at current levels or will be sufficient to meet our future needs. Any
supply interruption could harm our ability to manufacture our products until a new source of supply is identified and qualified.
We may not be able to find sufficient alternative suppliers in a reasonable time period, or on commercially reasonable terms,
if at all, and our ability to produce and supply our products could be impaired.
We use raw materials derived from animal sources to produce certain of our products, and there is no guarantee that we
will be able to continue to utilize this source of material in the future.
Our manufacturing processes and research and development efforts for some of our ophthalmic and veterinary
products involve products derived from animals. We procure our animal-derived raw materials from a qualified vendor, who
controls for contamination and has processes that effectively inactivate infectious agents; however, we cannot assure you that
we can completely eliminate the risk of transmission of infectious agents. Furthermore, regulatory authorities could in the
future impose restrictions on the use of animal-derived raw materials that could impact our business.
22
The utilization of animals in research and development and product commercialization is subject to increasing focus
by animal rights activists. The activities of animal rights groups and other organizations that have protested animal based
research and development programs or boycotted the products resulting from such programs could cause an interruption in
our manufacturing processes and research and development efforts. The occurrence of material operational problems,
including but not limited to the events described above, could have a material adverse effect on our business, financial
condition, and results of operations during the period of such operational difficulties and beyond.
We lease properties in the United States and Italy, and there is no guarantee that these leaseholds will be without issue or
sufficient to support future growth.
We lease approximately 134,000 square feet of administrative, research and development, and manufacturing space
in Bedford, MA and approximately 33,000 square feet of office, research and development, training, and warehousing space
in Padova, Italy. The current term of the Bedford lease extends to 2022, and the current term of the Padova lease extends to
2032, each with several options for renewal. Please see Item 2 – Properties for additional information on our current leases.
The nature of these leaseholds presents certain risks. We must maintain a positive working relationship with the respective
owners as a dispute with either owner over payment, maintenance, or any other matter could be disruptive to our business.
Additionally, there is a possibility that changes to our business or the geographic location of the facilities could make either
location less suitable to our operations. Any renegotiation or termination of either lease could result in substantial cost or
business interruption to our operations. Additionally, there is no guarantee that our current space will be sufficient to support
our future growth or that any future relocation or expansion of our operations would be completed smoothly or in a timely
manner due to, among other things, unexpected construction delays or unexpected difficulties related to the achievement of
necessary permitting. Any business disruption as a result of any of these factors could have a material impact on our business,
financial condition, and results of operations.
We may face circumstances in the future that will result in impairment charges, including, but not limited to, goodwill
impairment and In-Process Research and Development (“IPR&D”) charges.
As of December 31, 2018, we had long-lived assets, including goodwill and IPR&D, of $76.1 million. If the fair
value of any of our long-lived assets decreases as a result of an economic slowdown, a downturn in the markets where we
sell products and services, or a downturn in our financial performance or future outlook, we may be required to record an
impairment charge on such assets.
We are required to test intangible assets with indefinite life periods for potential impairment annually and on an
interim basis if there are indicators of a potential impairment. We also are required to evaluate amortizable intangible assets
and fixed assets for impairment if there are indicators of a possible impairment. Impairment charges could have a negative
impact on our results of operations and financial position, as well as on the market price of our common stock.
We could become subject to product liability claims, which, if successful, could materially adversely affect our business,
financial condition, and results of operations.
The testing, marketing, and sale of human health care products entail an inherent risk of allegations of product
liability, and there can be no assurance that substantial product liability claims will not be asserted against us. Although we
have not received any material product liability claims to date and have an insurance policy of $5.0 million per occurrence
and $5.0 million in the aggregate to cover such product liability claims should they arise, there can be no assurance that
material claims will not arise in the future or that our insurance will be adequate to cover all situations. Moreover, there can
be no assurance that such insurance, or additional insurance, if required, will be available in the future or, if available, will
be available on commercially reasonable terms. Any product liability claim, if successful, could have a material adverse effect
on our business, financial condition, and results of operations.
23
Our business is dependent upon hiring and retaining qualified management and technical personnel.
We are highly dependent on the members of our management and technical staff, the loss of one or more of whom
could have a material adverse effect on us. We have experienced a number of management changes in recent years, and there
can be no assurances that any future management changes will not adversely affect our business. We believe that our future
success will depend in large part upon our ability to attract and retain technical and highly skilled executive, managerial,
professional, and technical personnel. We face significant competition for such personnel from competitive companies,
research and academic institutions, government entities, and other organizations. There can be no assurance that we will be
successful in hiring or retaining the personnel we require. The failure to hire and retain such personnel could have a material
adverse effect on our business, financial condition, and results of operations.
Currency exchange rate fluctuations may have a negative impact on our reported earnings.
Approximately 5% of our business during 2018 was conducted in functional currencies other than the U.S. dollar,
which is our reporting currency. Thus, currency fluctuations among the U.S. dollar and the other currencies in which we do
business have caused and will continue to cause foreign currency transaction gains and losses. Currently, we attempt to
manage foreign currency risk through the matching of assets and liabilities. In the future, we may undertake to manage foreign
currency risk through additional hedging methods. We recognize foreign currency gains or losses arising from our operations
in the period incurred. We cannot guarantee that we will be successful in managing foreign currency risk or in predicting the
effects of exchange rate fluctuations upon our future operating results because of the variability of currency exposure and the
potential volatility of currency exchange rates.
Information security breaches or business system disruptions may adversely affect our business.
We rely on our information technology infrastructure and management information systems to effectively run our
business. While we have not previously experienced a material information security breach caused by illegal hacking,
computer viruses, or acts of vandalism or terrorism, we may in the future be subject to such a breach. Our security measures
or those of our third-party service providers may not detect or prevent such breaches. Any such compromise to our
information security could result in an interruption in our operations, the unauthorized publication of our confidential business
or proprietary information, the unauthorized release of customer, vendor, or employee data, the violation of privacy, including
under the GDPR recently promulgated in the European Union, or other laws and exposure to litigation, any of which could
harm our business and operating results.
Risks Related to Our Intellectual Property
We may be unable to adequately protect our intellectual property rights, which could have a material impact on our
business and future financial results.
Our efforts to enforce our intellectual property rights may not be successful. We rely on a combination of copyright,
trademark, patent, and trade secret laws, confidentiality procedures, and contractual provisions to protect our proprietary
rights. Our success will depend, in part, on our ability to obtain and enforce patents and trademarks, to protect trade secrets,
to obtain licenses to technology owned by third parties when necessary, and to conduct our business without infringing on
the proprietary rights of others. The patent positions of pharmaceutical, medical product, and biotechnology firms, including
ours, can be uncertain and involve complex legal and factual questions. There can be no assurance that any patent applications
will result in the issuance of patents or, if any patents are issued, that they will provide significant proprietary protection or
commercial advantage or will not be circumvented by others. Filing and prosecution of patent applications, litigation to
establish the validity and scope of patents, assertion of patent infringement claims against others, and the defense of patent
infringement claims by others can be expensive and time consuming. There can be no assurance that, in the event that any
claims with respect to any of our patents, if issued, are challenged by one or more third parties, any court or patent authority
ruling on such challenge will determine that such patent claims are valid and enforceable. An adverse outcome in such
litigation or patent review process could cause us to lose exclusivity covered by the disputed rights. If a third party is found
to have rights covering products or processes used by us, we could be forced to cease using the technologies or marketing the
products covered by such rights, we could be subject to significant liabilities to such third party, and we could be required to
license technologies from such third party in order to continue production of the products. Furthermore, even if our patents
are determined to be valid, enforceable, and broad in scope, there can be no assurance that competitors will not be able to
design around such patents and compete with us using the resulting alternative technology. We have a policy of seeking
patent protection for patentable aspects of our proprietary technology. We intend to seek patent protection with respect to
products and processes developed in the course of our activities when we believe such protection is in our best interest and
when the cost of seeking such protection is not inordinate. However, no assurance can be given that any patent application
will be filed, that any filed applications will result in issued patents, or that any issued patents will provide us with a
24
competitive advantage or will not be successfully challenged by third parties. The protections afforded by patents will depend
upon their scope and validity, and others may be able to design around our patents.
We also rely upon trade secrets and proprietary know-how for certain non-patented aspects of our technology. To
protect such information, we require all employees, consultants, and licensees to enter into confidentiality agreements limiting
the disclosure and use of such information. There can be no assurance that these agreements provide meaningful protection
or that they will not be breached, that we would have adequate remedies for any such breach, or that our trade secrets,
proprietary know-how, and our technological advances will not otherwise become known to others. In addition, there can be
no assurance that, despite precautions taken by us, others have not and will not obtain access to our proprietary technology.
Further, there can be no assurance that third parties will not independently develop substantially equivalent or better
technology.
There can be no assurance that we will not infringe upon the intellectual property rights of others, which could have a
significant impact on our business and financial results.
Other entities have filed patent applications for, or have been issued patents concerning, various aspects of HA-
related products or processes, including in the segments in which we do business. There can be no assurance that the products
or processes developed by us will not infringe on the patent rights of others in the future. The cost of defending infringement
suits is typically large, and there is no guarantee that any future defense would be successful. In addition, infringement could
lead to substantial damages payouts or our inability to produce or market certain of our current or future products. As a result,
any such infringement may have a material adverse effect on our business, financial condition, and results of operations.
Risks Related to Ownership of Our Common Stock
Our stock price may be highly volatile, and we cannot assure you that market making in our common stock will continue.
The market price of shares of our common stock may be highly volatile. Factors such as announcements of new
commercial products or technological innovations by us or our competitors, disclosure of results of clinical testing or
regulatory proceedings, government regulation and approvals, developments in patent or other proprietary rights, public
concern as to the safety of products developed by us, and general market conditions may have a significant effect on the
market price of our common stock. The trading price of our common stock could be subject to wide fluctuations in response
to quarter-to-quarter variations in our operating results, material announcements by us or our competitors, governmental
regulatory action, conditions in the health care industry generally or in the medical products industry specifically, or other
events or factors, many of which are beyond our control. In addition, the stock market has experienced extreme price and
volume fluctuations, which have particularly affected the market prices of many medical products companies and which often
have been unrelated to the operating performance of such companies. Our operating results in future quarters may be below
the expectations of equity research analysts and investors. In such an event, the price of our common stock would likely
decline, perhaps substantially.
If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our
market, or if they adversely change their recommendations regarding our stock, our stock price and trading volume could
decline.
The trading market for our common stock is influenced by the research and reports that securities or industry analysts
may publish about us, our business, our market, or our competitors. No person is under any obligation to publish research or
reports on us, and any person publishing research or reports on us may discontinue doing so at any time without notice. If
adequate research coverage is not maintained on our company or if any of the analysts who cover us downgrade our stock or
publish inaccurate or unfavorable research about our business or provide relatively more favorable recommendations about
our competitors, our stock price would likely decline. If any analysts who cover us were to cease coverage of our company
or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock
price or trading volume to decline.
25
We currently do not intend to pay dividends on our common stock in the foreseeable future.
We have never declared or paid any cash dividends on our common stock. We currently intend to retain earnings, if
any, for use in our business and do not anticipate paying cash dividends on our common stock in the foreseeable future.
Accordingly, investors are not likely to receive any dividends on their common stock in the foreseeable future, and their
ability to achieve a return on their investment will therefore depend on appreciation in the price of our common stock.
Our charter documents contain anti-takeover provisions that may prevent or delay an acquisition of our company.
Our charter documents continue to contain anti-takeover provisions that could prevent or delay an acquisition of our
company. The provisions include, among others, a classified board of directors, advance notice to the board of stockholder
proposals, limitations on the ability of stockholders to remove directors and to call stockholder meetings, and a provision that
allows vacancies on the Board of Directors to be filled by vote of a majority of the remaining directors. We are also subject
to Section 203 of the Delaware General Corporate Law which, subject to certain exceptions, prohibits a Delaware corporation
from engaging in any of a broad range of business combinations with any “interested stockholder” for a period of three years
following the date that such stockholder becomes an interested stockholder. Those provisions could have the effect of
discouraging a third party from pursuing a non-negotiated takeover of our company at a price considered attractive by many
stockholders and could have the effect of preventing or delaying a potential acquirer from acquiring control of our company.
ITEM 2. PROPERTIES
Our corporate headquarters is located in Bedford, Massachusetts, where we lease approximately 134,000 square feet
of administrative, research and development, and manufacturing space. We entered into this lease in January 2007, and the
lease commenced in May 2007 for an initial term of ten and a half years. In October 2016, we exercised the first option under
the lease to extend its term for five years. There are two additional renewal periods, each of which is subject to the condition
that we notify the landlord of our exercise of such option at least one year prior to the expiration of the then current term.
Two additional renewal options each extend the term an additional five years, and the final renewal option extends the term
an additional six years.
In October 2015, Anika S.r.l. entered into a build-to-suit lease agreement for a new European headquarters facility
consisting of approximately 33,000 square feet of general office, research and development, training, and warehousing space
located in Padova, Italy. This lease, which has an initial term of fifteen years, commenced in February 2017 in accordance
with the lease agreement, as amended in February 2017. The lease will automatically renew for up to three additional six-
year terms, subject to certain terms and conditions. Anika S.r.l. may elect to early withdraw from this lease subject to certain
financial penalties after six years and with no penalties after the ninth year. The lease provides for an initial yearly rent of
approximately $0.3 million.
Prior to April 2017, Anika S.r.l. leased approximately 28,000 square feet of laboratory, warehouse, and office space
in Abano Terme, Italy from Fidia. The lease commenced in December 2009. In December 2016, following discussions
between Anika S.r.l. and Fidia, Anika S.r.l. notified Fidia of its intention to terminate this lease agreement as of March 2017,
in accordance with the terms of the lease.
In 2018, we had aggregate facility lease expenses of approximately $1.8 million. We believe that the capacity of our
Bedford, Massachusetts corporate headquarters is sufficient to satisfy our needs for the immediately foreseeable future. We
also believe that Anika S.r.l.’s leased facility in Padova, Italy will be sufficient to satisfy its needs for the foreseeable future.
26
ITEM 3. LEGAL PROCEEDINGS
We are involved from time-to-time in various legal proceedings arising in the normal course of business. Although
the outcomes of these legal proceedings are inherently difficult to predict, we do not expect the resolution of these proceedings
to have a material adverse effect on our financial position, results of operations, or cash flow.
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES
Common Stock Information
Our common stock has traded on the NASDAQ Global Select Market since November 25, 1997, under the symbol
“ANIK.”
At December 31, 2018, the closing price per share of our common stock was $33.61 as reported on the NASDAQ
Global Select Market, and there were 121 holders of record. We believe that the number of beneficial owners of our common
stock at that date was substantially greater, due to shares being held by intermediaries.
We have never declared or paid any cash dividends on our common stock. We currently intend to retain earnings, if
any, for use in our business and do not anticipate paying cash dividends on our common stock in the foreseeable future.
Payment of future dividends, if any, on our common stock will be at the discretion of our Board of Directors after taking into
account various factors, including our financial condition, operating results, anticipated cash needs, and plans for expansion.
27
Performance Graph
Set forth below is a graph comparing the total returns of our company, the NASDAQ Composite Index, and the
NASDAQ Biotechnology Index. The graph assumes $100 is invested on December 31, 2013 in our common stock and each
of the indices. Past performance is not indicative of future results.
Dec-13
Dec-14
Dec-15
Dec-16
Dec-17
Dec-18
Anika Therapeutics, Inc. ............... $
NASDAQ Composite Index .......... $
NASDAQ Biotechnology Index .... $
100.00 $
100.00 $
100.00 $
106.76 $
113.40 $
134.10 $
100.00 $
119.89 $
149.42 $
128.30 $
128.89 $
117.02 $
141.27 $
165.29 $
141.66 $
88.08
158.87
128.45
Securities Authorized for Issuance Under Equity Compensation Plans
For information regarding securities authorized for issuance under our employee stock-based compensation plans,
see Part III, Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,
included elsewhere in this Annual Report on Form 10-K.
ITEM 6. SELECTED FINANCIAL DATA
The following selected consolidated financial data should be read in conjunction with the Consolidated Financial
Statements and the Notes thereto and the section captioned “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” included elsewhere in this Annual Report on Form 10-K. The Balance Sheet Data at
December 31, 2018 and 2017 and the Statement of Operations Data for each of the three years ended December 31, 2018,
2017, and 2016 have been derived from the audited Consolidated Financial Statements for such years, included elsewhere
in this Annual Report on Form 10-K. The Balance Sheet Data at December 31, 2016, 2015, and 2014, and the Statement of
Operations Data for each of the two years in the period ended December 31, 2015 and 2014 have been derived from audited
consolidated financial statements for such years not included in this Annual Report on Form 10-K.
28
2018
Years ended December 31,
2016
(in thousands, except per share data)
2015
2017
2014
Statements of Operations Data:
Product revenue .............................................................. $ 105,531 $ 107,783 $ 102,932 $
Licensing, milestone and contract revenue .....................
447
Total revenue .................................................................. 105,555 113,420 103,379
24,027
Cost of product revenue .................................................
Product gross profit ........................................................
78,905
Product gross margin ......................................................
77 %
Total operating expenses ................................................
52,772
32,547
Net income .....................................................................
2.15 $
Diluted net income per common share ........................... $
Diluted common shares outstanding ..............................
15,116
31,280
74,251
70%
83,806
18,722
1.27 $
14,689
27,364
80,419
75%
67,691
31,816
2.11 $
15,068
5,637
24
87,696 $ 75,474
5,303
30,121
92,999 105,595
20,930
21,053
54,544
66,643
72%
76%
44,148
44,865
38,319
30,758
2.51
2.01 $
15,269
15,321
2018
2017
Years ended December 31,
2016
(in thousands)
2015
2014
Balance Sheet Data:
Cash, cash equivalents and investments ......................... $ 159,014 $ 157,256 $ 124,761 $ 138,458 $ 106,906
Working capital .............................................................. 191,654 193,254 161,641 159,155 131,863
Total assets ..................................................................... 278,993 282,617 240,246 235,748 192,808
Long-term liabilities .......................................................
8,737
Retained earnings ........................................................... 218,233 199,511 168,209 135,662 104,904
Stockholders' equity ....................................................... 263,612 263,491 222,773 210,848 178,098
6,054
8,674
4,092
7,622
*
In 2015, the Company adopted new accounting guidance related to the presentation of deferred income taxes, which has been applied above
retrospectively. Current deferred tax assets and liabilities have been reclassified as non-current deferred tax assets and liabilities.
** The Company adopted the guidance in the FASB’s Accounting Standards Codification (“ASC”) Revenue from Contracts with Customers (ASC 606)
using the modified retrospective method effective January 1, 2018. Revenues for all periods prior to January 1, 2018 were recognized under ASC 605,
Revenue Recognition.
The following section contains statements that are not statements of historical fact and are forward-looking statements within
the meaning of the federal securities laws. These statements involve known and unknown risks, uncertainties, and other
factors that may cause our actual results, performance, or achievement to differ materially from anticipated results,
performance, or achievement, expressed or implied in such forward-looking statements. These statements reflect our current
views with respect to future events, are based on assumptions, and are subject to risks and uncertainties. We discuss many of
these risks and uncertainties at the beginning of this Annual Report on Form 10-K and under the sections captioned
“Business” and “Risk Factors.” The following discussion should also be read in conjunction with the consolidated financial
statements and the Notes thereto appearing elsewhere in this Annual Report on Form 10-K.
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Management Overview
We are a global, integrated orthopedic and regenerative medicines company committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the
continuum of care, from palliative pain management to regenerative tissue repair. We have over two decades of global
expertise developing, manufacturing, and commercializing our products based on our proprietary hyaluronic acid (“HA”)
technology. Our orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain
and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair
and regeneration.
Our therapeutic offerings consist of products in the following areas: Orthobiologics, Dermal, Surgical, and Other,
which includes our ophthalmic and veterinary products. All of our products are based on HA, a naturally occurring,
biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an
important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the
maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.
29
Our proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to
therapeutic use. Our patented technology chemically modifies HA to allow for longer residence time in the body. We also
offer products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an
autocross-linked polymer of HA. Our technologies are protected by an extensive portfolio of owned and licensed patents.
Since our inception in 1992, we have utilized a commercial partnership model for the distribution of our products to
end-users. Our strong, worldwide network of distributors has historically provided, and continues to provide, a solid
foundation for our revenue growth and territorial expansion. For near-term and long-term opportunities in the U.S. market,
we have evaluated a potential hybrid commercial approach that would see us balance a small direct model with an optimal
form of strategic partnership, an approach we intend to utilize for the commercialization of our injectable, HA-based surgical
bone repair product. For longer-term future products in the U.S. market, we intend to evaluate the appropriate commercial
model for each instance on a case-by-case basis, based on market dynamics and other factors. These models could include
direct sales, distribution partnerships, or a hybrid of those forms. We believe that the combination of the direct and distribution
commercial models will maximize the revenue potential from our current and future product portfolio.
On May 2, 2018, we publicly disclosed a voluntary recall of certain production lots of our HYAFF-based products,
HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. We communicated with all affected distributors in advance of
that announcement, and we have taken all required or otherwise appropriate actions with respect to applicable regulatory
bodies. We initiated the voluntary recall following internal quality testing, which indicated that the products were at risk of
not maintaining certain measures throughout their entire shelf life. While there was no indication of any safety or efficacy
issue related to the products, we are committed to the highest standards of quality and removed the products from the field as
a precautionary measure. During the first quarter of 2018, we recorded a revenue reserve of $1.1 million, $0.9 million of
which related to revenue recorded in prior periods, and adjustments during the balance of the year were immaterial. We also
recorded an inventory charge for fiscal year 2018 of $0.8 million for the related non-saleable inventory, and we incurred $0.3
million of expenses associated with the administration and remediation of the voluntary recall. During the fourth quarter of
2018, we resolved this matter and resumed shipment of these products, and all of the affected products had been returned
with no material change to the related reserves as of December 31, 2018. As a result of this voluntary recall, revenue generated
from the affected products during fiscal year 2018 declined between $1 million and $2 million as compared to fiscal year
2017.
The following sections provide more information about our products:
Orthobiologics
Our orthobiologics business contributed 89% of our product revenue for the year ended December 31, 2018. Our
orthobiologics products primarily consist of viscosupplement and regenerative orthopedic products. Our viscosupplement
products include ORTHOVISC, ORTHOVISC mini, and MONOVISC, each of which is commercialized in various territories
worldwide, and CINGAL, our next generation viscosupplement launched internationally in Canada and the European Union
in the second quarter of 2016 after receiving Health Canada and CE Mark approval. ORTHOVISC, our original
viscosupplement product, is a three-injection osteoarthritis treatment marketed by us in the United States since 2004 and
internationally since 1996 through various distribution agreements. MONOVISC, our second generation viscosupplement, is
a single-injection osteoarthritis treatment marketed in the United States since 2014 and internationally since 2008.
ORTHOVISC mini is available in Europe and is designed for the treatment of osteoarthritis in small joints. We are currently
seeking regulatory approval for CINGAL, our third generation, single-injection osteoarthritis product, in the United States.
We currently offer several orthopedic products used in connection with regenerative medicine. The products
currently available in Europe and certain international markets include HYALOFAST, a biodegradable support for human
bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery;
HYALONECT, a resorbable knitted fabric mesh for use in orthopedic and trauma reconstructive procedures to maintain the
relative position of engrafted bone tissue or bone fragments from comminuted fractures; and HYALOSS, HYAFF fibers used
to mix blood/bone grafts to form a paste for bone regeneration. We also offer HYALOGLIDE, an ACP gel used in tenolysis
treatment that, with additional clinical data, may demonstrate potential for flexor tendon adhesion prevention and for the
treatment of adhesive capsulitis prevention in the shoulder. This product is commercialized through a network of distributors,
primarily in Europe and the Middle East. We believe that the U.S. market offers excellent expansion potential to increase
revenue for these products, and this will continue to be a focus area for us moving forward.
30
In addition to the products discussed above, we received CE Mark approval in December 2016 for a product which
utilizes our proprietary HA technology to treat pain associated with lateral epicondylitis, better known as tennis elbow.
Outside of the United States, this product is marketed under the trade name ORTHOVISC-T. Additionally, in the second
quarter of 2016, we submitted an IDE to the FDA to conduct a Phase III clinical trial for this treatment, and the IDE was
approved by the FDA in June 2016. We also received 510(k) clearance for an injectable, HA-based surgical bone repair
product in December 2017, which we intend to launch in the U.S. during 2019 utilizing the previously-described hybrid
commercialization approach.
Our strategy is to continue to add new products, to expand the indications for use of both our current and any new
products, and to expand our commercial reach. The orthobiologics area has been our fastest growing area, generating 67%
growth from 2013 to 2018. We continue to seek new distribution partnerships around the world, in concert with entering new
markets with other appropriate sales strategies, and we expect total orthobiologics product sales to decrease modestly in 2019
compared to 2018 based mainly on pricing declines in the U.S. market partially offset by increased sales of MONOVISC and
CINGAL internationally.
Dermal
Our dermal products contributed less than 1% to our product revenue for the year ended December 31, 2018 mainly
due to the previously-described voluntary recall of certain production lots of our HYAFF-based products. Our dermal
franchise consists of advanced wound care products, which are based on the HYAFF technology, and an aesthetic dermal
filler. We offer products for the treatment of skin wounds ranging from burns to diabetic ulcers. The products cover a variety
of wound treatment solutions including debridement agents, advanced therapies, and scaffolds used as skin substitutes.
Leading products include HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and
ulcers, and for use in connection with the regeneration of skin. Our dermal products are commercialized through a network
of distributors, primarily in the United States, Europe, Latin America, and the Middle East. Products cleared for sale in the
United States include HYALOMATRIX, HYALOFILL, HYALOGRAN, HYALOSAFE, and HYALOMATRIX 3D. We
have a commercial partnership agreement with Medline Industries, Inc. to commercialize HYALOMATRIX in the United
States on an exclusive basis through 2022.
Our aesthetic dermatology product is a dermal filler based on our proprietary, chemically modified, cross-linked
HA, and it is primarily commercialized in certain countries in the Middle East. Internationally, this product is marketed under
the ELEVESS trade name. In the United States, the trade name is HYDRELLE, although the product is not currently marketed
in the United States.
Surgical
Our surgical group consists of products used to prevent surgical adhesions and to treat ENT disorders. For the year
ended December 31, 2018, sales of surgical products contributed 5% of our product revenue. Included in our surgical
franchise is HYALOBARRIER, a clinically proven post-operative adhesion barrier for use in the abdomino-pelvic area. The
product is currently commercialized in Europe, the Middle East, and certain African and Asian countries through a
distribution network, but it is not approved in the United States.
We also offer several products used in connection with the treatment of ENT disorders. The lead products are
MEROGEL, a woven fleece nasal packing, and MEROGEL INJECTABLE, a thick, viscous hydrogel composed of cross-
linked HA, a biocompatible agent that creates a moist wound-healing environment. We partner with Medtronic for the
worldwide distribution of these products.
31
Other
Our other products include our ophthalmic and veterinary products, which constituted 6% of our product revenue
for the year ended December 31, 2018. These legacy products are not a part of our core business. Our ophthalmic business
includes HA viscoelastic products used in ophthalmic surgery. Sales of ophthalmic products contributed 2% of our product
revenue and sales of HYVISC, our veterinary product used for the treatment of equine osteoarthritis, contributed 4% of our
product revenue for the year ended December 31, 2018.
Research and Development
Our research and development efforts primarily consist of the development of new medical applications for our
HA-based technology, the management of clinical trials for certain product candidates, the preparation and processing of
applications for regulatory approvals or clearances at all relevant stages of product development, and process development
and scale-up manufacturing activities for our existing and new products. Our development focus is orthopedic and
regenerative medicine and includes products for tissue protection, repair, and regeneration. We anticipate that we will
continue to commit significant resources in the near future to research and development activities, including in relation to
preclinical activities and clinical trials. These activities are aimed at the delivery of a steady cascade of new product
development and launches over the next several years.
Our research and development efforts primarily consist of the development of new medical applications for our HA-
based technology, the management of clinical trials for certain product candidates, the preparation and processing of
applications for regulatory approvals or clearances at all relevant stages of product development, and process development
and scale-up manufacturing activities for our existing and new products. Our development focus is orthopedic and
regenerative medicines and includes products for tissue protection, repair, and regeneration. For the years ended
December 31, 2018, 2017 and 2016, these expenses were $18.2 million, $18.8 million, and $10.7 million, respectively. We
anticipate that we will continue to commit significant resources to, and increase our aggregate spending on, research and
development activities, including in relation to preclinical activities and clinical trials, in the future.
Our third generation, single-injection osteoarthritis product under development in the United States, CINGAL,
which is composed of our proprietary cross-linked HA material combined with an approved steroid and is designed to provide
both short- and long-term pain relief to patients, is our lead pipeline product and a critical component of our growth strategy.
We completed an initial CINGAL Phase III clinical trial, including the associated statistical analysis for 368 enrolled patients,
during the fourth quarter of 2014 with data indicating that the product met all primary and secondary endpoints relative to
placebo set forth for the trial. During the first half of 2015, we completed a CINGAL retreatment study with 242 patients who
had participated in the Phase III clinical trial and reported safety data related to the retreatment study. This initial Phase III
clinical trial and the associated retreatment study supported the Health Canada and CE Mark approval of the product, and the
commercial launch of the product in both Canada and the European Union occurred in the second quarter of 2016. In the
United States, after discussions with the FDA related to the regulatory pathway for CINGAL, we conducted a formal meeting
with the FDA’s OCP to present and discuss our data in September 2015, and we submitted a formal request for designation
with OCP a month later. In its response to our formal request for designation, OCP assigned the product to the FDA’s CDER
as the lead agency center for premarket review and regulation. We then held discussions with CDER to understand the
requirements for submitting an NDA for CINGAL. We held a meeting with CDER in September 2016 to align on an approval
framework and on submission requirements for this NDA for CINGAL, including the execution of an additional Phase III
clinical trial to supplement our existing CINGAL pivotal study data. We submitted an IND in late 2016, and discussions with
CDER indicated that they did not have objections to our clinical protocol design. As a result, we commenced work on this
second Phase III clinical trial (“CINGAL 16-02 Study”) in the first quarter of 2017, and the first patient was treated in the
second quarter of 2017. Enrollment of the 576 patients in this second Phase III clinical trial was completed during October
2017, and we completed the six-month patient follow-up in April 2018. We received and analyzed the data from the CINGAL
16-02 Study during the second quarter of 2018, and, while substantial pain reduction associated with CINGAL was evident
at each measurement point, we determined based on statistical analysis that it did not meet the primary study endpoint of
demonstrating a statistically significant difference in pain reduction between CINGAL and the approved steroid component
of CINGAL at the six-month time point. In the third quarter of 2017, we initiated an additional three-month extended follow-
up study in conjunction with the CINGAL 16-02 Study to investigate the efficacy of CINGAL over this longer period. The
first patients were enrolled in this follow-up study in the fourth quarter of 2017 and we completed the nine-month patient
follow-up in the third quarter of 2018. Given the totality of the results from our studies related to CINGAL, we have evaluated
multiple strategies to optimize the potential U.S. regulatory pathway for the product. We recently met with FDA to discuss
this potential approval pathway for CINGAL in the United States moving forward. In the meeting, FDA indicated that an
additional Phase III clinical trial would be necessary to support U.S. marketing approval for CINGAL, and we are continuing
to align with FDA on the parameters and requirements for this additional clinical trial, which we expect to commence once
alignment is achieved.
32
We have several research and development programs underway for new products, including for HYALOFAST (in
the United States), an innovative product for cartilage tissue repair, and other early stage regenerative medicine development
programs. HYALOFAST, which received CE Mark approval in September 2009, is commercially available in Europe and
certain international countries. During the first quarter of 2015, we submitted an Investigational Device Exemption (“IDE”)
for HYALOFAST to the FDA, which was approved in July 2015. We commenced patient enrollment in a clinical trial in
December 2015, and we are advancing site initiations and patient enrollment activities. In the second quarter of 2016, a
supplement to the HYALOFAST IDE was approved to expand the inclusion criteria for the clinical study, which was aimed
at decreasing the time needed to complete the clinical trial. The previously-described voluntary recall of certain production
lots of our HYAFF-based products did not impact the HYALOFAST clinical trial, as the product used in the clinical trial is
not sourced from the affected production lots. Given the changing medical landscape with respect to the randomization arm
for this trial, the microfracture procedure, we are actively pursuing alternative strategies to accelerate patient enrollment.
In the third quarter of 2017, we submitted an application to the FDA for 510(k) clearance of an injectable, HA-based
surgical bone repair product that is reabsorbed by the body and replaced by the growth of new bone during the healing process.
The 510(k) clearance was received from the FDA in December 2017, and we expect to make this bone repair product
commercially available in the United States during 2019 utilizing the previously-described hybrid commercial approach. In
addition to other early stage research and development initiatives we are currently undertaking, we are working to expand
our regenerative medicine pipeline with a new product candidate in the form of an implant for rotator cuff repair utilizing our
proprietary solid HA, which could be used to repair partial and full-thickness rotator cuff tears. We finalized development of
an initial product prototype during the fourth quarter of 2018, and we are performing important preclinical testing of and
developing the surgical instrumentation for the potential product.
We are also currently proceeding with other research and development programs, one of which utilizes our
proprietary HA technology to treat pain associated with common repetitive overuse injuries, such as lateral epicondylitis, also
known as tennis elbow. We submitted a CE Mark application for this treatment during the first quarter of 2016 and received
a CE Mark for the treatment of pain associated with tennis elbow in December 2016. We began work towards a post-market
clinical study in relation to the CE Mark for this product in the fourth quarter of 2018. Outside of the United States, this
product is marketed under the trade name ORTHOVISC-T. Additionally, in the second quarter of 2016, we submitted an IDE
to the FDA to conduct a Phase III clinical trial for this treatment, which was approved by the FDA in June 2016. We also
have several other research and development programs underway focused on expanding the indications of our current
products, including MONOVISC. Notwithstanding those internal programs, the previously-disclosed program conducted and
funded by Mitek seeking to expand MONOVISC’s indication to include treatment of pain associated with osteoarthritis of
the hip was cancelled in the fourth quarter of 2018 after the performance of an independent interim analysis required by the
related clinical protocol. During 2019, we will also be performing post-market clinical work in relation to the CE Mark for
MONOVISC.
In June 2015, we entered into an agreement with the Institute for Applied Life Sciences at the University of
Massachusetts Amherst to collaborate on research to develop a therapy for rheumatoid arthritis. The purpose of this research
was to develop a novel modality for the treatment of rheumatoid arthritis. The agreement with the University of Massachusetts
Amherst was extended in January 2018, and it was terminated in October 2018 after discussions between the parties. In
January 2018, we entered into an agreement with the University of Liverpool to develop an injectable mesenchymal stem cell
therapy for the treatment of age-related osteoarthritis with the goal of bringing a therapeutics candidate through clinical trials
to market to meet an unmet therapeutic need. We are currently in the preclinical phase of this program and aim to finalize
proof of concept during the second quarter of 2020.
33
Summary of Critical Accounting Policies; Significant Judgments and Estimates
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated
financial statements included elsewhere in this Annual Report on Form 10-K, which consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these
consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. We monitor our estimates on
an ongoing basis for changes in facts and circumstances, and material changes in these estimates could occur in the future.
Changes in estimates are recorded in the period in which they become known. We base our estimates on historical experience
and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates
if past experience or other assumptions do not turn out to be substantially accurate.
We have identified the policies below as critical to our business operations and the understanding of our results of
operations. The impact and any associated risks related to these policies on our business operations are discussed throughout
this section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations” where
such policies affect our reported and expected financial results. For a detailed discussion on the application of these and other
accounting policies, see Note 2 to the consolidated financial statements included elsewhere in this Annual Report on Form
10-K.
Revenue Recognition - General
We adopted the guidance in the ASC 606 using the modified retrospective method effective January 1, 2018. The
adoption of ASC 606 was applied to all contracts not completed as of the date of adoption. The adoption did not have a
material impact on the amount and timing of revenue recognized in the consolidated financial statements. We made no
adjustments to our previously reported product and total revenue, as those periods continue to be presented in accordance
with our historical accounting practices under Topic 605, Revenue Recognition.
Pursuant to ASC 606, we recognize revenue when a customer obtains control of promised goods or services. The
amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services.
We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services
in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether
they are capable of being distinct or distinct in the context of the contract; (iii) measurement of the transaction price, including
the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v)
recognition of revenue when (or as) we satisfy each performance obligation.
We have agreements with Mitek that include the grant of certain licenses, performance of development services, and
the supply of product at Mitek’s option. Revenues from the agreements with Mitek represent 73% of total revenues for the
year-ended December 31, 2018. We completed the performance obligations related to granted licenses and development
services under these agreements prior to 2016. We have no remaining material performance obligations under the Mitek
agreements.
We have agreements with other customers that may include the delivery of a license and supply of product. The
upfront payments under such agreements upon the delivery of the license have not been material.
Our typical supply agreements represent a promise to deliver product at the customer’s discretion that are considered
options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate
performance obligations. The majority of our supply agreements do not provide options that are considered material rights.
Certain of our agreements include sales-based royalties and milestones. As we consider the license to be the
predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized
when the later of the underlying sale occurs or the performance obligation to which some or all of the sales-based royalty has
been satisfied (or partially satisfied). This is generally in the same period that our licensees complete their product sales in
their territory, for which we are contractually entitled to a percentage-based royalty. Revenue from sales-based royalties is
included in product revenues.
Product Revenue
We sell our products principally to a number of distributors (i.e., our customers) under legally-enforceable, executed
contracts. Our distributors subsequently resell the products to sub-distributors and health care providers, among others. We
recognize revenue from product sales when the distributor obtains control of our product, which typically occurs upon
34
shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled
quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting
period is generally immaterial.
Our payment terms are consistent with prevailing practice in the respective markets in which we do business. Most
of our distributors make payments based on fixed-price contract terms, which are not affected by contingent events that could
impact the transaction price. Payment terms fall within the one-year guidance for the practical expedient, which allows us to
forgo adjustment of the contractual payment amount of consideration for the effects of a significant financing component.
Our contracts with customers do not customarily provide a right of return, unless certain product quality standards are not
met.
Some of our distributor agreements have volume based discounts with tiered pricing which are generally prospective
in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential
material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be
separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue
allocated to the material right is recognized when the additional goods are transferred to the customer or when the option
expires. During 2018, the consideration allocated to material rights was not significant.
We receive payments from our customers based on billing schedules established in each contract. Up-front payments
and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a
future period until we perform our obligations under these arrangements. Amounts are recorded as accounts receivable when
our right to consideration is unconditional.
Generally, distributor contracts contain Free on Board (FOB) or Ex-Works (EXW) shipping point terms where the
customer pays the shipping company directly for all shipping and handling costs. In those contracts in which we pay for the
shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost
of product revenue when control over the products has transferred to the customer. We do not collect sales tax on product
sales as it is not applicable. Value-add and other taxes collected by us concurrently with revenue-producing activities are
excluded from revenue. Our general product warranty does not extend beyond an assurance that the product or services
delivered will be consistent with stated contractual specifications, which does not create a separate performance obligation.
We recognize the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the
assets that we otherwise would have recognized is one year or less in accordance with the practical expedient in paragraph
ASC 340-40-25-4. These costs are included in selling, general & administrative expenses.
Included as a component of product revenue is sales-based royalty revenue, which represents the utilization of our
intellectual property licensed by our commercial partners. We record royalty revenues based on estimated net sales of licensed
products as reported to us by our commercial partners. Differences between actual and estimated royalty revenues have not
been material and are typically adjusted in the following quarter when the actual amounts are known.
Licensing, Milestone and Contract Revenue
The agreements with Mitek include variable consideration such as contingent development and regulatory
milestones. As of the date of adoption of ASC 606, there is one remaining regulatory milestone related to the Mitek
agreements and we have no performance obligation related to this milestone. In general, variable consideration is included in
the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable
to occur. Future payments for regulatory milestones will be recognized as revenue when the regulatory milestone is
considered probable of being achieved.
Inventories
Inventories are stated at the lower of standard cost and net realizable value, with approximate cost determined using
the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing
overhead. Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized
if we believe there is probable future commercial use and future economic benefit.
Our policy is to write-down inventory when conditions exist that suggest inventory may be in excess of anticipated
demand or is obsolete based upon assumptions about future demand for our products and market conditions. We regularly
evaluate our ability to realize the value of inventory based on a combination of factors including, but not limited to, historical
usage rates, forecasted sales or usage, product end of life dates, and estimated current or future market values. Purchasing
requirements and alternative usage avenues are explored within these processes to mitigate inventory exposure.
35
Goodwill and Acquired In-Process Research and Development
Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the
fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&D”)
represents the fair value assigned to research and development assets that we acquire that have not been completed at the date
of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&D is
determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the
resulting revenue from the projects, and discounting the net cash flows to present value.
Goodwill and IPR&D are evaluated for impairment annually, or more frequently if events or changes in
circumstances indicate that the asset might be impaired. Factors we consider important, on an overall company basis, that
could trigger an impairment review include significant underperformance relative to historical or projected future operating
results, significant changes in our use of the acquired assets or the strategy for our overall business, significant negative
industry or economic trends, a significant decline in our stock price for a sustained period, or a reduction of our market
capitalization relative to net book value.
To conduct impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the
reporting unit’s carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of
goodwill exceeds its implied fair value. Our annual assessment for impairment of goodwill as of November 30, 2018 indicated
that the fair value of our reporting unit exceeded the carrying value of the reporting unit.
To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the
carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&D project
exceeds its fair value. We estimate the fair value for IPR&D projects using discounted cash flow valuation models, which
require the use of significant estimates and assumptions, including, but not limited to, estimating the timing of and expected
costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from product sales
resulting from completed projects and in-process projects, and developing appropriate discount rates. Our annual assessment
for impairment of IPR&D indicated that the fair value of our other IPR&D assets as of November 30, 2018 exceeded their
respective carrying values. See also the section captioned “Risk Factors—Risks Related to Risks Related to Our Product
Development and Regulatory Compliance — Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign
governmental approvals for our products may have a material adverse effect on our business, financial condition and results
of operations” for a discussion regarding the effect that failure to obtain, or any delay in obtaining, FDA or other U.S. and
foreign governmental approvals could have on our business and financial performance.
Through December 31, 2018, there have not been any events or changes in circumstances that indicate that the
carrying value of goodwill or acquired intangible assets may not be recoverable. We continue to monitor and evaluate the
financial performance of our business, including the impact of general economic conditions, to assess the potential for the
fair value of the reporting unit to decline below its book value. There can be no assurance that, at the time future impairment
tests are completed, a material impairment charge will not be recorded.
Long-Lived Assets
Long-lived assets primarily include property and equipment and intangible assets with finite lives. Our intangible
assets are comprised of purchased developed technologies, distributor relationships, patents, and a fully amortized trade name.
The distributor relationships and trade name were fully amortized as of December 31, 2018. These intangible assets are
carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets'
useful lives, which range from 5 to 16 years. We review long-lived assets for impairment when events or changes in business
circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of those
assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flows to the recorded
value of the asset. If impairment is indicated, the asset is written down to its estimated fair value based on a discounted cash
flow analysis.
36
Stock-Based Compensation
We measure the compensation cost of award recipients’ services received in exchange for an award of equity
instruments based on the grant-date fair value of the underlying award. That cost is recognized over the period during which
an employee is required to provide service in exchange for the award. For performance-based awards with financial
achievement targets, we recognize expense using the graded vesting methodology based on the number of shares expected to
vest. Compensation cost associated with performance grants is estimated using the Black-Scholes valuation method
multiplied by the expected number of shares to be issued, which is adjusted based on the estimated probabilities of achieving
the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in
adjustments to the related share-based compensation expense that will be recorded in the period of the change. If the
performance targets are not achieved, no compensation cost is recognized and any previously recognized compensation cost
is reversed. See Note 13, Equity Incentive Plan, to the consolidated financial statements included elsewhere in this Annual
Report on Form 10-K for a description of the types of stock-based awards granted, the compensation expense related to such
awards, and detail of equity-based awards outstanding. See Note 16, Income Taxes, to the consolidated financial statements
included elsewhere in this Annual Report on Form 10-K for details related to the tax benefit recognized in the consolidated
statement of operations for stock-based compensation.
Income Taxes
Our income tax expense includes U.S. and international income taxes. Certain items of income and expense are not
reported in tax returns and financial statements in the same year. The tax effects of these differences are reported as deferred
tax assets and liabilities. Deferred tax assets are recognized for the estimated future tax effects of deductible temporary
differences and tax operating loss and credit carry-forwards. Changes in deferred tax assets and liabilities are recorded in the
provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable income,
and to the extent we believe that it is more likely than not that all or a portion of deferred tax assets will not be realized, we
establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we
include an expense within the tax provision in the consolidated statement of operations.
37
Results of Operations
Year ended December 31, 2018 compared to year ended December 31, 2017
Statement of Operations Detail
Years Ended December 31,
2017
2018
(in thousands, except percentages)
$ Inc/(Dec) % Inc/(Dec)
Product revenue .................................................................. $ 105,531 $ 107,783 $
Licensing, milestone and contract revenue .........................
5,637
113,420
Total revenue ..................................................................
24
105,555
(2,252)
(5,613)
(7,865)
(2%)
(100%)
(7%)
Operating expenses:
Cost of product revenue .................................................
Research & development ................................................
Selling, general & administrative ...................................
Total operating expenses ....................................................
Income from operations ......................................................
Interest income, net ........................................................
Income before income taxes ...............................................
Provision for income taxes .............................................
Net income ......................................................................... $
Product gross profit ................................................................ $
Product gross margin ..............................................................
31,280
18,190
34,336
83,806
21,749
1,458
23,207
4,485
18,722 $
74,251 $
70%
27,364
18,787
21,540
67,691
45,729
473
46,202
14,386
31,816 $
80,419 $
75%
3,916
(597)
12,796
16,115
(23,980)
985
(22,995)
(9,901)
(13,094)
(6,168)
14%
(3%)
59%
24%
(52%)
208%
(50%)
(69%)
(41%)
(8%)
Total revenue
Total revenue for the year ended December 31, 2018 decreased by $7.9 million, as compared to the prior year, to
$105.6 million. This decrease was primarily due to the achievement of a one-time $5.0 million milestone in 2017 for reaching
a target MONOVISC U.S. end-user sales threshold set forth in the Mitek MONOVISC Agreement and the absence of an
equivalent milestone payment in 2018, as well as the impact of pricing declines in the U.S. viscosupplement market and the
previously-described voluntary recall of certain production lots of certain of our HYAFF-based products.
Product revenue
Product revenue for the year ended December 31, 2018 was $105.6 million, a decrease of $2.3 million, or 2.0%,
compared to prior year. A moderate decrease in our dermal and orthobiologics product revenue was partially offset by a
product revenue increase in our surgical and other franchises. The following table presents comparative product revenue
analysis by product franchise:
2018
Years Ended December 31,
2017
$ Inc/(Dec)
% Inc/(Dec)
Orthobiologics ................................. $
Dermal ............................................
Surgical ...........................................
Other ...............................................
$
93,556 $
396
5,514
6,065
105,531 $
93,816 $
2,755
5,262
5,950
107,783 $
(260)
(2,359)
252
115
(2,252)
(0%)
(86%)
5%
2%
(2%)
Orthobiologics
Our orthobiologics franchise consists of our joint health and orthopedic products. Overall, revenue from our
orthobiologics franchises decreased by $0.3 million in 2018 as compared to 2017 primarily as a result of the voluntary recall
of certain production lots of our HYAFF-based products and a decline in worldwide ORTHOVISC revenue offset in part by
strong growth in domestic MONOVISC and international CINGAL revenue. In addition, sales volume gains for our U.S.
viscosupplements were offset by pricing declines in the U.S. viscosupplement market, a trend we expect to continue in 2019.
Overall, we expect orthobiologics product revenue in 2019 to decrease as compared to 2018, primarily due to the
ORTHOVISC and MONOVISC pricing declines in the U.S. viscosupplement market, offset in part by growth in global
38
CINGAL revenue and the commercial launch of our injectable, HA-based surgical bone repair product via the previously-
described hybrid commercial approach.
Dermal
Our dermal franchise consists of advanced wound care products, which are based on our HYAFF technology, and
aesthetic dermal fillers. Our advanced wound care products treat complex skin wounds ranging from burns to diabetic ulcers,
with HYALOMATRIX and HYALOFILL as the lead products. Dermal revenue had a significant decline in 2018 as compared
to 2017 due to the previously-described voluntary recall of certain production lots of our HYAFF-based products. We
resolved the matter and resumed shipment of these products in November 2018, and we expect dermal revenue to increase in
2019 to pre-recall levels as compared to 2018.
Surgical
Our surgical franchise consists primarily of our anti-adhesion products, HYALOBARRIER and our ENT offerings,
of which MEROGEL is the leading product. We are partnered with Medtronic for the worldwide distribution of our ENT
products. Revenue from our surgical products increased $0.3 million, or 5%, in 2018 as compared to 2017. The increase of
surgical product revenue was primarily due to an increase in sales of our ENT products. We expect surgical product revenue
to increase in 2019 as compared to 2018 primarily due to increased worldwide revenue of surgical anti-adhesion product and
ENT sales in the U.S.
Other
Other product revenue was derived from sales of our ophthalmic and veterinary products. Other product revenue
increased modestly in 2018 as compared to 2017 primarily as a result of increased sales of ophthalmic products. We expect
other revenue to increase in 2019 as compared to 2018, driven by increases in demand for our ophthalmic and veterinary
products.
Licensing, milestone and contract revenue
Licensing, milestone and contract revenue for the year ended December 31, 2018 was insignificant, compared to
$5.6 million for 2017. This decrease was primarily due to the achievement of a one-time $5.0 million milestone in 2017 for
reaching a target MONOVISC U.S. end-user sales threshold set forth in the Mitek MONOVISC Agreement and the absence
of an equivalent milestone payment in 2018. We expect licensing, milestone and contract revenue to be at an equivalent level
in 2019 as compared to 2018.
Product gross profit and margin
Product gross profit for the year ended December 31, 2018 was $74.3 million, or 70% of product revenue, as
compared with $80.4 million, or 75% of product revenue, for the year ended December 31, 2017. The decrease in product
gross margin for the twelve-month period ended December 31, 2018 was primarily caused by an increase in inventory reserves
related to certain raw materials, inventory write-offs and charges associated with the previously described voluntary recall of
certain production lots of our HYAFF-based products, higher production costs, and revenue mix and pricing dynamics.
Research and development
Research and development expenses for the year ended December 31, 2018 decreased by $0.6 million, or 3%, as
compared to the prior year, mainly due to a decrease in expenses for our HYALOFAST and CINGAL phase III clinical trials,
partially offset by increases in our product development activities, including those related to the development of a product
for rotator cuff therapy and pre-commercial development of our injectable, HA-based surgical bone repair product. Research
and development expense as a percentage of total revenue was 17% in 2018 and 2017. Research and development expenses
are expected to increase in 2019 and beyond compared to 2018 as we further develop new products and initiate clinical trials
based on our development activities, perform required post-market clinical follow-ups for our MONOVISC and
ORTHOVISC-T products in the European Union, and as a result of current or future changes to the regulatory environments
in the jurisdictions in which we do business.
39
Selling, general and administrative
Selling, general and administrative expenses for the year ended December 31, 2018 increased by $12.8 million, or
59%, as compared to 2017. The increase was primarily due to non-cash stock-based compensation expense related to the
retirement of our former Chief Executive Officer, non-recurring CINGAL U.S. pre-launch market research activities, and
increased personnel and external professional fees. We expect selling, general and administrative expenses for 2019 to
approximate those for 2018 and include investments in our commercial capabilities and the implementation of improved
operational and financial technology platforms required to grow our business both domestically and internationally.
Income taxes
Provisions for income taxes were $4.5 million and $14.4 million for the years ended December 31, 2018 and 2017,
respectively. The decrease in the effective tax rate in 2018 of 11.8%, as compared to 2017, is primarily due to the reduction
of Federal Corporate Income Tax rate as a result of the Tax Cuts and Jobs Act of 2017 (“Tax Act”) tax reform legislation.
This legislation makes significant changes to the U.S. tax law, including a reduction in the corporate tax rate from 35% to
21% starting in 2018. In addition, the Company realized a windfall tax benefit in 2018 related to exercises of employee equity
awards resulting in a discrete period income tax benefit of $1.5 million compared to $0.4 million in 2017.
A reconciliation of the U.S. federal statutory tax rate to the effective tax rate for the periods ending December 31 is
as follows:
Years ended December 31,
Statutory federal income tax rate ..................................................
State tax expense, net of federal benefit .......................................
Impact of rate change on deferred taxes .......................................
State investment tax credit ............................................................
Federal, state and foreign research and development credits .......
Foreign rate differential ................................................................
Domestic production deduction ....................................................
Stock compensation ......................................................................
Non-deductible Section 162(m) compensation limitation ............
Foreign derived intangible income deduction ..............................
Other, including nondeductible expenses .....................................
Effective income tax rate ..............................................................
2018
21.0%
5.5%
0.0%
(0.2)%
(3.4)%
(0.4)%
0.0%
(4.8)%
4.3%
(1.3)%
(1.4)%
19.3%
2017
35.0%
4.8%
(4.9)%
(0.7)%
(1.4)%
0.5%
(2.8)%
(0.2)%
0.7%
0.0%
0.1%
31.1%
As of December 31, 2018, we had gross net operating losses (“NOL”) for income tax purposes in Italy of $5.8
million with no expiration date. In connection with the preparation of the financial statements, we performed an analysis to
ascertain if it was more likely than not that we would be able to utilize, in future periods, the net deferred tax assets associated
with our NOL carry-forward. We have concluded that the positive evidence outweighs the negative evidence and, thus, that
the deferred tax assets are realizable on a “more likely than not” basis. As such, we have not recorded a valuation allowance
at December 31, 2018 or 2017.
In the normal course of business, Anika and its subsidiaries may be periodically examined by various taxing
authorities. We file income tax returns in the U.S. federal jurisdiction, in certain U.S. states, and in Italy. The associated tax
filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which
those filings relate. The 2015 through 2017 tax years remain subject to examination by the IRS and other taxing authorities
for U.S. federal and state tax purposes. The 2012 through 2017 tax years remain subject to examination by the appropriate
governmental authorities for Italy.
Net income
For the year ended December 31, 2018, net income was $18.7 million, or $1.27 per diluted share, compared to $31.8
million, or $2.11 per diluted share, for the same period in the prior year. The decrease in net income and diluted earnings per
share was primarily a result of decreased total revenue, decreased product gross margin, the impact of the previously-
described voluntary recall of certain production lots of certain of our HYAFF-based products, and one-time expenses
associated with the retirement of our former CEO and CINGAL U.S. pre-launch market research activities. The decreased
revenue and increased expenses are offset by a decreased effective federal income tax rate as a result of the 2017 Income Tax
Reform Legislation.
40
Year ended December 31, 2017 compared to year ended December 31, 2016
Statement of Operations Detail
Product revenue ................................................................ $
Licensing, milestone and contract revenue .......................
Total revenue ................................................................
107,783 $
5,637
113,420
102,932 $
447
103,379
4,851
5,190
10,041
5%
1,161%
10%
Years Ended December 31,
2017
2016
$ Inc/(Dec) %Inc/(Dec)
(in thousands, except percentages)
Operating expenses:
Cost of product revenue ...............................................
Research & development ..............................................
Selling, general & administrative .................................
Total operating expenses ..................................................
Income from operations ....................................................
Interest income, net ......................................................
Income before income taxes .............................................
Provision for income taxes ...........................................
Net income ....................................................................... $
Product gross profit .............................................................. $
Product gross margin ............................................................
Total revenue
27,364
18,787
21,540
67,691
45,729
473
46,202
14,386
31,816 $
80,419 $
75%
24,027
10,732
18,013
52,772
50,607
263
50,870
18,323
32,547 $
78,905 $
77%
3,337
8,055
3,527
14,919
(4,878)
210
(4,668)
(3,937)
(731)
1,514
14%
75%
20%
28%
(10%)
80%
(9%)
(21%)
(2%)
2%
Total revenue for the year ended December 31, 2017 increased by $10.0 million, as compared to the prior year, to
$113.4 million. This increase was primarily due to the growth of our orthobiologics franchise, specifically an increase in
global MONOVISC revenue and our achievement of $5.0 million of milestone revenue in 2017 for reaching a target
MONOVISC U.S. end-user sales threshold set forth in the Mitek MONOVISC Agreement.
Product revenue
Product revenue for the year ended December 31, 2017 was $107.8 million, an increase of $4.9 million, or 5.0%,
compared to the prior year. Product revenue increases in our Orthobiologics, Dermal, and Other franchises were partially
offset by moderate decreases in product revenue in our Surgical franchise. The following table presents comparative product
revenue analysis by product franchise:
Years Ended December 31,
2017
2016
$ Inc/(Dec) % Inc/(Dec)
Orthobiologics ................ $
Dermal ............................
Surgical ..........................
Other ..............................
$
Orthobiologics
93,816 $
2,755
5,262
5,950
107,783 $
(in thousands, except percentages)
4,121
(4)
(165)
899
4,851
89,695 $
2,759
5,427
5,051
102,932 $
5%
(0%)
(3%)
18%
5%
Our orthobiologics franchise consists of our joint health and orthopedic products. Overall, revenue from our
orthobiologics franchises increased $4.1 million, or 5%, in 2017 as compared to 2016. The growth in 2017 reflected a growing
end-user demand, continued market penetration, increased revenue from worldwide MONOVISC sales, and CINGAL
revenue associated with the product’s commercial launch in Canada and Europe in 2016. ORTHOVISC and MONOVISC
global revenue also increased 1% in 2017 as compared to 2016. The increase in international viscosupplement revenue in
2017 was driven primarily by increased sales of MONOVISC resulting from a robust and growing end-user demand.
41
Dermal
Our dermal franchise consists of advanced wound care products, which are based on our HYAFF technology, and
aesthetic dermal fillers. Our advanced wound care products treat complex skin wounds ranging from burns to diabetic ulcers,
with HYALOMATRIX and HYALOFILL as the lead products. Dermal revenue had no significant change in 2017 as
compared to 2016. The revenue, in part, is from the agreement we entered into in July 2014 with Medline Industries, Inc. to
commercialize HYALOMATRIX in the United States on an exclusive basis through 2022.
Surgical
Our surgical franchise consists of products used to prevent surgical adhesions and to treat ear, nose, and throat
(“ENT”) disorders. Sales of our surgical products decreased $0.2 million, or 3%, in 2017 as compared to 2016. The decrease
of surgical product revenue was primarily due to a decrease in sales generated by our ENT products and unfavorable impact
from foreign currency exchange rate fluctuations compared with the same periods in the prior year. Our surgical franchise
consists primarily of our anti-adhesion products, including HYALOBARRIER and our ENT offerings, of which MEROGEL
is the leading product. We are partnered with Medtronic for the worldwide distribution of our ENT products.
Other
Other product revenue includes revenues from ophthalmic and veterinary products. The other product revenue
increased in 2017 from 2016 due to a recovery from weak 2016 sales volume for these franchises.
Licensing, milestone and contract revenue
Licensing, milestone and contract revenue for the year ended December 31, 2017 was $5.6 million, compared to
$0.4 million for 2016. The year over year increase was primarily the result of the recognition of licensing and milestone
revenue for the year ended December 31, 2017 of $5.0 million for the achievement of a milestone payment under the Mitek
MONOVISC Agreement. During the second quarter of 2017, we collected and fully recognized revenue for a milestone
payment of $5.0 million as a result of U.S. MONOVISC 12-month end-user sales exceeding $100 million.
Product gross profit and margin
Product gross profit for the year ended December 31, 2017 was $80.4 million, or 75% of product revenue, as
compared with $78.9 million, or 77% of product revenue, for the year ended December 31, 2016. The increase in product
gross profit was primarily due to the increased volume compared to the prior year, while the decrease in product gross margin
was due to inventory write-offs in 2017, as well as certain lower than anticipated product yields during the insource of the
manufacturing of certain products to our Bedford facility.
Research and development
Research and development expenses for the year ended December 31, 2017 increased by $8.1 million, or 75%, as
compared to the prior year, mainly due to an increase in expenses for our HYALOFAST and CINGAL phase III clinical
trials. We also increased our pre-clinical product development activities, including with respect to achieving a 510(k)
clearance of an injectable, HA-based surgical bone repair product. Research and development expense as a percentage of
total revenue was 17% in 2017 and 10% in 2016.
Selling, general and administrative
Selling, general and administrative expenses for the year ended December 31, 2017 increased by $3.5 million, or
20%, as compared to 2016. The increase was primarily as a result of increased personnel related costs, external professional
fees, and additions to our allowance for doubtful accounts.
42
Income taxes
Provisions for income taxes were $14.4 million and $18.3 million for the years ended December 31, 2017 and 2016,
respectively. The decrease in the effective tax rate in 2017 of 4.9%, as compared to 2016, is primarily due to the revaluation
of the deferred tax liability as a result of the Tax Cuts and Jobs Act tax reform legislation and an increased benefit from
research and development activities. In accordance with Staff Accounting Bulletin No. 118, which provides guidance on
accounting for the tax effects of the 2017 Tax Act, we have recorded a reasonable estimate of the impact on the consolidated
financial statements. The provisional amounts incorporate assumptions made based upon our current interpretation and
implementation guidance of the 2017 Tax Act.
A reconciliation of the U.S. federal statutory tax rate to the effective tax rate for the periods ending December 31 is
as follows:
Statutory federal income tax rate .................................................
State tax expense, net of federal benefit .......................................
Impact of rate change on deferred taxes .......................................
Permanent items, including nondeductible expenses ...................
State investment tax credit ...........................................................
Federal, state and foreign research and development credits .......
Foreign rate differential ................................................................
Domestic production deduction ...................................................
Effective income tax rate .............................................................
Years ended December 31,
2017
2016
35.0%
4.8%
(4.9%)
0.6%
(0.7%)
(1.4%)
0.5%
(2.8%)
31.1%
35.0%
4.5%
0.0%
0.5%
(0.1%)
(0.9%)
(0.1%)
(2.9%)
36.0%
As of December 31, 2017, we had gross NOL for income tax purposes in Italy of $4.0 million with no expiration
date. In connection with the preparation of the financial statements, we performed an analysis to ascertain if it was more
likely than not that we would be able to utilize, in future periods, the net deferred tax assets associated with our NOL carry-
forward. We have concluded that the positive evidence outweighs the negative evidence and, thus, that the deferred tax assets
not otherwise subject to a valuation allowance are realizable on a “more likely than not” basis. As such, we have not recorded
a valuation allowance at December 31, 2017 or 2016.
In the normal course of business, Anika and its subsidiaries may be periodically examined by various taxing
authorities. We file income tax returns in the U.S. federal jurisdiction, in certain U.S. states, and in Italy. The associated tax
filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which
those filings relate.
Net income
For the year ended December 31, 2017, net income was $31.8 million, or $2.11 per diluted share, compared to $32.5,
or $2.15 per diluted share, for the same period in the prior year. The decrease in net income and diluted earnings per share
was primarily a result of increased expenses for our HYALOFAST and CINGAL phase III clinical trials and increases in
personnel related costs, external professional fees, and additions to our allowance for doubtful accounts. These increased
expenses are offset by increased total revenue and a decreased effective federal income tax rate as a result of the 2017 Income
Tax Reform Legislation.
Concentration of Risk
We have historically derived the majority of our revenues from a small number of customers, most of whom resell
our products to end-users and most of whom are significantly larger companies than us. For the year ended December 31,
2018, five customers accounted for 86% of product revenue, with Mitek alone accounting for 73% of product revenue. We
expect to continue to be dependent on a small number of large customers, especially Mitek, for the majority of our revenues
for the foreseeable future. The failure of these customers to purchase our products in the amounts they historically have or in
amounts that we expect would seriously harm our business.
43
In addition, if present and future customers terminate their purchasing arrangements with us, significantly reduce or
delay their orders, or seek to renegotiate their agreements on terms less favorable to us, our business, financial condition, and
results of operations will be adversely affected. If we accept terms less favorable than the terms of the current agreements,
such renegotiations may have a material adverse effect on our business, financial condition, and/or results of operations.
Furthermore, in any future negotiations we may be subject to the perceived or actual leverage that these customers may have
given their relative size and importance to us. Any termination, change, reduction, or delay in orders could seriously harm
our business, financial condition, and results of operations. Accordingly, unless and until we diversify and expand our
customer base, our future success will significantly depend upon the timing and size of future purchases by our largest
customers and the financial and operational success of these customers. The loss of any one of our major customers or the
delay of significant orders from such customers, even if only temporary, could reduce or delay our recognition of revenues,
harm our reputation in the industry, and reduce our ability to accurately predict cash flow, and, as a consequence, it could
seriously harm our business, financial condition, and results of operations.
See Note 3, Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic
Information, to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information
regarding significant customers.
Liquidity and Capital Resources
We require cash to fund our operating expenses and to make capital expenditures. Historically we have generated
positive cash flow from operations, which, together with our available cash, investments, and debt, have met our cash
requirements. Cash, cash equivalents, and investments totaled $159.0 million and $157.3 million, and working capital totaled
$191.7 million and $193.3 million, at December 31, 2018 and December 31, 2017, respectively. As of December 31, 2018,
we have $50.0 million of available credit under our senior revolving credit facility with Bank of America, N.A., and we were
in compliance with the terms of said credit agreement. We believe that we have adequate financial resources to support our
business for at least the next twelve months.
Cash provided by operating activities was $34.9 million, $40.8 million, and $24.4 million for 2018, 2017, and 2016,
respectively. The decrease in cash provided by operations in 2018 was due primarily to higher operating expenses in
manufacturing operations, sales and marketing, and an increase in inventory on hand offset by a decrease in accounts
receivable.
Cash used in investing activities was $50.3 million, $12.5 million, and $6.8 million for 2018, 2017, and 2016,
respectively. The increase was due to increased purchases of investments, partially offset by lower capital expenditures as
compared to 2017 and 2016.
Cash provided (used) by financing activities was ($28.9) million, $0.3 million, and ($24.0) million for 2018, 2017,
and 2016, respectively. The increase in cash used in financing activities for the year ended December 31, 2018 was primarily
attributable to the utilization of $30.0 million cash to repurchase outstanding common stock under the Fixed Dollar
Accelerated Share Repurchase program and $1.8 million of tax payments related to employee tax withholdings on vested
RSAs which were retired, offset in part by $2.9 million in proceeds from equity awards. Similarly, the Company initiated a
$25.0 million accelerated share repurchase program in February 2016 and concluded the program in August 2016.
44
Contractual Obligations and Other Commercial Commitments
The table below summarizes our non-cancelable operating leases, purchase commitments, and contractual
obligations related to future periods which are not reflected in our consolidated balance sheet at December 31, 2018. Purchase
commitments relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal
course of business:
Payments due by period (in thousands)
Less than
More than
Total
1 year
1 - 3 years
3 - 5 years
5 years
Operating Leases (1) .................................... $
Purchase Commitments (2) ..........................
Year Ended December 31, 2018 ................. $
8,703 $
17,591
26,294 $
1,879 $
13,132
15,011 $
3,841 $
2,087
5,928 $
2,086 $
1,589
3,675 $
897
783
1,680
(1)
(2)
Includes a lease we entered into in January 2007, pursuant to which we lease our corporate headquarters facility, which consists of approximately
134,000 square feet of general office, research and development, and manufacturing space located in Bedford, Massachusetts. The lease has an initial
term of ten and one-half years, and commenced in May 2007. In February 2017, we finalized the exercise of its first option under the lease to extend
the terms from November 1, 2017 through October 31, 2022, including the determination of a new annual base rent of $1.5 million which is included
in the disclosure above. No other terms of this lease were altered. We have an option under this lease to extend its lease-term for up to three additional
periods subject to the condition that the Company notify the landlord that we are exercising each option at least one year prior to the expiration of the
original or then-current term. The next two renewal options each extend the term an additional five years, while the final renewal option extends the
term by six years. This schedule does not include the amounts that would be due if the company exercised the renewal options.
Also includes a lease entered into pursuant to which Anika S.r.l. leases its Italian facility. In October 2015, Anika S.r.l, entered into a build-to-
suit lease agreement for a new European headquarters facility consisting of approximately 33,000 square feet of general office, research and
development, training, and warehousing space located in Padova, Italy. This lease has an initial term of fifteen years which commenced in February
2017. The lease will automatically renew for up to three additional six-year terms, subject to certain terms and conditions. We have the ability to
withdraw from this lease subject to certain financial penalties after six years and with no penalties after the ninth year. As such, lease commitments
through the ninth year are included in the table above. The lease provides for an initial yearly rent of approximately $0.3 million. See the section
captioned “Item 2—Properties” in this Annual Report on Form 10-K for additional discussion regarding these leases.
Includes purchase commitments for materials, clinical trials, and other day to day business requirements.
Accounting for Off-Balance Sheet Arrangements
We do not use special purpose entities or other off-balance sheet financing techniques, except for operating leases
as disclosed in the contractual obligations table above, that we believe have or are reasonably likely to have a current or future
material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
or capital resources.
Recent Accounting Pronouncements
A discussion of recent accounting pronouncements is included in Note 2 to the consolidated financial statements in
this Annual Report on Form 10-K.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Primary Market Risk Exposures
We manage our investment portfolio in accordance with our investment policy. The primary objectives of our
investment policy are to preserve principal, maintain a high degree of liquidity to meet operating and other needs, and obtain
competitive returns subject to prevailing market conditions without significantly increasing risk. To achieve this objective,
we maintain our portfolio of cash equivalents and investments in a variety of high quality securities, including money market
funds and bank certificates of deposits. The investments are classified as available-for-sale and consequently are recorded at
fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive income
(loss). Our portfolio of cash equivalents and investments is subject to interest rate fluctuations, changes in credit quality of
the issuer, and other factors.
Foreign Exchange Risk
Our primary market risk exposures are in the area of currency exchange rate risk. A significant portion of Anika
S.r.l.’s revenue and operating expenses are denominated in Euros. We are utilizing clinical vendors which are located in
various countries outside of the United States and invoice us in their local currency. We do not engage in foreign currency
hedging arrangements for our accounts payable, and, consequently, foreign currency fluctuations may adversely affect our
45
earnings. In addition, we have one major supplier contract denominated in a foreign currency. Gains and losses arising from
transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to
be temporary in nature and cash, accounts payable, and accounts receivable denominated in non-functional currencies.
Unfavorable fluctuations in exchange rates would have a negative impact on our financial statements. The impact of currency
exchange rate fluctuations for the contract on our financial statements was immaterial in 2018. In the future, we may undertake
to manage foreign currency risk through additional hedging methods. We recognize foreign currency gains or losses arising
from our operations in the period incurred.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ANIKA THERAPEUTICS, INC. AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Reports of Independent Registered Public Accounting Firms ...........................................................................................
Consolidated Balance Sheets as of December 31, 2018 and 2017 ....................................................................................
Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2018, 2017
and 2016 ........................................................................................................................................................................
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2018, 2017 and 2016 ..................
Consolidated Statements of Cash Flows for the Years Ended December 31, 2018, 2017 and 2016 .................................
Notes to Consolidated Financial Statements .....................................................................................................................
47
49
50
51
52
53
46
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Anika Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Anika Therapeutics, Inc. and subsidiaries (the "Company")
as of December 31, 2018 and 2017, the related consolidated statements of operations and comprehensive income,
stockholders’ equity and cash flows for the years ended December 31, 2018 and 2017, and the related notes (collectively
referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for
the years ended December 31, 2018 and 2017, in conformity with the accounting principles generally accepted in the United
States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in
Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway
Commission and our report dated February 26, 2019, expressed an unqualified opinion on the Company's internal control
over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion
on the Company's financial statements based on our audit. We are a public accounting firm registered with the PCAOB and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the
overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 26, 2019
We have served as the Company’s auditor since 2017.
47
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Anika Therapeutics, Inc.
In our opinion, the consolidated statements of operations and comprehensive income, of stockholders’ equity and of cash
flows for the year ended December 31, 2016 present fairly, in all material respects, the results of operations and cash flows
of Anika Therapeutics, Inc. and its subsidiaries for the year ended December 31, 2016, in conformity with accounting
principles generally accepted in the United States of America. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We
conducted our audit of these financial statements in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and
significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our
audit provides a reasonable basis for our opinion.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 24, 2017
48
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
Current assets:
ASSETS
Cash and cash equivalents ....................................................................................... $
Investments ..............................................................................................................
Accounts receivable, net of reserves of $1,525 and $1,914 at December 31, 2018
and December 31, 2017, respectively ..................................................................
Inventories, net ........................................................................................................
Prepaid expenses and other current assets ...............................................................
Total current assets ..............................................................................................
Property and equipment, net ........................................................................................
Other long-term assets .................................................................................................
Intangible assets, net ...................................................................................................
Goodwill ......................................................................................................................
Total assets .................................................................................................................. $
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable .................................................................................................... $
Accrued expenses and other current liabilities ........................................................
Total current liabilities ........................................................................................
Other long-term liabilities ...........................................................................................
Deferred tax liability ...................................................................................................
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and
December 31,
2018
2017
89,042 $
69,972
20,775
21,300
1,854
202,943
54,111
4,897
9,191
7,851
278,993 $
3,143 $
8,146
11,289
550
3,542
133,256
24,000
23,825
22,035
3,211
206,327
56,183
1,254
10,635
8,218
282,617
6,747
6,326
13,073
660
5,393
outstanding at December 31, 2018 and December 31, 2017, respectively ..........
-
-
Common stock, $.01 par value; 90,000 and 60,000 shares authorized, 14,210 and
14,688 shares issued and outstanding at December 31, 2018 and December 31,
2017, respectively ................................................................................................
Additional paid-in-capital ........................................................................................
Accumulated other comprehensive loss ..................................................................
Retained earnings ....................................................................................................
Total stockholders’ equity ...................................................................................
Total liabilities and stockholders’ equity..................................................................... $
142
50,763
(5,526 )
218,233
263,612
278,993 $
147
68,617
(4,784 )
199,511
263,491
282,617
The accompanying notes are an integral part of these consolidated financial statements.
49
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Income
(in thousands, except per share data)
For the Years Ended December 31,
2017
107,783 $
5,637
113,420
2018
105,531 $
24
105,555
2016
102,932
447
103,379
24,027
10,732
18,013
52,772
50,607
263
50,870
18,323
32,547
2.22
14,682
2.15
15,116
32,547
(668)
31,879
Product Revenue ............................................................................ $
Licensing, milestone and contract revenue .....................................
Total revenue ..............................................................................
Operating expenses:
Cost of product revenue .............................................................
Research & development ............................................................
Selling, general & administrative ...............................................
Total operating expenses ................................................................
Income from operations ..................................................................
Interest and other income, net ....................................................
Income before income taxes ...........................................................
Provision for income taxes .........................................................
Net income ..................................................................................... $
31,280
18,190
34,336
83,806
21,749
1,458
23,207
4,485
18,722 $
27,364
18,787
21,540
67,691
45,729
473
46,202
14,386
31,816 $
Basic net income per share:
Net income ................................................................................. $
Basic weighted average common shares outstanding .................
1.30 $
14,442
2.18 $
14,575
Diluted net income per share:
Net income ................................................................................. $
Diluted weighted average common shares outstanding ..............
1.27 $
14,689
2.11 $
15,068
Net income ......................................................................................... $
Foreign currency translation adjustment ....................................
Comprehensive income ...................................................................... $
18,722 $
(742)
17,980 $
31,816 $
2,533
34,349 $
The accompanying notes are an integral part of these consolidated financial statements.
50
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Stockholders' Equity
(in thousands)
Common Stock
Accumulated
Other
Total
Number of $.01 Par Additional Paid Retained Comprehensive Stockholders'
Shares
Earnings
in Capital
Value
Loss
Equity
210,848
Balance, December 31, 2015 ................... 15,037 $ 150 $
81,685 $135,662 $
(6,649) $
Issuance of common stock for equity
awards .............................................
Tax benefit related to equity awards....
Stock-based compensation expense.....
Repurchase of common stock ..............
Net income ..........................................
Other comprehensive loss ...................
1
-
-
(5)
-
-
Balance, December 31, 2016 ................... 14,627 $ 146 $
121
-
-
(531)
-
-
1,006
647
3,392
(24,995)
-
-
-
-
- 32,547
-
-
61,735 $168,209 $
-
-
-
-
-
(668)
(7,317) $
1,007
647
3,392
(25,000)
32,547
(668)
222,773
Issuance of common stock for equity
61
-
1
-
313
5,807
-
-
-
-
314
5,807
awards .............................................
Stock-based compensation expense.....
Cumulative effect of change in
accounting for stock-based
compensation ...................................
Net income ..........................................
Other comprehensive income ..............
-
-
-
Balance, December 31, 2017 ................... 14,688 $ 147 $
-
-
-
762
(514)
- 31,816
-
-
68,617 $199,511 $
-
-
2,533
(4,784) $
248
31,816
2,533
263,491
Issuance of common stock for equity
awards .............................................
362
4
2,882
-
-
2,886
Retirement of common stock for
minimum tax withholdings ..............
Stock-based compensation expense.....
Repurchase of common stock ..............
Net income ..........................................
Other comprehensive loss ...................
(1)
-
(8)
-
-
Balance, December 31, 2018 ................... 14,210 $ 142 $
(34)
-
(806)
-
-
(1,790)
11,046
(29,992)
-
-
-
- 18,722
-
-
50,763 $218,233 $
-
-
-
-
(742)
(5,526) $
(1,791)
11,046
(30,000)
18,722
(742)
263,612
The accompanying notes are an integral part of these consolidated financial statements.
51
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
For the years ended December 31,
2017
2016
2018
18,722 $
31,816 $
32,547
Cash flows from operating activities:
Net income ..................................................................................... $
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization ...................................................
Loss on disposal of fixed assets ..................................................
Stock-based compensation expense ............................................
Deferred income taxes ................................................................
Provision for doubtful accounts ..................................................
Provision for inventory ...............................................................
Accretion to amortized cost of investments................................
Changes in operating assets and liabilities:
Accounts receivable ...............................................................
Inventories ..............................................................................
Prepaid expenses, other current and long-term assets ............
Accounts payable ...................................................................
Accrued expenses, other current and long-term liabilities......
Income taxes payable .............................................................
Net cash provided by operating activities ...........................................
5,910
152
11,046
(1,817)
57
4,419
(371)
2,914
(7,577)
899
(1,671)
1,313
922
34,918
4,290
150
5,807
(1,198)
1,609
695
-
2,674
(6,521)
(1,454)
3,890
(1,313)
367
40,812
Cash flows from investing activities:
Proceeds from maturity of investments ..........................................
Purchase of investments .................................................................
Purchase of property and equipment ..............................................
Net cash (used in) investing activities ................................................
46,000
(91,601)
(4,656)
(50,257)
41,500
(45,000)
(8,980)
(12,480)
Cash flows from financing activities:
Repurchase of common stock .........................................................
Tax payments related to witholdings on vested restricted stock.....
Proceeds from exercise of equity awards .......................................
Net cash (used in) provided by financing activities ............................
(30,000)
(1,790)
2,886
(28,904)
-
-
314
314
3,734
-
3,392
(65)
52
654
-
(6,201)
(1,738)
(898)
(5,059)
1,582
(3,552)
24,448
46,500
(39,249)
(14,014)
(6,763)
(25,000)
-
1,007
(23,993)
Exchange rate impact on cash ............................................................
29
349
(138)
Increase (Decrease) in cash and cash equivalents ..............................
Cash and cash equivalents at beginning of period ..............................
Cash and cash equivalents at end of period ........................................ $
Supplemental disclosure of cash flow information:
(44,214)
133,256
89,042 $
28,995
104,261
133,256 $
(6,446)
110,707
104,261
Cash paid for income taxes............................................................. $
5,560 $
15,088 $
22,826
Non-cash Investing Activities:
Purchases of property and equipment included in accounts
payable and accrued expenses .................................................... $
Build-to-suit lease agreement ......................................................... $
351 $
- $
1,891 $
- $
1,257
1,723
The accompanying notes are an integral part of these consolidated financial statements.
52
Anika Therapeutics, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(amounts in thousands, except share and per share amounts or as otherwise noted)
1. Nature of Business
Anika Therapeutics, Inc. (the “Company”) is a global, integrated orthopedic and regenerative medicines company
committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically
meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The
Company has over two decades of global expertise developing, manufacturing, and commercializing products based on its
proprietary Hyaluronic Acid (“HA”) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC,
MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration.
The Company is subject to risks common to companies in the biotechnology and medical device industries including,
but not limited to, development by the Company or its competitors of new technological innovations, dependence on key
personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S.
Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the
Company’s business through appropriate commercial strategies.
At the Company’s annual stockholders’ meeting on May 31, 2018, the Company’s stockholders approved an increase
in the number of shares of common stock that the Company is authorized to issue from 60 million to 90 million and ratified
a change in the Company’s state of incorporation from the Commonwealth of Massachusetts to the State of Delaware,
pursuant to a plan of domestication. The Company became a Delaware corporation with the authorization to issue up to 90
million shares of its common stock on June 6, 2018. Upon its domestication in Delaware, the affairs of the Company became
subject to the Delaware General Corporation Law, the Company implemented a new certificate of incorporation and new
bylaws, and each previously outstanding share of the Company’s common stock as a Massachusetts corporation (Anika
Massachusetts) converted into an outstanding share of common stock of the Company as a Delaware corporation (Anika
Delaware). The domestication was a tax-free reorganization under the U.S. Internal Revenue Code, and it did not affect the
Company’s business operations.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United
States of America requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly
owned subsidiaries, Anika Securities, Inc. (a Massachusetts Securities Corporation), and Anika Therapeutics S.r.l. (“Anika
S.r.l.”). All intercompany balances and transactions have been eliminated in consolidation.
53
Foreign Currency Translation
The functional currency of the Company’s foreign subsidiary is the Euro. Assets and liabilities of the foreign
subsidiary are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are
translated using the average exchange rates for the period. The translation adjustments resulting from this process are included
in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss)
from foreign currency translation of ($0.7) million, $2.5 million, and ($0.7) million for the years ended December 31, 2018,
2017, and 2016, respectively.
Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of
operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the
functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of
operations. The Company recognized a gain (loss) from foreign currency transactions of ($0.4) million, $0.7 million, and
($0.3) million during the years ended December 31, 2018, 2017, and 2016, respectively.
Fair Value Measurements
Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an
orderly transaction between market participants at the measurement date. When determining the fair value measurements for
assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market
in which it would transact and considers assumptions that market participants would use when pricing the asset or liability,
such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value
hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value.
A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that
is significant to the fair value measurement. Three levels of inputs that may be used to measure fair value are:
• Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1
instruments include securities traded on active exchange markets, such as the New York Stock Exchange.
• Level 2 – Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical
or similar instruments in markets that are not active and model-based valuation techniques for which all significant
assumptions are directly observable in the market.
• Level 3 – Valuation is generated from model-based techniques that use significant assumptions not observable in
the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market
participants would use in pricing the instrument.
The Company’s financial assets have been classified as Levels 1. The Company’s financial assets (which include
cash equivalents and investments) have been initially valued at the transaction price and subsequently valued, at the end of
each reporting period, utilizing third party pricing services or other market observable data.
54
Allowance for Doubtful Accounts
The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its
customers to make required payments, which is included in selling, general and administrative expenses in the accompanying
consolidated statements of operations. In determining the adequacy of the allowance for doubtful accounts, management
specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer credit-
worthiness, current economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment
terms. A summary of activity in the allowance for doubtful accounts is as follows:
2018
December 31,
2017
2016
Balance, beginning of the year ..................... $
Amounts provided ....................................
Amounts recovered ..................................
Amounts written off .................................
Translation adjustments ............................
Balance, end of the year ............................... $
1,914 $
57
(360)
-
(86)
1,525 $
194 $
1,609
-
(6)
117
1,914 $
167
52
-
(16)
(9)
194
Revenue Recognition - General
The Company adopted the guidance the FASB’s Accounting Standards Codification (“ASC”) Revenue from
Contracts with Customers (ASC 606) using the modified retrospective method effective January 1, 2018. The adoption of
ASC 606 was applied to all contracts not completed as of the date of adoption. The adoption did not have a material impact
on the amount and timing of revenue recognized in the consolidated financial statements. The Company made no adjustments
to previously reported product and total revenue, as those periods continue to be presented in accordance with historical
accounting practices under Topic 605, Revenue Recognition.
Pursuant to ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or
services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange
for those goods or services. The Company applies the following five-step model in order to determine this amount: (i)
identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are capable of being distinct or distinct in the context of the contract;
(iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction
price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance
obligation.
The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc.
(“Mitek”) that include the grant of certain licenses, performance of development services, and the supply of product at Mitek’s
option. Revenues from the agreements with Mitek represent 73% of total revenues for the year-ended December 31, 2018.
The Company completed the performance obligations related to granted licenses and development services under these
agreements prior to 2016. The Company has no remaining material performance obligations under the Mitek agreements.
The Company has agreements with other customers that may include the delivery of a license and supply of product.
The upfront payments under such agreements upon the delivery of the license have not been material.
The Company’s typical supply agreements represent a promise to deliver product at the customer’s discretion that
are considered options. The Company assessed if these options provide a material right to the licensee and if so, they are
accounted for as separate performance obligations. The majority of the Company’s supply agreements do not provide options
that are considered material rights.
Certain of the Company’s agreements include sales-based royalties and milestones. As the Company considered the
license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are
only recognized when the later of the underlying sale occurs or the performance obligation to which some or all of the sales-
based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees
complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty.
Revenue from sales-based royalties is included in product revenues.
55
Product Revenue
The Company sells its products principally to a number of distributors (i.e., its customers) under legally-enforceable,
executed contracts. The Company’s distributors subsequently resell the products to sub-distributors and health care providers,
among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s
product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration.
Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied
performance obligations at the end of any reporting period is generally immaterial.
The Company’s payment terms are consistent with prevailing practice in the respective markets in which the
Company does business. Most of the Company’s distributors make payments based on fixed-price contract terms, which are
not affected by contingent events that could impact the transaction price. Payment terms fall within the one-year guidance
for the practical expedient, which allows us to forgo adjustment of the contractual payment amount of consideration for the
effects of a significant financing component. The Company’s contracts with customers do not customarily provide a right of
return, unless certain product quality standards are not met.
Some of the Company’s distributor agreements have volume based discounts with tiered pricing which are generally
prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as
potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these
would be separate performance obligations and a portion of the sales transaction price is allocated to the material right.
Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the
option expires. During 2018, the consideration allocated to material rights was not significant.
The Company receives payments from its customers based on billing schedules established in each contract. Up-
front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue
recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded
as accounts receivable when its right to consideration is unconditional. As of January 1, 2018 and December 31, 2018 deferred
revenue was $0.
Generally, distributor contracts contain Free on Board (FOB) or Ex-Works (EXW) shipping point terms where the
customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company
pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of
shipment in cost of product revenue when control over the products has transferred to the customer. The Company does not
collect sales tax on product sales as it is not applicable. Value-add and other taxes collected by us concurrently with revenue-
producing activities are excluded from revenue. The Company’s general product warranty does not extend beyond an
assurance that the product or services delivered will be consistent with stated contractual specifications, which does not create
a separate performance obligation. The Company recognizes the incremental costs of obtaining contracts as an expense when
incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less in
accordance with the practical expedient in paragraph ASC 340-40-25-4. These costs are included in selling, general &
administrative expenses.
Included as a component of product revenue is sales-based royalty revenue, which represents the utilization of the
Company’s intellectual property licensed by its commercial partners. The Company records royalty revenues based on
estimated net sales of licensed products as reported to us by the Company’s commercial partners. Differences between actual
and estimated royalty revenues have not been material and are typically adjusted in the following quarter when the actual
amounts are known.
Licensing, Milestone and Contract Revenue
The agreements with Mitek include variable consideration such as contingent development and regulatory
milestones. As of the date of adoption of ASC 606, there is one remaining regulatory milestone related to the Mitek
agreements and the Company has no performance obligation related to this milestone. In general, variable consideration is
included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is
not probable to occur. Future payments for regulatory milestones will be recognized as revenue when the regulatory milestone
is considered probable of being achieved.
56
Cash and Cash Equivalents
The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature
within three months from date of purchase to be cash equivalents. The Company’s cash equivalents consist of money market
funds, mutual funds, and bank certificates of deposit with an original maturity of less than 90 days.
Investments
The Company’s investments consist of U.S. treasury bills. The Company has designated all investments as available-
for-sale, and therefore such investments are reported at fair value, with unrealized gains and losses recorded in accumulated
other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific
identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net.
Interest is recorded when earned. Investments with original maturities greater than approximately three months and remaining
maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one
year are classified as long-term investments. The Company considers securities with original maturities of three months or
less from the purchase date to be cash equivalents.
All of the Company’s investments are subject to a periodic impairment review. The Company recognizes an
impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-
temporary. Factors considered in determining whether a loss is temporary include the extent and length of time the
investment's fair value has been lower than its cost basis, the financial condition and near-term prospects of the investee,
extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the
security, and whether or not the Company will be required to sell the security prior the expected recovery of the investment's
amortized cost basis. During the years ended December 31, 2018 and 2017, the Company did not record any other-than-
temporary impairment charges on its available-for-sale securities because the Company does not intend to sell the securities
and it is not more likely than not that the Company will be required to sell these securities before the recovery of their cost
basis.
Concentration of Credit Risk and Significant Customers
The Company has no significant off-balance sheet risks related to foreign exchange contracts, option contracts, or
other foreign hedging arrangements. The Company’s cash equivalents and investments are held with two major international
financial institutions.
The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes
that its accounts receivable credit risk exposure is limited.
As of December 31, 2018 and 2017, Mitek represented 75% and 68%, respectively, of the Company’s accounts
receivable balance, no other single customer accounted for more than 10% of accounts receivable in either period.
Inventories
Inventories are stated at the lower of standard cost and net realizable value, with approximate cost determined using
the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing
overhead. Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized
if the Company believes there is probable future commercial use and future economic benefit.
The Company’s policy is to write-down inventory when conditions exist that suggest inventory may be in excess
of anticipated demand or is obsolete based upon assumptions about future demand for the Company’s products and market
conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors
including, but not limited to, historical usage rates, forecasted sales or usage, product end of life dates, and estimated current
or future market values. Purchasing requirements and alternative usage avenues are explored within these processes to
mitigate inventory exposure.
57
When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable
value. Inventory of $25.1 million, including $3.8 million within Other long-term assets, and $22.0 million as of December
31, 2018 and 2017, respectively, is stated net of inventory reserves of approximately $3.5 million and $1.7 million,
respectively. If actual demand for the Company’s products deteriorates, or if market conditions are less favorable than those
projected, additional inventory write-downs may be required.
Property and Equipment
Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated
useful lives, which are typically:
Asset
Computer equipment and software .......................
Furniture and fixtures ...........................................
Equipment ............................................................
Leasehold improvements ...................................... Shorter of useful life or term of lease
Estimated useful life
(in years)
3-10
5-7
5-20
Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully
depreciated assets are retained in the accounts until they are no longer used and no further charge for depreciation is made in
respect of these assets. When an item is sold, retired or removed from service, the cost and related accumulated depreciation
is relieved, and the resulting gain or loss, if any, is recognized in income.
Construction-in-process is stated at cost, which includes the cost of construction and other direct costs attributable
to the construction. Construction-in-process is not depreciated until such time as the relevant assets are completed and put
into use.
Goodwill and Acquired Intangible Assets
Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the
fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&D”)
represents the fair value assigned to research and development assets that the Company acquires that have not been completed
at the date of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&D
is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the
resulting revenue from the projects, and discounting the net cash flows to present value.
Goodwill and IPR&D are evaluated for impairment annually or more frequently if events or changes in
circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company
basis, that could trigger an impairment review include significant underperformance relative to historical or projected future
operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business,
significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or
a reduction of its market capitalization relative to net book value.
To conduct impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the
reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying
value of goodwill exceeds its implied fair value. The Company’s annual assessment for impairment of goodwill as of
November 30, 2018 indicated that the fair value of its reporting unit exceeded the carrying value of the reporting unit.
To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the
carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the
IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D using discounted cash flow valuation
models, which require the use of significant estimates and assumptions, including but not limited to, estimating the timing of
and expected costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows from
product sales resulting from completed projects and in-process projects, and developing appropriate discount rates. The
Company’s annual assessment for impairment of IPR&D indicated that the fair value of its other IPR&D assets as of
November 30, 2018 and 2017 exceeded the respective carrying values.
58
Long-Lived Assets
Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s
intangible assets are comprised of purchased developed technologies, patents, and trade names. These intangible assets are
carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets'
useful lives, which range from approximately five to sixteen years. The Company reviews long-lived assets for impairment
when events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable
or that the useful lives of those assets are no longer appropriate. Each impairment test is based on a comparison of the
undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated
fair value based on a discounted cash flow analysis.
Research and Development
Research and development costs consist primarily of clinical trials, salaries and related expenses for personnel, and
fees paid to outside consultants and outside service providers, including costs associated with licensing, milestone and
contract revenue. Research and development costs are expensed as incurred.
Stock-Based Compensation
The Company has stock-based compensation plans under which it grants various types of equity-based awards,
including restricted stock units (“RSUs”), restricted stock awards (“RSAs”), performance options, and stock options. The
Company measures the compensation cost of award recipients’ services received in exchange for an award of equity
instruments based on the grant date fair value of the underlying award. That cost is recognized over the period during which
an employee is required to provide service in exchange for the award.
For performance-based options with financial and business milestone achievement targets, the Company recognizes
expense using the graded vesting methodology over the service period. Compensation cost associated with performance-
based options is based on the probable outcome of the performance conditions. Changes to the probability assessment and
the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be
recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized, and
any previously recognized compensation cost is reversed. The Company recorded $0.7 million, $0.8 million, and $0.3 million
related to performance-based options in 2018, 2017, and 2016, respectively.
See Note 13, Equity Incentive Plan, to the consolidated financial statements included elsewhere in this Annual
Report on Form 10-K for a description of the types of stock-based awards granted, the compensation expense related to such
awards, and detail of equity-based awards outstanding.
Income Taxes
The Company’s income tax expense includes U.S. and international income taxes. Certain items of income and
expense are not reported in tax returns and financial statements in the same year. The tax effects of these timing differences
are reported as deferred tax assets and liabilities. Deferred tax assets are recognized for the estimated future tax effects of
deductible temporary differences, tax operating losses, and tax credit carry-forwards (including investment tax credits).
Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the
likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes that it is more
likely than not that all or a portion of deferred tax assets will not be realized, the Company establishes a valuation allowance
to reduce the deferred tax assets to the appropriate valuation. To the extent the Company establishes a valuation allowance
or increases or decreases this allowance in a given period, it includes the related tax expense or tax benefit within the tax
provision in the consolidated statement of operations in that period.
59
Comprehensive Income
Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign
currency translation adjustments. For the purposes of comprehensive income disclosures, the Company does not record tax
provisions or benefits for the net changes in the foreign currency translation adjustment, as it intends to indefinitely reinvest
undistributed earnings of its foreign subsidiary. Accumulated other comprehensive income (loss) is reported as a component
of stockholders' equity.
Segment Information
Operating segments are components of an enterprise about which separate financial information is available that is
evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources
and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer.
Based on the criteria established by ASC 280, Segment Reporting, the Company has one operating and reportable segment.
Contingencies
In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other
matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The
Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been
incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when
making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently
difficult to predict, the Company does not expect the resolution of any potential legal proceedings to have a material adverse
effect on its financial position, results of operations, or cash flow.
Subsequent Events
Events occurring subsequent to December 31, 2018 have been evaluated for potential recognition or disclosure in
the consolidated financial statements. As a result of the evaluation, no subsequent events were required to be recognized or
disclosed.
Recent Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update
(“ASU”) No. 2016-02, Leases (Topic 842), which amends existing leasing accounting requirements. The most significant
change will result in the recognition of lease assets and lease liabilities by lessees for virtually all leases. The new guidance
will also require significant additional disclosures about the amount, timing, and uncertainty of cash flows from leases. ASU
2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018. This updated guidance provided
an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and
the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period
of adoption. The Company adopted the new standard beginning on January 1, 2019 and elected the optional transition method
with no restatement of prior period amounts. A number of optional practical expedients may be elected to simplify the impact
of adoption. The Company has assessed ASU 2016-02 and the impact that adopting this new accounting standard will have
on its consolidated financial statements and footnote disclosures. The Company expects to record, upon adoption right-of-
use assets of approximately $20.0 to $23.0 million and corresponding liabilities related to its real estate leases with terms of
more than 12 months that are not treated as financing leases under Topic 842. The adoption of this standard is not expected
to have a significant impact on the Company’s consolidated statements of operations and comprehensive income and
consolidated statements of cash flows.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use
Software (Subtopic 350-40), which amends ASU No. 2015-05, Customers Accounting for Fees in a Cloud Computing
Agreement, to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting
arrangement) by providing guidance for determining when the arrangement includes a software license. The most significant
change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service
contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and
hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU 2018-15 require an
entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which
implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is
effective for fiscal years and interim periods beginning after December 15, 2019. Early adoption is permitted, including
60
adoption in any interim period for all entities. The Company is assessing ASU 2018-15 and the impact that adopting this new
accounting standard will have on its consolidated financial statements and footnote disclosures.
3. Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information
Product revenue by product group is as follows:
2018
Years Ended December 31,
2017
2016
Orthobiologics .......................................... $
Dermal ......................................................
Surgical ....................................................
Other .........................................................
Percentage
of Product
Revenue
Percentage
of Product
Revenue
Revenue
93,556
396
5,514
6,065
$ 105,531
Revenue
93,816
2,755
5,262
5,950
100% $ 107,783
89% $
0%
5%
6%
Revenue
87% $ 89,695
2,759
5,427
5,051
100% $ 102,932
3%
5%
5%
Percentage
of Product
Revenue
87%
3%
5%
5%
100%
Product revenue from the Company’s sole significant customer, Mitek, as a percentage of the Company’s total
product revenue was 73%, 73%, and 75% for the years ended December 31, 2018, 2017, and 2016, respectively.
ORTHOVISC became available for sale in the United States on March 1, 2004, and it is marketed exclusively by
Mitek under the terms of an initial ten-year licensing, distribution, supply, and marketing agreement entered into in December
2003. The agreement was extended by Mitek for additional five-year terms in 2012 and in 2017, with the current agreement
to expire on December 20, 2023.
In December 2011, the Company entered into a fifteen-year licensing agreement with Mitek to exclusively market
MONOVISC in the United States. The agreement provides certain milestone payments to the Company when rolling end-
user sales of U.S. MONOVISC exceed certain target sales goals. For the years ended December 31, 2018, 2017, and 2016,
the Company recognized milestone revenue of $0.0 million, $5.0 million, and $0.0 million, respectively. The milestone
revenue of $5.0 million in 2017 was as a result of MONOVISC achieving end-user sales in 2017 of $100 million within a
consecutive 12-month period in the United States.
Total revenue by geographic location based on the location of the customer in total and as a percentage of total
revenue are as follows:
Total
Revenue
2018
Percentage of
Revenue
Years Ended December 31,
2017
Percentage of
Revenue
Total
Revenue
Total
Revenue
2016
Percentage of
Revenue
Geographic Location:
United States ....................................... $ 85,351
Europe ................................................. 11,730
Other ....................................................
8,474
Total ................................................ $ 105,555
81% $ 92,905
11% 12,435
8,080
8%
100% $ 113,420
82% $ 83,972
11% 10,953
8,454
7%
100% $ 103,379
81%
11%
8%
100%
61
On May 2, 2018, the Company publicly disclosed a voluntary recall of certain production lots of its HYAFF-based
products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the voluntary recall after
internal quality testing, which indicated that the products were at risk of not maintaining certain measures throughout their
entire shelf life. While there was no indication of any safety or efficacy issue related to the products at the time, the Company
removed the products from the field as a precautionary measure. During the three-month period ended March 31, 2018 the
Company recorded a revenue reserve for this voluntary recall of $1.1 million of which $0.9 million was related to revenue
recorded in prior periods. The adjustments related to the initial revenue reserve subsequent to March 31, 2018 were
immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and all geographic locations.
Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are
generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they
are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows:
United States ............................................................. $
Italy ...........................................................................
Total ...................................................................... $
51,385 $
2,726
54,111 $
52,828
3,355
56,183
Years Ended December 31,
2018
2017
4. Investments
All of the Company’s investments are classified as available-for-sale and are carried at fair value with unrealized
gains and losses recorded as a component of accumulated other comprehensive income (loss), net of related income taxes.
The Company held U.S. treasury bills of $70.0 million at December 31, 2018. The Company held certificates of deposit of
$24.0 million at December 31, 2017. Unrealized losses and the associated tax impact on the Company’s available-for-sale
securities were insignificant as of December 31, 2018 and December 31, 2017, respectively.
5. Fair Value Measurements
The Company’s investments are all classified within Level 1 of the fair value hierarchy. The Company’s investments
classified within Level 1 of the fair value hierarchy are valued based quoted prices in active markets. Level 2 are based on
matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest rates, yield curves,
and credit risk. For cash and cash equivalents, current receivables, accounts payable, and interest accrual, the carrying
amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is
not included in the table below.
62
The classification of the Company’s cash equivalents and investments within the fair value hierarchy is as follows:
Fair Value Measurements at Reporting Date Using
Quoted Prices
in Active
Markets
for Identical
Assets (Level 1)
Significant
Other
Observable
Inputs (Level 2)
Significant
Unobservable
Inputs (Level 3)
December 31,
2018
Amortized Cost
Cash equivalents:
Money Market Funds .................... $
Investments:
U.S. treasury bills .......................... $
4,984 $
4,984 $
69,972 $
69,972 $
- $
- $
- $
4,984
- $
69,972
Fair Value Measurements at Reporting Date Using
Quoted Prices
in Active
Markets
for Identical
Assets (Level 1)
Significant
Other
Observable
Inputs (Level 2)
Significant
Unobservable
Inputs (Level 3)
December 31,
2017
Amortized Cost
Cash equivalents:
Money market funds ...................... $
Bank certificates of deposit ............
Total cash equivalents .................... $
Investments:
Bank certificates of deposit ............ $
5,893 $
500
6,393 $
5,893 $
-
5,893 $
- $
500
500 $
- $
-
- $
5,893
500
6,393
24,000 $
- $
24,000 $
- $
24,000
The Company did not have transfers in or out of Level 3 of the fair value hierarchy during the years ended December
31, 2018 and 2017.
6. Earnings per Share (“EPS”)
Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the
period. Unvested RSAs, although legally issued and outstanding, are not considered outstanding for purposes of calculating
basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares
outstanding plus the dilutive effect, if any, of outstanding stock options, stock appreciation rights (“SARs”), RSAs, and RSUs
using the treasury stock method.
The following table provides share information used in the calculation of the Company's basic and diluted earnings
per share:
Shares used in the calculation of basic earnings per share ...................
Effect of dilutive securities:
Stock options, SARs, RSAs and RSUs .........................................
Diluted shares used in the calculation of earnings per share ................
Years Ended December 31,
2017
2016
2018
14,442
14,575
14,682
247
14,689
493
15,068
434
15,116
Stock options to purchase 0.7 million shares, 0.5 million shares, and 0.4 million shares for the years ended December
31, 2018, 2017, and 2016, respectively, were excluded from the computation of diluted EPS as their effect would have been
anti-dilutive. The anti-dilutive restricted shares for the years 2018, 2017 and 2016 were insignificant.
At December 31, 2018, 2017, and 2016 a total of 42 thousand, 0.1 million, and 0.1 million shares of issued and
outstanding unvested RSAs were excluded from the basic earnings per share.
On May 24, 2018, the Company entered into an accelerated stock repurchase agreement with Morgan Stanley & Co.
LLC (“Morgan Stanley”) pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement") to
purchase $30.0 million of shares of its common stock. Pursuant to the terms of the ASR Agreement, the Company delivered
$30.0 million cash to Morgan Stanley and received an initial delivery of 0.4 million shares of the Company’s common stock
63
on May 24, 2018 based on a closing market price of $41.41 and the applicable contractual discount. This was approximately
60% of the then estimated total number of shares expected to be repurchased under the ASR Agreement.
On July 16, 2018, the Company settled the approximately $12.0 million remaining under the ASR Agreement, which
was recorded as an equity forward sale contract and was included in additional paid-in-capital in stockholders' equity in the
consolidated balance sheet as it met the criteria for equity accounting. Pursuant to the terms of the ASR Agreement, the final
number of shares and the average purchase price was determined at the end of the applicable purchase period, which was
July 16, 2018. Based on the volume-weighted average price since the effective date of the ASR Agreement less the applicable
contractual discount, Morgan Stanley delivered 0.4 million additional shares to the Company on July 19, 2018. In total, 0.8
million shares were repurchased under the ASR Agreement at an average repurchase price of $37.18 per share. These shares
are held by the Company as authorized but unissued shares. All shares were repurchased in accordance with the publicly
announced program, and the Company will not make any further purchases under the program. The initial and final delivery
of shares resulted in an immediate reduction of the number of outstanding shares used to calculate the weighted-average
common shares outstanding for basic and diluted net income per share on the effective date of the ASR Agreement.
On February 26, 2016, the Company entered into an accelerated stock repurchase agreement with Morgan Stanley
pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement") to purchase $25.0 million of
shares of its common stock. Pursuant to the terms of the ASR Agreement, the Company paid Morgan Stanley $25.0 million in
cash and received an initial delivery of 0.4 million shares of the Company’s common stock on February 29, 2016 based on a
closing market price of $46.40 per share and the applicable contractual discount.
On August 26, 2016, the Company settled the approximately $7.5 million remaining under the ASR Agreement,
which was recorded as an equity forward sale contract and was included in additional paid-in capital in stockholders' equity
in the consolidated balance sheet as it met the criteria for equity accounting. Pursuant to the terms of the ASR Agreement,
the final number of shares and the average purchase price was determined at the end of the applicable purchase period, which
was August 26, 2016. Based on the volume-weighted average price since the effective date of the ASR Agreement less the
applicable contractual discount, Morgan Stanley delivered 0.1 million additional shares to the Company on August 31, 2016.
In total, 0.5 million shares were repurchased under the ASR Agreement at an average repurchase price of $47.08 per share.
These shares are held by the Company as authorized but unissued shares. The initial and final delivery of shares resulted in
immediate reductions of the outstanding shares used to calculate the weighted-average common shares outstanding for basic
and diluted net income per share.
7. Inventories
Inventories consist of the following:
December 31,
2018
2017
Raw materials ............................................................................. $
Work-in-process .........................................................................
Finished goods............................................................................
Total ....................................................................................... $
13,688 $
4,626
6,819
25,133 $
Inventories .................................................................................. $
Other long-term assets ................................................................
21,300 $
3,833
11,296
6,062
4,677
22,035
22,035
-
Other long-term assets include inventory expected to remain on hand beyond one year as of December 31, 2018.
64
As a result of the voluntary recall of certain production lots of the Company’s HYAFF-based products, more fully
described in Note 3, the Company recorded an inventory reserve of $0.8 million for non-saleable inventory. In addition, the
Company recorded a net inventory reserve of $1.3 million for certain HA raw materials, and it recorded a lower of cost or
net realizable value adjustment of $1.2 million for certain HYAFF-based products during the year ended December 31, 2018.
8. Property and Equipment
Property and equipment is stated at cost and consists of the following:
December 31,
2018
2017
Equipment and software ............................................................. $
Furniture and fixtures .................................................................
Leasehold improvements ............................................................
Construction in progress .............................................................
Subtotal ..................................................................................
Less accumulated depreciation ...................................................
Total ....................................................................................... $
39,646 $
2,014
33,801
2,720
78,181
(24,070)
54,111 $
37,137
1,947
31,459
5,830
76,373
(20,190)
56,183
Construction-in-progress at December 31, 2018 and 2017 primarily represents the costs incurred for the development
of an injectable, HA-based surgical bone repair product expected to launch in 2019. In addition, construction-in-progress at
December 31, 2017 also included the costs incurred for the implementation of a new ERP that was placed in service in January
2018.
Depreciation expense was $4.9 million, $3.3 million, and $2.7 million for the years ended December 31, 2018, 2017,
and 2016, respectively.
65
9. Acquired Intangible Assets, Net
Intangible assets consist of the following:
December 31, 2018
December 31, 2017
Accumulated
Currency
Translation
Adjustment
Accumulated
Amortization
Net Book
Value
Accumulated
Currency
Translation
Adjustment
Accumulated
Amortization
Net Book
Value
Useful
Life
(in years)
Gross Value
Developed
technology ........ $
In-process
research &
development .....
Distributor
relationships ......
Patents ................
Elevess trade
name .................
Total ............... $
17,100 $
(2,824) $
(8,672) $ 5,604 $
(2,550) $
(7,723) $ 6,827
15
4,406
(1,168)
- 3,238
(1,015)
3,391 Indefinite
4,700
1,000
(415)
(169)
(4,285)
(482)
-
349
(415)
(152)
(4,285)
(431)
-
417
1,000
28,206 $
-
(4,576) $
(1,000)
-
(14,439) $ 9,191 $
-
(4,132) $
(1,000)
-
(13,439) $ 10,635
5
16
9
The Company performed an annual assessment of IPR&D intangible assets as of November 30, 2018. Based upon
that assessment, for the fiscal year 2018 there were no events or changes in circumstances that would result in a change in
the carrying value of IPR&D.
Total amortization expense was $1.0 million, $1.0 million, and $1.1 million for the years ended December 31, 2018,
2017, and 2016, respectively. Amortization expense on intangible assets is expected to be approximately $1.0 million in 2019,
$1.0 million annually through 2022, and approximately $2.1 million in aggregate thereafter.
10. Goodwill
The Company completed its annual impairment review as of November 30, 2018 and concluded that no impairment
in the carrying value exists as of that date with respect to goodwill. Through December 31, 2018, there have not been any
events or changes in circumstances that indicate that the carrying value of goodwill may not be recoverable. Changes in the
carrying value of goodwill were as follows:
Balance, beginning ..................................................................... $
Effect of foreign currency adjustments ......................................
Balance, ending .......................................................................... $
8,218
(367)
7,851
December 31,
2018
66
11. Accrued Expenses
Accrued expenses consist of the following:
December 31,
2018
2017
Compensation and related expenses .................................. $
Professional fees................................................................
Voluntary recall .................................................................
Research grants .................................................................
Clinical trial costs ..............................................................
Income taxes payable ........................................................
Other .................................................................................
Total .............................................................................. $
4,446 $
1,989
116
400
577
385
233
8,146 $
2,893
448
-
419
2,318
-
248
6,326
Included in Compensation and related expenses as of December 31, 2018 are the accrued and unpaid costs related
to the retirement of the Company’s former Chief Executive Officer as of March 9, 2018. On March 8, 2018 the Company
entered into a $0.3 million one-year, post-retirement consulting agreement with the former Chief Executive Officer to provide
certain services as may be requested by the Company through February 28, 2019. On the same date, the Company and the
former Chief Executive Officer entered into a release agreement related to terms in his employment agreement. Under the
terms of these agreements, the former Chief Executive Officer is entitled to receive from the Company, as a result of his
retirement, aggregate benefits of $1.7 million over the 18-month period subsequent to March 9, 2018, among other benefits.
As more fully described in Note 13, all of the former Chief Executive Officer’s outstanding equity awards vested in full and
became exercisable upon his retirement.
Accrued liabilities related to the previously-described product recall of certain production lots of the Company’s
HYAFF-based products, more fully described in Note 3, includes an accrual as of December 31, 2018 of $0.1 million of
expenses associated with the administration and remediation of the voluntary recall.
12. Commitments and Contingencies
Leasing Arrangements
On October 9, 2015, the Company’s Italian subsidiary, Anika S.r.l. entered into a build-to-suit lease agreement with
Consorzio Zona Industriale E Porto Fluviale di Padova (“ZIP”) as landlord, pursuant to which Anika S.r.l. leases a new
European headquarters facility, consisting of approximately 33,000 square feet of general office, research and development,
training, and warehousing space located in Padova, Italy. The lease has an initial term of fifteen years, which commenced on
March 1, 2017. The lease will automatically renew for up to three additional six-year terms, subject to certain terms and
conditions. The Company has the ability to withdraw from this lease subject to certain financial penalties after six years and
with no penalties after the ninth year. Beginning on the commencement date, the lease provides for an initial yearly rent of
approximately $0.3 million.
Construction of the new facility commenced during the first quarter of 2016. During the period of construction, the
Company was the deemed owner of the facility. Accordingly, the landlord's costs of constructing the facility were capitalized,
as a non-cash transaction, offset by a corresponding facility lease obligation in the Company’s consolidated balance sheet.
When the construction concluded on March 1, 2017, the Company removed the construction-in-process asset of $3.1 million
and related liability from its consolidated balance sheet. The Company commissioned ZIP for additional tenant improvements
of $0.8 million, which are recorded within Other long-term assets and amortized over the life of the lease on a straight line
basis. The lease is accounted for as an operating lease based on the Company’s assessment of the applicable accounting
principles.
67
Rental expense in connection with the various facility leases totaled $1.8 million, $1.8 million, and $1.3 million for
the years ended December 31, 2018, 2017, and 2016, respectively. The increased expense in 2017 is primarily a result of
finalizing the exercise of the Company’s first option under the lease to extend the terms from November 1, 2017 through
October 31, 2022, including the determination of a new annual base rent for the Company’s headquarters facility in Bedford,
Massachusetts.
The Company’s future lease commitments as of December 31, 2018 are as follows:
2019 .................................................................................. $
2020 ..................................................................................
2021 ..................................................................................
2022 ..................................................................................
2023 ..................................................................................
2024 and thereafter ...........................................................
Total .............................................................................. $
1,879
1,917
1,924
1,672
414
897
8,703
Warranty and Guarantor Arrangements
In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the
product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the
products it manufactures do not infringe, violate or breach any U.S. patent or intellectual property rights, trade secret, or other
proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any
and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or
alleged defect in any product caused by the negligence or acts or omissions of the Company. The Company maintains a
products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in
combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification
agreements is immaterial. The Company has no accrued warranties at December 31, 2018 or 2017, respectively, and has no
history of claims paid.
Legal Proceedings
The Company is involved from time-to-time in various legal proceedings arising in the normal course of business.
Although the outcomes of potential legal proceedings are inherently difficult to predict, the Company does not expect the
resolution of potential legal proceedings to have a material adverse effect on its financial position, results of operations, or
cash flow.
13. Equity Incentive Plan
Equity Incentive Plan
The Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”) was approved by the Company’s
stockholders on June 13, 2017 and provides for the grant of incentive stock options, nonqualified stock options, SARs, RSAs,
RSUs, and performance options that may be settled in cash, stock, or other property. In accordance with the 2017 Plan
approved by the Company’s stockholders, each share award other than stock options or SAR’s will reduce the number of
total shares available for grant by 2.0 shares. Subject to adjustment for specified types of changes in the Company’s
capitalization, no more than 1.2 million shares of common stock may be issued under the 2017 Plan. There are 0.9 million
shares available for future grant at December 31, 2018.
68
The 2017 Plan replaced the Anika Therapeutics, Inc. Stock Option and Incentive Plan, as amended, (the “2003
Plan”), as the plan under which future grants to employees, directors, officers, and consultants will be made. The terms of the
2003 Plan provide for grants of nonqualified and incentive stock options, common stock, RSAs, RSUs, and SARs to
employees, directors, officers, and consultants. The 2003 Plan was approved by the Company’s stockholders on June 4, 2003
and subsequently amended by the Board of Directors on May 29, 2009 and by the Company’s stockholders on June 7, 2011
and June 18, 2013 to increase the number of shares reserved for issuance. Pursuant to the 2011 amendment, each share award
issued after June 7, 2011, other than stock options or SARs, reduced the number of total shares available for grant by 1.9
shares. Pursuant to the 2013 amendment, each share award issued after June 18, 2013, other than stock options or SARs,
reduced the number of total shares available for grant by 1.5 shares.
The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other
equity-based awards, with either newly-issued shares or shares reacquired by the Company. Stock-based awards are granted
with an exercise price equal to the market price of the Company’s stock on the date of grant. Awards contain service
conditions or service and performance conditions, and they generally become exercisable ratably over one to four years with
a maximum contractual term of ten years.
The Company estimates the fair value of stock options and SARs using the Black-Scholes valuation model. Fair
value of restricted stock is measured by the grant-date price of the Company’s shares. Key input assumptions used to estimate
the fair value of stock options and SARs include the exercise price of the award, the expected award term, the expected
volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the award’s expected term,
and the Company’s expected annual dividend yield.
The expected volatility assumption is evaluated against the historical volatility of the Company’s common stock
over a 4.5 year average, and it is adjusted if there are material changes in historical volatility. The risk-free interest rate
assumption is based on U.S. Treasury interest rates at the time of grant.
The weighted-average grant-date fair value per share of stock options granted in 2018, 2017 and 2016 was $20.01,
$16.87 and $16.65, respectively. The fair value of each stock option during 2018, 2017, and 2016 was estimated on the grant
date using the Black-Scholes option-pricing model with the following assumptions:
Risk free interest rate ............................
Expected volatility ................................ 37.12% - 45.61% 38.74% - 44.31% 47.33% - 51.61%
Expected life (years) .............................
Expected dividend yield ........................
4.0 - 4.5
0.00%
4.5
0.00%
4.0
0.00%
2018
2.15% - 2.82%
2017
1.60% - 1.86%
2016
0.94% - 1.55%
Stock Options and Restricted Stock
The following table sets forth share information for stock-based compensation awards granted and exercised during
the period ended December 31, 2018 and 2017:
Twelve Months Ended
December 31,
2018
2017
Grants:
Stock options ............................................
RSAs ........................................................
RSUs ........................................................
199,970
64,578
15,457
Exercises:
Stock options ............................................
SARs ........................................................
284,548
-
440,688
26,306
9,970
12,941
5,000
69
The Company recorded $11.0 million, $5.8 million, and $3.4 million of stock-based compensation expense for the
years ended December 31, 2018, 2017, and 2016, respectively, for stock options, SARs, RSAs and RSUs with corresponding
tax benefits of $1.5 million, $0.4 million and $0.6 million, respectively. Upon the retirement of the Company’s former Chief
Executive Officer on March 9, 2018, all of his outstanding stock-based compensation awards vested in full and became
exercisable in accordance with their terms, resulting in a one-time expense of $6.2 million that was fully recognized during
the three-month period ended March 31, 2018.
The Company presents the expenses related to stock-based compensation awards in the same expense line items as
cash compensation paid to each of its employees as follows:
Cost of product revenue ............................................................... $
Research & development ..............................................................
Selling, general & administrative .................................................
Total stock-based compensation expense ..................................... $
(160) $
851
10,355
11,046 $
439 $
564
4,804
5,807 $
148
467
2,777
3,392
2018
2017
2016
The decrease in stock-based compensation expense within the cost of product revenue line item for the year ended
December 31, 2018 is due to forfeitures associated with unvested stock option awards from the resignation of a former
executive.
The combined stock options and SARs activity for the year ended December 31, 2018 is as follows:
2018
Options and SARs outstanding at beginning of year ...........................................
Granted ............................................................................................................
Cancelled .........................................................................................................
Expired ............................................................................................................
Exercised .........................................................................................................
Options and SARs outstanding at end of year .....................................................
Number of
Shares
Weighted
Average Exercise
Price Per Share
33.70
58.11
50.19
46.49
10.14
42.06
1,327,200 $
199,970 $
(104,629) $
(1,079) $
(284,548) $
1,136,914 $
All the 1,136,914 stock options and SARs outstanding at December 31, 2018 are vested or are expected to vest, with
a weighted-average exercise price of $42.06 as well as an aggregate intrinsic value of $3.7 million. The weighted average
remaining contractual term of the vested and expected to vest stock options and SARs was 5.0 years as of December 31,
2018.
As of December 31, 2018, total unrecognized compensation costs related to non-vested stock options and SARs was
approximately $4.4 million and is expected to be recognized over a weighted average period of 2.4 years.
70
The exercisable options and SARs at December 31, 2018 are as follows:
Number
Outstanding
Weighted Avg
Exercise Price
Weighted
Average
Remaining
Term
(in years)
Incentive stock options ............................
Non-qualified stock options ....................
Performance awards ................................
Stock appreciation rights .........................
139,674 $
453,790 $
100,963 $
35,250 $
24.53
40.74
40.72
6.36
4.1
3.2
3.1
1.1
The total intrinsic value of stock options and SARs exercised was $8.5 million, $0.5 million and $2.1 million for the
years ended December 31, 2018, 2017 and 2016, respectively.
The total fair value of stock options and SARs vested during the years ended December 31, 2018, 2017 and 2016
was approximately $6.7 million, $2.1 million and $1.3 million, respectively.
The RSA and RSU activity for the year ended December 31, 2018 is as follows:
2018
Weighted
Average
Grant Date
Fair Value
Number of
Shares
Unvested at Beginning of year ..................................................
Granted..................................................................................
Cancelled ..............................................................................
Vested/Released ....................................................................
Unvested at end of year .............................................................
229,226 $
80,035 $
(126,946) $
(123,232) $
59,083 $
42.47
58.84
42.47
50.80
47.26
The total fair value of RSAs and RSUs vested during the years ended December 31, 2018, 2017 and 2016 was $6.8
million, $2.3 million and $1.0 million. The weighted-average grant-date fair value of RSAs and RSUs granted during the
years ended December 31, 2018, 2017 and 2016 was $58.84, $52.03 and $38.11, respectively.
14. Employee Benefit Plan
The Company’s U.S. employees are eligible to participate in the Company’s 401(k) savings plan. Employees may
elect to contribute a percentage of their compensation to the plan, and the Company will make 140% matching contributions
up to a limit of 5% of an employee’s eligible compensation. In addition, the Company may make annual discretionary
contributions. The Company made matching contributions of $0.8 million, $0.6 million, and $0.6 million for the years ended
December 31, 2018, 2017, and 2016, respectively.
15. Shareholder Rights Plan
On April 4, 2008, the Board of Directors of the Company adopted a Shareholder Rights Plan (the “2008 Plan”). The
2008 Plan expired on April 8, 2018, and the Company did not extend the 2008 Plan or adopt a new Shareholder Rights Plan.
16. Income Taxes
On December 22, 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted. This legislation made
significant changes to the U.S. tax law, including a reduction in the corporate tax rate from 35% to 21% starting in 2018.
In accordance with Staff Accounting Bulletin No. 118, which provides guidance on accounting for the tax effects of
the 2017 Tax Act, the Company has recorded the impact on the consolidated financial statements. There were no significant
changes in the provisional amount recorded in 2017 related to the finalization of the Company’s analysis. The other provisions
of the Tax Act did not have a material impact on the 2017 consolidated financial statements.
71
Income Tax Expense
The components of the Company’s income before income taxes and its provision for (benefit from) income taxes
consist of the following:
Income before income taxes
Years ended December 31,
2017
2018
2016
Domestic .................................................................................. $
Foreign .....................................................................................
$
26,227 $
(3,020)
23,207 $
48,446 $
(2,244)
46,202 $
50,181
689
50,870
Provision for (benefit from) income taxes:
Current provision:
Federal ...................................................................................... $
State ..........................................................................................
Foreign .....................................................................................
Deferred provision:
Federal ......................................................................................
State ..........................................................................................
Foreign .....................................................................................
Total provision ......................................................................... $
Years ended December 31,
2017
2018
2016
4,783 $
1,644
405
6,832
(992)
(152)
(1,203)
(2,347)
4,485 $
12,608 $
2,737
31
15,376
(426)
(68)
(496)
(990)
14,386 $
14,982
3,265
302
18,549
(70)
(84)
(72)
(226)
18,323
72
Deferred Tax Assets and Liabilities
Significant components of the Company’s deferred tax assets and liabilities consist of the following:
December 31,
2018
2017
Deferred tax assets:
Net operating loss carry forward, foreign ................ $
Stock-based compensation expense ........................
Foreign currency exchange .....................................
Accrued expenses and other ....................................
Inventory reserve .....................................................
Deferred tax assets .................................................. $
1,382 $
3,148
363
818
1,500
7,211 $
959
2,309
265
496
740
4,769
December 31,
2018
2017
Deferred tax liabilities:
Acquisition-related Intangibles ............................... $
Depreciation ............................................................
Deferred tax liabilities ............................................. $
(2,405) $
(8,348)
(10,753) $
(2,743)
(7,419)
(10,162)
Net deferred tax liabilities ........................................... $
(3,542) $
(5,393)
Tax Rate
The reconciliation between the U.S. federal statutory rate and the Company’s effective rate is summarized as
follows:
Years ended December 31,
2017
2016
2018
Statutory federal income tax rate ...................................................................
State tax expense, net of federal benefit ........................................................
Impact of rate change on deferred taxes ........................................................
Permanent items, including nondeductible expenses ....................................
State investment tax credit ............................................................................
Federal, state and foreign research and development credits ........................
Foreign rate differential .................................................................................
Domestic production deduction .....................................................................
Stock compensation .......................................................................................
Non-deductible Section 162(m) compensation limitation .............................
Foreign derived intangible income deduction ...............................................
Effective income tax rate ...............................................................................
21.0%
5.5%
0.0%
(1.4%)
(0.2%)
(3.4%)
(0.4%)
0.0%
(4.8%)
4.3%
(1.3%)
19.3%
35.0%
4.8%
(4.9%)
0.1%
(0.7%)
(1.4%)
0.5%
(2.8%)
(0.2%)
0.7%
0.0%
31.1%
35.0%
4.5%
0.0%
0.1%
(0.1%)
(0.9%)
(0.1%)
(2.9%)
0.1%
0.3%
0.0%
36.0%
As of December 31, 2018, the Company had NOL’s for income tax purposes in Italy of $5.8 million that do not
expire.
Accounting for Uncertainty in Income Taxes
The Company had no unrecognized tax benefits for the years ended December 31, 2018 and 2017, respectively. The
Company does not anticipate experiencing any significant increases or decreases in its unrecognized tax benefits within the
twelve months following December 31, 2018.
In the normal course of business, Anika and its subsidiaries may be periodically examined by various taxing
authorities. We file income tax returns in the U.S. federal jurisdiction, in certain U.S. states, and in Italy. The associated tax
filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which
those filings relate. The 2015 through 2017 tax years remain subject to examination by the IRS and other taxing authorities
for U.S. federal and state tax purposes. The 2012 through 2017 tax years remain subject to examination by the appropriate
governmental authorities for Italy.
73
Upon the settlement of certain stock-based awards (i.e., exercise, vesting, forfeiture, or cancellation), the actual tax
deduction is compared with cumulative financial reporting compensation cost, and any excess tax deduction related to these
awards is considered a windfall tax benefit. With the adoption of ASU 2016-09 in 2017, the Company records windfall tax
benefits to income tax expense. The Company follows the with-and-without approach for the direct effects of
windfall/shortfall items and to determine the timing of the recognition of any related benefits. The Company recorded a
windfall tax benefit in income tax expense of $1.5 million in 2018 compared to $0.4 million in 2017.
17. Revolving Credit Agreement
On October 24, 2017, the Company, as borrower, entered into a new five-year agreement with Bank of America,
N.A., as administrative agent, swingline lender and issuer of letters of credit, for a $50.0 million senior revolving line of
credit (the “Credit Agreement”). Subject to certain conditions, the Company may request up to an additional $50.0 million in
commitments for a maximum aggregate commitment of $100.0 million, which requests must be approved by the Revolving
Lenders (as defined in the Credit Agreement). Loans under the Credit Agreement generally bear interest equal to, at the
Company’s option, either: (i) LIBOR plus the Applicable Margin, as defined below, or the (ii) Base Rate, defined as the
highest of: (a) the Federal Funds Rate plus 0.50%, (b) Bank of America, N.A.’s prime rate and (c) the one month LIBOR
adjusted daily plus 1.0%, plus the Applicable Margin. The Applicable Margin ranges from 0.25% to 1.75% based on the
Company’s consolidated leverage ratios at the time of the borrowings under the Credit Agreement. The Company has agreed
to pay a commitment fee in an amount that is equal to 0.25% per annum on the actual daily unused amount of the credit
facility and that is due and payable quarterly in arrears. Loan origination costs are included in Other long-term assets and are
being amortized over the five-year term of the Credit Agreement. As of December 31, 2018 and 2017, there are no outstanding
borrowings under the Credit Agreement and the Company is in compliance with the terms of the Credit Agreement.
The Credit Agreement contains customary representations, warranties, affirmative and negative covenants,
including financial covenants, events of default and indemnification provisions in favor of the Lenders (as defined in the
Credit Agreement). The covenants include restrictions governing the Company’s leverage ratio and interest coverage ratio,
its incurrence of liens and indebtedness, and its entry into certain merger and acquisition transactions or dispositions and
other matters, all subject to certain exceptions. The financial covenants require the Company not to exceed certain maximum
leverage and interest coverage ratios. The Lenders have been granted a first priority lien and security interest in substantially
all of the Company’s assets, except for certain intangible assets.
74
18. Quarterly Financial Data (Unaudited)
Year 2018
Product revenue .................................................................. $
Total revenue ......................................................................
Cost of product revenue .....................................................
Gross profit on product revenue .........................................
Net income ......................................................................... $
Per common share information:
Basic net income per share ............................................. $
Basic common shares outstanding ..................................
Diluted net income per share .......................................... $
Diluted common shares outstanding ..............................
Quarter ended
December 31
Quarter ended
September 30
Quarter ended
June 30
Quarter ended
March 31
26,950 $
26,956
7,001
19,949
7,717 $
0.54 $
14,168
0.54 $
14,299
26,781 $
26,787
8,282
18,499
7,599 $
0.53 $
14,237
0.53 $
14,377
30,542 $
30,548
8,152
22,390
10,092 $
0.69 $
14,652
0.68 $
14,915
21,258
21,264
7,845
13,413
(6,686 )
(0.46 )
14,679
(0.46 )
14,679
Quarter ended
December 31
Quarter ended
September 30
Quarter ended
June 30
Quarter ended
March 31
28,884 $
29,388
8,716
20,168
8,067 $
0.55 $
14,596
0.53 $
15,141
27,178 $
27,184
6,250
20,928
6,887 $
0.47 $
14,579
0.46 $
15,115
28,340 $
33,462
6,315
22,025
11,369 $
0.78 $
14,588
0.76 $
15,044
23,381
23,386
6,083
17,298
5,493
0.38
14,576
0.37
15,043
Year 2017
Product revenue .................................................................. $
Total revenue ......................................................................
Cost of product revenue .....................................................
Gross profit on product revenue .........................................
Net income ......................................................................... $
Per common share information:
Basic net income per share ............................................. $
Basic common shares outstanding ..................................
Diluted net income per share .......................................... $
Diluted common shares outstanding ..............................
75
ITEM 9A. CONTROLS AND PROCEDURES
(a)
Evaluation of disclosure controls and procedures.
As required by Rule 13a-15 under the Securities Exchange Act of 1934 (“Exchange Act”), we carried out an
evaluation under the supervision and with the participation of our management, including our chief executive officer and
chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end
of the period covered by this report. Based upon that evaluation, the chief executive officer and chief financial officer have
concluded that our disclosure controls and procedures are effective as of December 31, 2018 to ensure that information
required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized, and
reported within the time periods specified in SEC rules and forms. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports
we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief
executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions
regarding required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and
our internal control over financial reporting, and we may from time to time make changes aimed at enhancing their
effectiveness and ensuring that our systems evolve with our business.
(b)
Changes in internal controls over financial reporting.
In January 2018, we placed in service our new enterprise resource planning software. In this regard, we reviewed
and modified our internal controls, as necessary. There were no changes in our internal control over financial reporting during
the quarter ended December 31, 2018 that have materially affected, or that are reasonably likely to materially affect, our
internal controls over financial reporting.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting
as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles in the United States.
Because of its inherent limitations, internal control over financial reporting can provide only reasonable assurance,
and it may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance
with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2018.
In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the
Treadway Commission in its 2013 Internal Control—Integrated Framework.
Based on its assessment and those criteria, our management believes that our company maintained effective internal
control over financial reporting as of December 31, 2018.
The effectiveness of our internal control over financial reporting as of December 31, 2018 has been audited by
Deloitte & Touche LLP an independent registered public accounting firm, as stated in their report which is included below
in this Item 9A of this annual report on Form 10-K.
76
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Anika Therapeutics, Inc.
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Anika Therapeutics, Inc. and subsidiaries (the “Company”)
as of December 31, 2018, based on criteria established in Internal Control — Integrated Framework (2013) issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in
all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established
in Internal Control — Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated financial statements as of and for the year ended December 31, 2018, of the Company and our
report dated February 26, 2019, expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's
Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s
internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in
all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the
risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based
on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that
our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 26, 2019
77
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required under this item is incorporated herein by reference to our definitive proxy statement
pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our
fiscal year ended December 31, 2018.
ITEM 11. EXECUTIVE COMPENSATION
The information required under this item is incorporated herein by reference to our definitive proxy statement
pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our
fiscal year ended December 31, 2018.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The information required under this item and Item 5 of this Annual Report on Form 10-K under the heading “Equity
Compensation Plan Information” is incorporated herein by reference to our definitive proxy statement pursuant to
Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year
ended December 31, 2018.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
The information required under this item is incorporated herein by reference to our definitive proxy statement
pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our
fiscal year ended December 31, 2018.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required under this item is incorporated herein by reference to our definitive proxy statement
pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our
fiscal year ended December 31, 2018.
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
PART IV
(a)
Documents filed as part of Form 10-K.
(1) Financial Statements
Reports of Independent Registered Public Accounting Firms ...........................................................................
47
49
Consolidated Balance Sheets .............................................................................................................................
50
Consolidated Statements of Operations and Comprehensive Income ...............................................................
Consolidated Statements of Stockholders’ Equity ............................................................................................
51
Consolidated Statements of Cash Flows ...........................................................................................................
52
Notes to Consolidated Financial Statements ..................................................................................................... 53-75
(2) Schedules
Schedules have been omitted as all required information has been disclosed in the financial statements and related
footnotes.
78
(3) Exhibits
Exhibit
Number
Description
3.1
3.2
10.1a
10.1b
10.2a
10.2b
10.2c
10.2d
10.2e
10.3a
10.3b
10.4a
10.4b
10.5
10.6a
10.6b
10.7
*10.8
*10.9
Certificate of Incorporation of Anika Therapeutics, Inc.
Bylaws of Anika Therapeutics, Inc., effective as of June 6, 2018
Lease, dated January 3, 2007, between Anika Therapeutics, Inc. and Farley White Wiggins, LLC, relating to 32
Wiggins Avenue, Bedford, Massachusetts
Amendment No. 1 to Lease, dated February 1, 2007, between Anika Therapeutics, Inc. and Farley White
Wiggins, LLC, relating to 32 Wiggins Avenue, Bedford, Massachusetts
Lease Agreement, dated December 30, 2009, between Fidia Farmaceutici S.p.A. and Fidia Advanced
Biopolymers S.r.l., relating to Via Ponte della Fabbrica 3/A and 3/B Abano Terme, Padua, Italy
Amendment No. 1 to Lease Agreement, dated June 18, 2010, between Fidia Farmaceutici S.p.A. and Anika
Therapeutics S.r.l. (formerly Fidia Advanced Biopolymers S.r.l.) relating to Via Ponte Della Fabbrica 3/A and
3/B Abano Terme, Padua, Italy
Amendment No. 2 to Lease Agreement, dated September 20, 2010, between Fidia Farmaceutici S.p.A. and Anika
Therapeutics S.r.l. (formerly Fidia Advanced Biopolymers S.r.l.) relating to Via Ponte Della Fabbrica 3/A and
3/B Abano Terme, Padua, Italy
Translation of Amendment No. 3 to Lease Agreement, dated April 16, 2012, between Fidia Farmaceutici S.p.A.
and Anika Therapeutics S.r.l. (formerly Fidia Advanced Biopolymers S.r.l.) relating to Via Ponte Della Fabbrica
3/A and 3/B Abano Terme, Padua, Italy
Translation of Amendment No. 4 to Lease Agreement, dated February 22, 2016, between Fidia Farmaceutici
S.p.A. and Anika Therapeutics S.r.l. (formerly Fidia Advanced Biopolymers S.r.l.) relating to Via Ponte Della
Fabbrica 3/A and 3/B Abano Terme, Padua, Italy
Translation of Lease Agreement, dated October 9, 2015, between Anika Therapeutics S.r.l. and Consorzio Zona
Industriale E Porto Fluviale di Padova relating to Land Registry of the Municipality of Padova, Page 148,
cadastral map 516 and 517
Translation of Amendment No. 1 to Lease Agreement, dated February 2, 2017, between Anika Therapeutics
S.r.l. and Consorzio Zona Industriale E Porto Fluviale di Padova relating to Land Registry of the Municipality
of Padova, Page 148, cadastral map 516 and 517
Credit Agreement, dated as of October 24, 2017, among Anika Therapeutics, Inc., certain subsidiaries of Anika
Therapeutics, Inc. as are or may from time to time become parties to the Credit Agreement, Bank of America,
N.A., as administrative agent, swingline lender and issuer of letters of credit, and the lenders party thereto.
Security and Pledge Agreement, dated as of October 24, 2017, among Anika Therapeutics, Inc., certain
subsidiaries of Anika Therapeutics, Inc. listed on the signature pages thereto, and Bank of America, N.A., as
administrative agent.
Sale and Purchase Agreement, dated December 30, 2009, by and between Fidia Farmaceutici S.p.A. and Anika
Therapeutics, Inc.
Tolling Agreement, dated December 30, 2009, between Fidia Farmaceutici S.p.A. and Fidia Advanced
Biopolymers S.r.l.
Amendment No. 1 to Tolling Agreement, dated January 1, 2012, between Fidia Farmaceutici S.p.A. and Anika
Therapeutics S.r.l. (formerly Fidia Advanced Biopolymers S.r.l.)
Registration Rights Agreement, dated December 30, 2009, between Anika Therapeutics, Inc. and Fidia
Farmaceutici S.p.A.
License Agreement, dated as of December 20, 2003, by and between Anika Therapeutics, Inc. and Ortho Biotech
Products, L.P.
License Agreement, dated as of December 21, 2011, by and between Anika Therapeutics, Inc. and DePuy Mitek,
Inc.
Anika Therapeutics, Inc. Senior Executive Incentive Compensation Plan
Anika Therapeutics, Inc. Non-Employee Director Compensation Policy
†10.10
†10.11
†10.12a Second Amended and Restated 2003 Stock Option and Incentive Plan (adopted April 5, 2011)
†10.12b Amendment to Second Amended and Restated 2003 Stock Option and Incentive Plan (adopted April 11, 2013)
79
Exhibit
Number
Description
†10.12c Form of Incentive Stock Option Agreement under Second Amended and Restated 2003 Stock Option and
Incentive Plan
†10.12d Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under Second Amended and
Restated 2003 Stock Option and Incentive Plan
Amendment No. 1 dated March 8, 2018 to Employment Agreement dated July 27, 2017 by and between Anika
Therapeutics, Inc. and Joseph G. Darling
Form of Notice of Grant of Incentive Stock Option, including Terms and Conditions of Stock Option, granted
under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.
Form of Notice of Grant of Nonqualified Stock Option, including Terms and Conditions of Stock Option, granted
under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan
Form of Notice of Grant of Restricted Stock Award, including Terms and Conditions of Restricted Stock Award,
granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.
Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units,
granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan
†10.13a Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan
†10.13b
†10.13c
†10.13d
†10.13e
†10.14a Employment Agreement, dated July 27, 2017, by and between Anika Therapeutics, Inc. and Joseph Darling
†10.14b
†10.15a Employment Agreement, dated March 22, 2010, between Anika Therapeutics, Inc. and Sylvia Cheung
†10.15b
†10.16a Employment Agreement, dated September 10, 2009, between Anika Therapeutics, Inc. and Frank J. Luppino
†10.16b
†10.17a
†10.17b
10.18
10.19
Amendment No. 1 to Employment Agreement, dated December 1, 2010, by and between Anika Therapeutics,
Inc. and Frank J. Luppino
Employment Agreement, dated October 17, 2008, between Anika Therapeutics, Inc. and Charles H. Sherwood,
Ph.D.
Amendment No. 1 to Employment Agreement, dated December 8, 2010, by and between Anika Therapeutics,
Inc. and Charles H. Sherwood, Ph.D.
Amendment No. 1 to the Employment Agreement, dated December 8, 2010, by and between Anika Therapeutics,
Inc. and Sylvia Cheung
Consulting Agreement between Anika Therapeutics, Inc. and Charles H. Sherwood, Ph.D., dated March 8, 2018
Fixed Dollar Accelerated Share Repurchase Transaction Confirmation entered into as of May 24, 2018 by and
between Morgan Stanley & Co. LLC and Anika Therapeutics, Inc.
21.1
23.1
23.2
31.1
31.2
**32.1
***101
List of Subsidiaries of Anika Therapeutics, Inc.
Consent of Deloitte & Touche LLP
Consent of PricewaterhouseCoopers LLP
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002
The following materials from the Annual Report on Form 10-K of Anika Therapeutics, Inc. for the fiscal year
ended December 31, 2018, formatted in XBRL: (i) Consolidated Balance Sheets as of December 31, 2018 and
December 31, 2017; (ii) Consolidated Statements of Operations and Comprehensive Income for the Years Ended
December 31, 2018, December 31, 2017, and December 31, 2016; (iii) Consolidated Statements of Stockholders’
Equity for the Years Ended December 31, 2018, December 31, 2017, and December 31, 2016; (iv) Consolidated
Statements of Cash Flows for the Years Ended December 31, 2018, December 31, 2017, and December 31,
2016; and (v) Notes to Consolidated Financial Statements
† Management contract or compensatory plan or arrangement.
*
**
Certain portions of this document have been omitted pursuant to a confidential treatment request filed with the
Securities and Exchange Commission. The omitted portions have been filed separately with the Commission.
The certification attached as Exhibit 32.1 that accompanies this Form 10-K is not deemed filed with the SEC and is
not to be incorporated by reference into any filing of Anika Therapeutics, Inc. under the Securities Act of 1933 or the
Securities Exchange Act of 1934, whether made before or after the date of this Form 10-K, irrespective of any general
incorporation language contained in such filing.
*** Pursuant to Rule 406T of Regulation S-T, XBRL (Extensible Business Reporting Language) information is deemed
not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of
1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934 and otherwise is not
subject to liability under these sections.
80
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: February 26, 2019
ANIKA THERAPEUTICS, INC.
By:
/s/ JOSEPH G. DARLING
Joseph G. Darling
President and Chief Executive Officer
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ JOSEPH G. DARLING.
Joseph G. Darling
Chief Executive Officer, President, Director
(Principal Executive Officer)
February 26, 2019
/s/ SYLVIA CHEUNG
Sylvia Cheung
Chief Financial Officer
(Principal Accounting Officer and Principal Financial Officer)
February 26, 2019
/s/ JOSEPH L. BOWER
Joseph L. Bower
Director, Chairman of the Board
/s/ CHERYL BLANCHARD
Cheryl Blanchard
Director
/s/ RAYMOND J. LAND
Raymond J. Land
Director
/s/ GLENN R. LARSEN, PH.D.
Glenn R. Larsen, Ph.D.
Director
/s/ JEFFERY S. THOMPSON
Jeffery S. Thompson
Director
/s/ SUSAN VOGT
Susan Vogt
Director
February 26, 2019
February 26, 2019
February 26, 2019
February 26, 2019
February 26, 2019
February 26, 2019
81
[THIS PAGE INTENTIONALLY LEFT BLANK]
[THIS PAGE INTENTIONALLY LEFT BLANK]
[THIS PAGE INTENTIONALLY LEFT BLANK]
32 Wiggins Avenue
Bedford, MA 01730 USA
www.anikatherapeutics.com
A
N
N
U
A
L
R
E
P
O
R
T
2
0
1
8